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Abstract
The XXII World Congress of Psychiatric Genetics, sponsored by the International Society of 
Psychiatric Genetics, took place in Copenhagen, Denmark, on 12–16 October 2014. A total of 883 
participants gathered to discuss the latest findings in the field. The following report was written by 
student and postdoctoral attendees. Each was assigned one or more sessions as a rapporteur. This 
manuscript represents topics covered in most, but not all of the oral presentations during the 
conference, and contains some of the major notable new findings reported. Psychiatr Genet 26:1–
47 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
The XXII World Congress of Psychiatric Genetics, sponsored by the International Society of 
Psychiatric Genetics (ISPG), took place on 12–16 October 2014, in Copenhagen, Denmark. 
A total of 883 researchers in the fields of psychiatry, psychology, and molecular genetics 
attended the conference to discuss the latest technological advances in the field and new 
findings on the genetics of mental disorders.
The ISPG was first established as a nonprofit corporation in the USA in 1992 and is now a 
worldwide organization that strives for the highest methodologies to the study of psychiatric 
disorders. It was formed to provide a stable structure for continual congresses in this field 
with the mission of overseeing an annual gathering at different international locations. The 
congress was co-chaired by Dr Ole Mors, Dr Thomas G. Schulze, and Dr Thomas Werge. 
Rapporteurs for these sessions were students or postdocs who covered the presentations. 
They were tasked to summarize individual sessions as well as relevant discussions. Similar 
accounts of the 2007, 2008, 2009, 2010, 2011, 2012, 2013, and 2014 congress held in New 
York (New York), Osaka (Japan), San Diego (California), Athens (Greece), Washington 
(District of Colombia), Hamburg (Germany), and Boston (Massachusetts), have been 
published previously (Alkelai et al., 2008; Bergen et al., 2009, 2011; Amstadter et al., 2010; 
Dai et al., 2012; Anderson-Schmidt et al., 2013, Akpudo et al., 2014).
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The following report represents the major findings covered during most oral sessions and 
they appear together under major topics, irrespective of the timing of specific sessions.
Keynote lecture: optical deconstruction of fully assembled biological 
systems – speaker Dr Karl Deisseroth (reported by Annika Forsingdal)
Dr Karl Deisseroth (Stanford University, USA) aims to achieve a deep understanding of 
basic biological mechanisms that can facilitate a better understanding of psychiatric 
diseases. To this end, and to achieve a deeper understanding of biological processes 
Deisseroth’s lab have developed the technologies Optogenetics and CLARITY. Optogenetics 
can induce patterns of activity or inhibition by illumination, with spatial resolution in 
specific cell types (Deisseroth, 2011). The first optogenetic studies showed how opsins could 
drive action potentials and affect behavior in animals.
There are two main categories of opsins: ion channels and pumps. Despite thorough 
searches, no inhibitory channels have been found. In 2012, the crystal structure of 
channelrhodopsin was obtained (Kato et al., 2012). This enabled engineering of 
channelrhodopsin, ultimately transforming it into a chloride channel, the first inhibitory ion 
channel opsin (Wietek et al., 2014). Engineering was performed by introducing mutations 
that were considered to increase the specificity toward chloride. Channelrhodopsin mutants 
were then expressed in primary neurons that were patched to study their effect on the 
channel properties. The mutants that had increased specificity for chloride were combined 
into a chloride channel that expressed well. Another characteristic that was searched for in 
the opsins was a stable change (i.e. to keep the cell switched off by a single light beam). This 
was achieved by the development of SwiChRs (Berndt et al., 2014).
Spatial specificity can be achieved with adenoviral constructs using a cell type-specific 
promoter; light can either be delivered to the same location as the virus or to another 
location. This spatial specificity has been exploited to study the circuitries and projections 
underlying different behaviors. By driving the basolateral amygdala (BLA) and projections 
from the BLA to the central nucleus of the amygdala (CeA), it was shown that BLA-CeA 
increases anxiolytic behavior in mice (Tye et al., 2011). Further optogenetic studies of the 
circuitries involved in anxiety and anxiolytic behavior described a role for the bed nucleus of 
the stria terminalis in anxiety-related behavior. It was shown that some projections from the 
bed nucleus of the stria terminalis were anxiolytic, whereas others increased anxiety (Kim et 
al., 2013).
Optogenetic studies of projections had never been tested without stimulation. Fiber 
photometry was developed to do exactly this. The technique enables measurement of activity 
of specific neurons (Gunaydin et al., 2014). Previous studies had shown that social behavior 
can be turned up and down by turning on dopamine neurons in the ventral tegmental area 
(VTA) [tyrosine hydroxylase (TH)-positive neurons]. VTA-TH neurons in a mouse become 
active when the animal is exploring a novel mouse or a novel object. This phenomenon was 
further investigated by moving the recording fiber to the nucleus accumbens (NAc). In the 
NAc, there is a stronger signal from the projections for social novelty than for novel objects. 
It was also shown that driving projection from VTA to NAc increased sociability of the 
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mice. Projections from VTA to the prefrontal cortex (PFC) do not increase sociability, but 
makes the animal more anxious, measured by less time spent in the open arms of an elevated 
plus maze (Gunaydin et al., 2014).
Dr Deisseroth’s lab also developed a technique for imaging intact tissue (e.g. a whole brain). 
Intact tissue is transformed into a hydrogel-hybridized form, which allows removal of lipids. 
When the lipids are removed, the light-scattering effect of the tissue is reduced and the tissue 
effectively becomes transparent (Chung et al., 2013). The tissue can then be stained with cell 
type-specific markers to examine specific cell types. Future plans include combining clarity 
with activity imaging.
Plenary sessions
Selective serotonin reuptake inhibitor pharmacogenomics and pharmacometabolomics – 
speaker: Dr Richard Weinshilboum (reported by Claudia Pisanu)
Dr Richard Weinshilboum (Mayo Medical School, Mayo Clinic, USA) first emphasized the 
importance of international consortia and collaborations between groups with 
complementary and overlapping expertise. Pharmacogenomics and pharmacometabolomics 
are central aspects of personalized medicine, which recognizes as major clinical goals 
avoidance of adverse drug reactions, maximization of drug efficacy, and selection of 
responsive patients. The scientific goals of personalized medicine include linking genomic 
and metabolomic variation to phenotypic variation (to predict which patients are going to 
experience an adverse reaction and which patients are going to respond or not respond to a 
drug), determination of the mechanisms responsible for that link, and, eventually, translation 
of that link into a better diagnosis, treatment, and prevention of disease.
Pharmacogenetics has evolved into pharmacogenomics, a broader approach used to study 
variations across the whole genome.
Professor Weinshilboum described – as an example – how breast cancer treatment has 
changed profoundly across the years as we have been able to use drugs such as selective 
estrogen receptor (ER) modulators, aromatase inhibitors, and trastuzumab to subclassify the 
disease and individualize therapy, and explained that this is a path that we may be able to 
follow with psychiatric diseases. In this sense, recent studies have used selective serotonin 
reuptake inhibitors (SSRIs) as molecular probes for major depressive disorder (MDD) 
molecular mechanisms. Professor Weinshilboum remembered Julius Axelrod’s major 
discovery of the reuptake of monoamine neurotransmitters, the mechanism inhibited by 
SSRI, and explained the design of the Mayo PGRN Citalopram–Escitalopram Clinical Trial, 
aimed at better understanding the SSRI molecular mechanism of action using both 
pharmacogenomics and pharmacometabolomics (Ji et al., 2013). The discovery study 
involved a large sample of 529 MDD patients at the Mayo Clinic, whereas the replication 
study was carried out on the DNA of patients from the Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) study (Trivedi et al., 2006; Howland, 2008; Zisook et al., 
2008) and samples from the International SSRI Pharmacogenomics Consortium (PGRN 
ISPC). In the Citalopram–Escitalopram Clinical Trial, most of the patients gained some 
benefit from SSRI therapy, but a number of patients still showed moderate to severe 
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symptomatology. The rs11144870 single nucleotide polymorphism (SNP) located in an 
intron of the riboflavin kinase (RFK) gene (P = 1.16 × 10−6) was associated with the 
response outcome. However, the association has not been replicated. It is well known that 
many genome-wide association study (GWAS) findings on SSRI response, like many GWAS 
in psychiatry, have proven difficult to replicate (Ising et al., 2009; Garriock et al., 2010; 
Uher et al., 2010; Ji et al., 2011) and included among possible explanations could be 
phenotypic heterogeneity and lack of objective biomarkers.
Genome-wide significant associations were observed for escitalopram concentrations with 
SNPs in or near the CYP2C19 gene (rs1074145, P = 4.1 × 10−9) and with S-
didesmethylcitalopram concentration for SNPs near the CYP2D6 locus (rs1065852, P = 2.0 
× 10−16) (Ji et al., 2014). Moreover, other hits with genome-wide significance were obtained 
after adjusting for the effect of CYP2C19 functional alleles. Plasma metabolomic assays 
using samples from the same patients were also performed using an LC-electrochemical 
array platform (Ji et al., 2014). This pharmacometabolomics-informed pharmacogenomic 
research strategy was applied to plasma samples from 20 escitalopram remitters and 20 
nonremitter MDD patients, and showed that glycine levels were negatively associated with 
treatment outcome (P = 0.0054) (Ji et al., 2011). When genotyping tag SNPs of genes 
encoding glycine synthesis and degradation enzymes in 529 SSRI-treated MDD patients, the 
rs10975641 SNP in the glycine dehydrogenase gene was associated with treatment outcome 
(Ji et al., 2011). Moreover, the subsequent application of a pharmacometabolomics-informed 
pharmacogenomics research strategy involving 300 MDD patients identified a series of 
candidate genes that are being pursued using functional genomic techniques.
Finally, during the discussion, Professor Weinshilboum stressed how 
pharmacometabolomics is an informative tool when observations from plasma metabolites 
are linked to genetic variation.
Dr Christine Klein (University of Lübeck, Germany) – translating genetic findings into 
clinical practice: the Parkinson example (reported by Zuzanna Misiewicz)
Almost two decades after the first mutation responsible for Parkinson’s disease (PD) was 
identified (Polymeropoulos et al., 1996), Dr Christine Klein (University of Lübeck, 
Germany) spoke on translation of genetic findings into pathways to therapy and prevention, 
as based on the Parkinson example. The content of her presentation reflected accurately the 
theme of the XXII World Congress of Psychiatric Genetics.
Dr Klein introduced the topic by briefly reviewing the genetic nomenclature of PD with a 
special focus on the monogenic, both recessive and dominant, forms of PDs caused by 
defects in single genes. They account for around 5% of all sporadic cases; therefore, 
although well established, they are relatively rare in comparison with idiopathic forms of 
likely multifactorial etiology. The idiopathic forms comprise the majority of Parkinson cases 
(95%). They are based on a more complex background, where combined effects of genetic 
variants in multiple genes, the environment, the complex interaction between them as well as 
other risk factors contribute toward the pathogenesis (Klein and Westenberger, 2012). More 
recently, GWASs have enabled a more direct approach in genetics of PD. As Dr Klein 
highlighted later in her presentation, the five performed GWAS and the subsequent meta-
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analyses (International Parkinson Disease Genomics Consortium et al., 2011) constituted a 
major contribution in genetic research of PD and facilitated the identification of further 
genetic risk factors associated with idiopathic PD, such as SNCA and LRRK2 genes, 
reported previously in monogenic PD.
Subsequently, Dr Klein vividly described the most common forms of dominant 
parkinsonism with mutations in the LRRK2 gene and the SNCA gene, and recessive 
parkinsonism, with a mutation in the Parkin gene. She presented examples of clinical 
phenotypes representative for each of them, respectively, rigidity, rest tremor, and 
bradykinesia. She stressed that all of them are indistinguishable from idiopathic cases of PD. 
She further emphasized that both forms of PD tend to converge on common 
pathophysiological pathways, such as mitochondrial dysfunction (PINK1, Parkin, DJ-1), 
endosomal vesicle protein recycling (LRRK2), and protein degradation (VPS35). Following 
Malkus et al. (2009), Dr Klein referred to it as a Bermuda Triangle.
All of the examples of similarities presented by Dr Klein allowed her to confidently 
conclude that the genetic PD can be used as an excellent model of PD. It allows us to more 
fully understand the complicated idiopathic form, a knowledge that can be applied in clinical 
practice and genetic consulting leading to earlier diagnosis of at-risk individuals.
Moreover, Dr Klein noted an interesting comorbidity between PD and psychiatric diseases, 
such as depression, anxiety, dementia, or sleep problems (Park and Stacy, 2009). For 
example, in idiopathic PD, about 30% of the patients suffer from depression, whereas the 
general prevalence in the population is about 15%. Furthermore, 41% of the carriers of the 
PINK1 mutation experience anxiety, which is significantly higher than the frequency in the 
general population (15–25%). These observations may underscore the fact that underlying 
biological processes among these distinct phenotypes are at least partially convergent.
Although a great deal of knowledge has been gained in the field of PD genetics, little 
progress has been made in translating genetic findings into clinical practice so far. The 
development of new disease models, such as animal models and induced pluripotent stem 
cells (iPSC), has contributed toward major advancements in the field. The examples 
presented by Dr Klein included a study by Vos et al. (2012), in which a high dosage of 
vitamin K2 could rescue pink1 mutation deficiency. The group led by Dr Klein currently 
tests this mitochondrial enhancer strategy on patients with the PINK1 mutation.
In conclusion, Dr Klein’s presentation showed that the complex picture of idiopathic PD 
provides cues of possible pathways to therapy and prevention and serves as an example for 
psychiatric diseases.
Dr Tine Bryan Stensbøl (Lundbeck), NEWMEDS – a public private partnership in psychiatry 
– objectives, outcomes, obstacles, and opportunities (reported by Annika Forsingdal)
Tine Bryan Stensbøl (Lundbeck) described the NEWMEDS consortium as a new way of 
collaborating between academia and industry. The Innovative Medicines Initiative was 
created with the vision of enhancing the position of Europe in biomedical research. One of 
the objectives was to invest in precompetitive collaborations between industry and academic 
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partners Dr Stensbøl invited the European pharmaceutical companies who were active in 
psychiatry in 2008 to Lundbeck. The companies agreed on four key deliverables that they 
expected from the collaboration: (i) identification of transcriptomic markers/blood markers 
relevant for segmentation and stratification of patient groups; (ii) development of preclinical 
models that translate systems biology of disease; (iii) development of animal models that 
translate to clinical endpoints; (iv) development of functional imaging and molecular 
neuroimaging paradigms for drug discovery in depression and schizophrenia (SCZ). In terms 
of intellectual property, Dr Stensbøl stated: ‘what we were not willing to share 5 years ago 
we are definitely willing to share today’. Academic research groups could apply to become 
part of the consortium and several academic groups were selected led by Shitij Kapur at 
Kings College London. Thereby, the NEWMEDS consortium was born under the Innovative 
Medicines Initiative umbrella in 2009. The partners of the NEWMEDS consortium agreed 
that the three major bottlenecks in the field were as follows:(i) lack of relevant disease 
models; (ii) lack of tools and tests in healthy volunteers to provide early indications of 
efficacy; (iii) the reliance of clinical trials on Diagnostic and statistical manual of mental 
disorders, 4th ed. (DSM-IV) and the heterogeneous groups of patients this resulted in. To 
address these challenges in the field, 11 work packages were outlined. Each work package 
was assigned an industry and an academic lead, which proved to be a good strategy because 
it forced the industry partners to take part in leading the work.
Initially, 14 animal models of SCZ were run through proteomic markers, but this approach 
was abandoned quickly. However, a smaller private–public partnership, of which Lundbeck 
was a part of, had generated three copy number variant (CNV) mouse models and these were 
shared within the NEWMEDS consortium.
Three successful outcomes of NEWMEDS that one partner could not have obtained on their 
own are (i) the clinical trial database with data from 29 placebo-controlled SCZ trials with 
23 000 patients. Evaluation of these data showed that data can be analyzed already after 4 
weeks instead of 6 weeks and that the placebo effect is lower in women than in men. (ii) 
Testing of cognition battery across species and sites. (iii) Advanced understanding of CNV 
biology partly through cognitive tests of deCODE CNV patients.
The CNV mice will be commercially available through a vendor.
Dr Oluf Borbye Pedersen (University of Copenhagen) – the gut microbiota and the impact 
on human health (reported by Laura Huckins)
Dr Pedersen stated that we might think of humans as ‘supra-organisms’, with two major 
genomes: the human genome and the microbiome (defined as the collective genomics of 
bacteria). Unlike the human genome, the structural configuration of the microbiome changes 
often. The largest reservoir of bacteria in humans is the gut, containing roughly 1–2 kg. Gut 
bacteria may be subdivided into six major phyla, and serve a variety of functions, including 
metabolic function, modulation of gut nutrient sensing, and conferring gut immunity.
The microbiome plays a role early in life as microbial components pass to the fetus through 
the placenta and amniotic fluid. During natural vaginal birth, the baby is further colonized 
with bacteria, for example lactobacillus, from the mother’s vagina and feces, a process that 
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is vital for normal immune system development. Microbiotic interaction between mother 
and child continues beyond birth, as breast milk increases DNA methylation and gene 
transcription rates, and has long-term effects on metabolic target genes.
The microbiome seems to play a role in psychiatric symptoms and disorders, and may act on 
a microbiome–gut–brain axis of communication, regulating anxiety, mood, cognition, and 
pain (Montiel-Castro et al., 2013). Further, there is epidemiological evidence suggesting that 
a severe infection during pregnancy increases the risk of a child developing autism spectrum 
disorder (ASD), which has been supported in mouse models. Notably, treatment with a 
serum metabolite could cure the disorder and reduce ASD-like symptoms in mice.
Pedersen also briefly discussed the effects of antibiotic use on gut microbiota, warning that 
the use of antibiotics leads to a microbial profile with increased capacity to extract energy 
from food. Further, antibiotic use in early childhood increased the risk of childhood obesity 
(Cho et al., 2012; Liou and Turnbaugh, 2012).
New DNA methods may hold the key to understanding more about the microbiome. The 
MetaHit project (Li et al., 2014) aims to establish a reference catalog of bacterial genes, 
mapping these to individual bacterial genomes and to cluster these into Meta Genome Units. 
To date, this project has identified in excess of 10 million genes, only ~ 10% of which may 
be mapped to known genomes. A MetaHit study of 292 individuals found that individuals 
low in ‘richness’ had increased lipids, weight, and number of proinflammatory bacterial 
species. Further, roughly one-fourth (40%) of the patients showed a severe reduction of gut 
microbiota and experienced a significant increase in disorders (Le Chatelier et al., 2013).
Pedersen discussed briefly the idea of gut bacteriotherapy, arguing that, along with 
probiotics and a healthy diet, there may be further bioactive bacterial compounds with 
therapeutic or disease-preventing effects. To exploit this fully, we need proof that the altered 
bacteria truly cause the disorders as well as novel preclinical models to test the efficacies of 
bacteriotherapy.
A question was posed on the potential effect of saccharine use on gut flora and on insulin 
resistance (Suez et al., 2014). Pedersen noted that this study does observe a major change in 
microbiota because of saccharine use and that this effect is validated in a rodent model. Four 
of seven human volunteers also became very glucose intolerant and showed a large change 
in flora. When stool from these patients was transplanted into mice, the effect was 
reproduced. This implies that we can assume that saccharine use at this level may induce 
severe glucose intolerance. However, levels of saccharine use studied in this paper are the 
maximum FDA-approved levels and likely to far exceed normal daily use.
Dr Preben Bo Mortensen (University of Aarhus, Denmark) – epidemiology in psychiatric 
genetics: putting the E into G × E (reported by Zuzanna Misiewicz)
Dr Preben Bo Mortensen (University of Aarhus, Denmark) presented his talk on the Danish 
total national birth cohort study called ‘The Initiative for Integrative Psychiatric Research’ 
Project – iPSYCH.
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The iPSYCH project studied five specific mental disorders: SCZ, bipolar disorder (BD), 
autism, attention-deficit hyperactivity disorder (ADHD), and depression. The main goal of 
the project is to identify the causes, both genetic and environmental, underlying the above-
mentioned disorders, to offer more personalized treatment to patients.
Dr Mortensen began his presentation by reminiscing about Danish psychiatrist Erik 
Strömgren. In the 1920s, Strömgren conducted a survey of mental illnesses on Bornholm, 
which is the home island of Mortensen. As one of the first psychiatrists, Strömgren realized 
the ideal conditions for research on epidemiology of genetic disorders in a geographically 
isolated population, but more importantly, a population built on open-mindedness and trust 
(Strömgren, 1982). Almost 40 years later, an initiative to create an electronic database, the 
nationwide Psychiatric Central Register, was brought to life by Annalise Dupont. By 
creating the database, she laid a foundation for the intertwined relationship between genetic 
and epidemiology studies in Denmark and, therefore, also the iPSYCH project (Mors et al., 
2011).
The iPSYCH project uses data on Danes born after 1955, with a specific subcohort of people 
born since 1981, from which neonatal dried blood spots are available, providing information 
on genetic, epigenetic, and other biomarkers. The retrieval of the samples as well as DNA 
amplification of the initial 80–85 000 cases and controls has already been completed and 
currently large-scale exome sequencing is taking place.
In his presentation, Dr Mortensen highlighted the specific ideas of the iPSYCH project, such 
as the integration of epidemiological, genetic, and experimental studies not only within a 
single disease but also between them. Furthermore, he spoke on the strong connections 
between numerous nationwide registers existing in Denmark, allowing the researcher to use 
the full potential of the data by being able to follow the patients and controls over time 
(Schmidt et al., 2014). Despite the impressive advantages, the iPSYCH project also presents 
some drawbacks: only clinical diagnoses of patients are available and no further phenotypic 
data can be collected as there is no possibility of recontacting the patient. As Mette Ebbesen 
(Aarhus University), a member of the Ethical Advisory Group for iPSYCH project, pointed 
out in the discussion following the presentation, autonomy of the patients is respected and 
the initial consent provided by the parents at the child’s birth can later be withdrawn.
Subsequently, Mortensen presented examples of how the collected data can be used. One 
such example was a study carried out by Borglum et al. (2014), in which a GWAS of 
maternal cytomegalovirus infection suggested a new SCZ locus (Borglum et al., 2014). The 
study analyzed all individuals born in Denmark after 1981 and diagnosed with the disease. 
Furthermore, Mortensen introduced a new study (VIA 7) of ~ 600 7-year-old children, either 
of parents with SCZ or BD, and controls. Elaborate neuropsychological information is 
available on all of those 600 children. This study will enable us to identify specific 
endophenotypes or indicators of vulnerability for the above-mentioned diseases and, 
therefore, also to develop methods of early intervention and prevention.
Aas et al. Page 9
Psychiatr Genet. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In conclusion, as shown by Dr Mortensen, the many dimensions of iPSYCH offer great 
opportunities for research as environmental factors and epidemiological information 
significantly contribute toward the risk of mental disorders.
The use of genetics to study functions and dysfunctions of the brain – speaker: Dr Kári 
Stefánsson (reported by Martin Tesli)
Dr Kári Stefánsson (deCODE genetics) discussed how molecular genetics can be used to 
increase our knowledge of the workings of the brain. He presented some examples from his 
own research at deCODE genetics, where more than 135 000 individuals have been chip 
typed. Two main approaches have been particularly successful. The first is to submit a large 
number of Icelanders to genetic and cognitive testing to identify variants associated with 
various aspects of cognitive function. The other is to investigate the ways in which genetic 
risk variants for neuropsychiatric disorders influence cognition in healthy individuals. As 
examples of the latter method, he mentioned studies of SCZ, autism, and Alzheimer’s 
disease (AD). In one recent report, it was shown that CNVs conferring risk to SCZ and 
autism were associated with cognitive deficits in healthy individuals. In particular, control 
participants carrying a chromosome 15q11.2 deletion had a history of dyslexia and 
dyscalculia, in addition to alterations in brain structures similar to those observed in first-
episode psychosis and dyslexia (Stefánsson et al., 2014). Stefánsson suggested that these 
findings indicate that cognitive abnormalities might be an underlying mechanism in SCZ as 
well as a consequence of the disorder. He also presented recent findings linking genetic risk 
for SCZ and BD to creativity. For this purpose, his research group made use of the 
Psychiatric Genomics Consortium’s (PGC’s) available data on common sequence variants 
that predispose to these disorders. They found that polygenic risk scores (PRSs) on the basis 
of these data were significantly higher in unaffected writers, musicians, painters, dancers, 
and accomplished chess players than in matched control participants, but this was not true 
for 20 diseases chosen as negative controls. These findings are in line with previous reports 
from the Stefánsson group – for example, that a common variant in the nicotinic 
acetylcholine receptor gene cluster on chromosome 15q24 has an effect on smoking 
quantity, nicotine dependence, and the risk of smoking-related diseases (Thorgeirsson et al., 
2008).
Dr Michael Meaney (McGill University, Canada) – parental effects on the epigenome 
(reported by Kate Wolfe)
Dr Michael Meaney (McGill University, Canada) explores the mechanisms by which 
childhood experiences, particularly maternal care, can be biologically embedded in the form 
of epigenetic modification and have enduring effects across the lifespan.
Meaney began with an overview of his work with rodents, where he investigated natural 
individual differences in maternal licking/grooming (LG) behaviors and the hypothalamic–
pituitary–adrenal (HPA) axis response to stress. He found that offspring of high LG mothers 
showed increased expression of glucocorticoid receptors (GRs) in the hippocampus, 
resulting in tighter regulation of the HPA axis in response to stress. These differences can be 
reversed by cross-fostering of rat offspring, confirming that maternal care is driving the 
differential expression patterns beyond genomic-based inheritance (Weaver et al., 2004). 
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Further work was carried out to understand the biological underpinnings of the differential 
GR expression. Analysis of the GR gene led to identification of an exon 17 promoter 
sequence that was expressed at higher levels in the hippocampus of off-spring of high LG 
mothers. Sequencing of the exon 17 promoter indicated a perfect consensus sequence for 
transcription factor NGFI-A. Increased occupancy of NGFI-A at the exon 17 promoter was 
also observed in adult offspring of high LG mothers, again serving to increase GR 
expression and regulate the HPA response to stress (Meaney and Szyf, 2005).
The transgenerational impact of maternal care and influences on the glutaminergic signaling 
pathway were also explored. The ERα, which is expressed in the medial preoptic area, 
showed increased expression in high LG offspring and the offspring themselves became high 
LG mothers. The ERα1b promoter region was implicated as a key site for differential 
methylation, in particular, the region that binds to Stat5b transcription factor, which is 
known to regulate ERα expression (Champagne et al., 2006). Reduced methylation of the 
GRM1 gene, which encodes the type I metabotropic glutamate receptor (mGluR1), was 
found in the hippocampus of adult rodents raised by high LG mothers. Increased MGluR1 
mRNA and protein expression in these offspring serves to regulate the postsynaptic impact 
of glutamate (Bagot et al., 2012).
Meaney examined comparable processes in humans. Adult hippocampal postmortem tissue 
was acquired from suicide victims and controls and methylation at the ortholog of the rodent 
exon 17 promoter sequence, the exon 1f sequence, was analyzed. An increase in GR 
transcripts, including exon 1f, was found in the brain tissue of controls compared with 
suicide victims. When this was correlated with various measures of psychopathology, it was 
found that GR and exon 1f expression was only decreased in the brain tissue of suicide 
victims with a history of child abuse. As in the rodent model, this was associated with 
increased methylation of the exon 1f promoter, decreased NGFI-A transcription factor 
binding, and lower regulation of the HPA axis. This is supported by previous research, which 
has shown that children who have been maltreated show an increased HPA response to stress 
(McGowan et al., 2009).
Epigenetic changes were also examined as a function of early development across the whole 
genome. A birth cohort from Singapore was investigated for methylation status utilizing the 
Illumina 450k differential methylation array and information was gathered on various 
measures of maternal care. Brain-derived neurotrophic factor (BDNF) was explored as a 
candidate gene. For offspring with the rs6265met/met BDNF genotype, 10% of all variably 
methylated CpGs were associated with prepartum maternal anxiety scores. Subsequent brain 
imaging showed that CpGs associated with maternal anxiety in the met/met group were 
mostly associated with right amygdala volume, whereas in the hippocampus, the association 
was stronger for the other genotypes. This would suggest that there is genome-wide 
environment interaction on the methylome, which expresses itself in a regionally specific 
manner in the brain.
Dr Meaney concluded that longitudinal studies will be key to deciphering the complex 
interface DNA methylation forms for imprinting dynamic social factors, such as maternal 
care, on a reasonably fixed genome.
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Plenary panel session – pathways to therapy and prevention (reported by Monica Aas)
Raimund Buller (Lundbeck) described the industry perspective on pathway to therapy and 
prevention in psychiatry. Current antipsychotics mainly work on positive symptoms, 
targeting dopamine, not targeting cognitive and negative symptoms, which may be more 
related to the long-term outcome of these patients.
Steve Hyman (Broad Institute) emphasized that we lacked new molecular targets and 
mentioned the challenges in using the DSM gold standard for this purpose.
Dr Daniel Geschwind (University of California, Los Angeles) – integrative genomics and 
the neurobiology of autism spectrum disorders (reported by Monique van der Voet)
Professor Daniel Geschwind (University of California, Los Angeles) spoke about ASD and 
how to navigate the complex road from genes to function in a heterogeneous disorder. No 
major gene accounts for over 1% of autism and over 1000 genes are estimated to contribute 
toward ASD. Three major themes below were addressed in the talk:
Despite the etiological heterogeneity, is there a shared pathology in the 
autism spectrum disorder brain? If there is, is it specific?—The study of 
differential expression in ASD cortical regions showed a shared molecular pathology 
(Voineagu et al., 2011). Clustering based on the top-200 genes showed decreased expression 
of synaptic signaling genes and increased inflammatory pathway expression. The network 
structure was robust and reproducible; this provides strong evidence for convergent 
molecular abnormalities in ASD. For the last 3 years, the lab has worked to replicate the 
finding in a larger set of samples (113 autism/control brains) using RNAseq. A robust gene 
expression pattern is shared by 60% of autism cases, including a recurrent, rare genetic form 
of ASD (15q11-−q13 duplication). This for the first time defines one aspect of a shared 
molecular pathology of autism. His lab is now working on a cross-disorder analysis to test 
how the pattern is preserved in other datasets such as SCZ.
Pathology cannot be confused with causality. Do autism risk genes converge 
on specific pathways and how do they map on normal brain development?—
The ASD genes were mapped to cortical development using BrainSpan RNAseq data. Two 
coexpression modules were found that are highly enriched for rare de-novo variants 
(Parikshak et al., 2013). Fragile X mental retardation protein (FMRP) targets are specifically 
enriched in the modules, which confirms that FMRP may be connecting a variety of 
developmental processes (Iossifov et al., 2012). Microarray data from macaque show that 
the genes are specifically enriched in neurons of the superficial lamina. More specific data 
sets point to upper layer glutamatergic neurons. This is consistent with a cognitive science 
model that part of autism is a long-range disconnection of higher-order cortical association 
areas, which would be served by these superficial layers.
How can we begin to model autism in Vitro to develop therapeutics?—
Geschwind explained the importance of understanding functional processes that are modeled 
with fidelity in Vitro before beginning to knock genes out. Cultured primary human neural 
progenitor cells (phNPCs) from acute fetal brain were discussed. After 12 weeks of 
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differentiation, these phNPCs match cortical developmental periods up to late mid-fetal 
periods, with strongest correspondence to the transition between the ventricular zone or the 
sub-ventricular zone to subplate and inner cortical plate (Stein et al., 2014). Many functional 
protein modules are conserved and there is a strong recapitulation of in-vivo development. 
However, it has to be recognized that differentiated phNPCs constitute fairly immature 
synapses. Similar analyses of iPSCs showed considerable variability in neuronal 
differentiation and the iPSC-derived neurons were also very immature. To model late-onset 
brain disorders, the maturation process of these in-vitro neurons needs to be encouraged.
In summary, despite the genetic etiologic heterogeneity in autism, there seems to be some 
convergence. Network context can enable in-vitro and in-vivo modeling and ultimately drug 
discovery.
Symposia sessions
New data on the genetics of attention-deficit hyperactivity disorder (reported by Joanna 
Martin)
Dr Anders Børglum (Aarhus University, Denmark) presented a status report of ongoing 
GWAS analyses of Danish population ADHD cases and controls on behalf of the Integrative 
Psychiatric Research (iPSYCH) research group. This GWAS utilizes blood spot data from 
the Danish Newborn Screening Biobank, which is a unique resource for biological analyses. 
Using personal identification numbers, information from the Danish Psychiatric Central 
Research Register was used to identify n = 18 726 individuals diagnosed with ADHD and 
link them with their genetic data. A population control group of over 30 000 individuals 
screened for psychiatric problems was also selected. The samples are being genotyped on 
the PsychChip by the Broad Institute (USA), and the first data freeze consists of n = 4186 
ADHD cases and n = 5652 controls after standard PGC quality control procedures. The 
current GWAS included ~ 8.35 million SNPs after quality control (QC). No SNPs reached 
genome-wide significance, but some of the top hits included an SNP within the gene FGFR1 
on chromosome 8 and another SNP near the gene PGM2 (chromosome 4). Efforts are 
underway to genotype the remaining Danish ADHD samples and to integrate these data with 
the PGC ADHD sample. In addition, data for n = 3755 ASD samples are also available from 
the Danish Newborn Screening Biobank and a joint ADHD and ASD GWAS also showed no 
significant SNPs. These Danish samples are likely to represent a considerable contribution to 
future PGC analyses.
Dr Benjamin Neale (Massachusetts General Hospital, USA) reported the latest results of the 
GWAS meta-analysis of ADHD, which builds on previous samples (Neale et al., 2010) and 
now includes additional cases from the Danish iPSYCH study (see above) as well as self-
identified ADHD cases and controls from the 23andMe personal genomics company. The 
current total sample included in the latest meta-analysis consists of n = 14 840 cases and n = 
76 029 controls. Although one SNP passed the threshold for genetic association, the 
imputation score for this SNP was very low and it appeared to be an isolated signal in that 
locus; thus, it is likely to be a spurious result. However, the QQ plot showed inflation as 
would be expected under a polygenic architecture of ADHD. Neale then outlined a recent 
method that he developed with Dr Brendan Bulik-Sullivan (UNC School of Medicine, USA) 
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and colleagues that uses linkage disequilibrium (LD) score regression to distinguish the 
effects of population stratification from true polygenicity in GWAS of complex diseases 
such as psychiatric disorders (Bulik-Sullivan et al., 2015). This method estimates the 
heritability of disease from common SNPs and is computationally more efficient than the 
commonly used genome wide restricted maximum likelihood GREML approach (Yang et 
al., 2011) as it uses only the summary statistics of GWAS. The estimation of SNP 
heritability for ADHD using this method ranged from approximately 21 to 33% depending 
on the subset of the sample analyzed.
Dr Beth Wilmot (Oregon Health & Science University, USA) outlined some of the major 
issues of pathway analytic approaches to parsing the biology of a complex disorder such as 
ADHD, including the use of gene ontologies (GOs) to define pathways, and the complexities 
of mapping SNPs to genes. There are now many different pathway analytic algorithms and 
methods, which have different features, biases, and strengths. Wilmot presented data using 
six different methods that utilize individual genotype data in two samples: a German ADHD 
case–control sample (Hinney et al., 2011) and the first PGC ADHD meta-analysis sample 
(Neale et al., 2010). No biological pathways were found to be significant across all six 
methods and most pathways found to be nominally significant were only detected by one or 
two of the methods. However, the top pathways picked up by 3–5 of the methods in both of 
the samples included those related to potassium channels, FGFR2b ligand binding and 
activation, voltage-gated potassium channels, and synaptic vesicle trafficking. Wilmot 
stressed the importance of manually curated pathways and outlined plans to use imputed 
data and covariates, and include CNV data in future analyses.
Dr Jan Haavik (University of Bergen, Norway) presented data from several of his group’s 
recent studies using different methods to investigate the disease mechanisms of ADHD by 
examining candidate genes, which could lead to future treatments. CDH13 is a gene that 
codes for the brain-expressed protein T-cadherin and was first implicated in ADHD through 
linkage analyses (Zhou et al., 2008). Haavik and colleagues sequenced this gene in adults 
with ADHD (from the IMPACT sample), but found no strong effects, although they did find 
a decrease in serum levels in individuals with missense variants in this gene. One possible 
mechanism through which missense variants may affect protein function is by affecting the 
folding; indeed, studies of the three-dimensional structure of mutations in the TH protein 
confirm altered substrate specificity (Fossbakk et al., 2014). Using another approach, Haavik 
and colleagues suggest that mis-folded proteins (specifically, TPH1 and TPH2, other 
candidate ADHD genes) may be rescued through the use of pharmacological ‘chaperones’ 
(Calvo et al., 2010). Haavik stressed that multiple approaches using the latest statistical tools 
and methodology (e.g. biochemical studies, in-silico modeling, and molecular systems 
biology approaches) will be needed to understand the etiology of ADHD.
Dr Barbara Franke (Radboud University Medical Center, the Netherlands) concluded the 
session by also highlighting the importance of using multiple approaches in the study of 
ADHD and the collaborative contribution of population-based samples such as the iPSYCH 
Danish sample to the PGC ADHD sample. Franke pointed out that although we still do not 
have any genome-wide significant ‘hits’ for ADHD, the growing sample sizes present a 
useful opportunity for downstream analyses – for example, by examining the effect of 
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candidate pathways in relation to symptoms (Bralten et al., 2013). Franke also highlighted 
the importance of using multiple methods to study this complex condition – for example, by 
looking at delays in brain maturation using neuroimaging or by using knockout animal (e.g. 
zebrafish) models to study the effects of candidate risk genes.
Telomeres and telomerase in mood disorder: markers for risk and treatment? (reported by 
Claudia Pisanu)
Professor Catharina Lavebratt (Karolinska Institutet): telomeres prevent loss of genomic 
content during replication of linear DNA. Telomere length (TL) decreased with cellular age 
and the shortening rate is about 14–60 base pairs/year. However, this shortening is, to some 
extent, reversible through the telomerase enzyme, which is expressed in germ cells, stem 
cells, and undifferentiated leukocytes (thus in areas of neurogenesis). Telomeres are sensitive 
to reactive oxidative molecules produced by oxidative stress in the cell. In postmitotic cells, 
in which telomerase is not expressed, increased oxidative stress induced by inflammation or 
increased HPA-axis activity causes excessive telomere shortening. Excessively short 
telomeres induce necrosis/apoptosis and, as a result, cell loss and tissue dysfunction. Short 
leukocyte telomere length (LTL) has been related to higher mortality (Cawthon et al., 2003), 
age-related diseases, and psychological stress-related diseases, such as cerebrovascular 
diseases, cardiovascular diseases, type 2 diabetes, dementia, and depression (Shalev et al., 
2014; Verhoeven et al., 2014a). Genetic variation (Codd et al., 2013), DNA methylation in 
subtelomeric regions (Buxton et al., 2014), sex (Verhoeven et al., 2014a), and life style have 
been reported to influence variation in LTL. Inflammation, dysregulation of HPA axis, and 
autonomic stress have all been associated with shorter LTL in individuals with depression 
and anxiety (Révész et al., 2014). Professor Lavebratt also provided an overview of studies 
that associated LTL with psychiatric disorders. In particular, MDD (Verhoeven et al., 2014a) 
and a high number of depressive episodes in MDD and BD (Wolkowitz et al., 2011; 
Martinsson et al., 2013) have been associated with shorter LTL. Finally, some studies have 
proposed a telomere-protecting effect of psychotropic drugs (Wolkowitz et al., 2011; 
Martinsson et al., 2013).
Professor Brenda Penninx (VU University Medical Center) presented data from the 
Netherlands Study of Depression and Anxiety (NESDA), one of the largest studies to 
measure LTL in psychiatric patients (Verhoeven et al., 2014a). MDD is strongly associated 
with the onset of many different aging-related somatic conditions (Penninx et al., 2013). In 
this sense, LTL is a most interesting biomarker of cellular aging to investigate in MDD 
patients. The NESDA is a large naturalistic cohort study that recruited over 2900 
participants, including MDD patients, patients with anxiety, and healthy controls (Penninx et 
al., 2008). Determination of LTL with quantitative CR showed a negative correlation with 
age (P< 0.001) and a longer LTL in women (P <0.001). Compared with healthy controls, 
sociodemographic-adjusted LTL was shorter among MDD patients in remission (P= 0.014) 
and current MDD patients (P =0.012). Within MDD, severity and duration were associated 
with shorter LTL (Verhoeven et al., 2014a). However, late-life depression was not associated 
with shorter LTL (Schaakxs et al., 2015). Compared with healthy controls, LTL was shorter 
among patients with current anxiety, but not among patients with remitted anxiety 
(Verhoeven et al., 2015). Possible pathways linking MDD and telomere shortening include 
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chronic hyperactivity of the HPA axis, autonomic stress, and low-grade inflammation, 
especially when all these dysfunctions occur together (Révész et al., 2014). An important 
question is whether cellular aging can be reversed through a therapeutic intervention 
(Verhoeven et al., 2014b). Psychotropic medications did not seem to impact LTL in the 
NESDA cohort.
Yabin Wei (Karolinska Hospital) showed that long-term lithium treatment in BD has been 
associated with longer TL (Martinsson et al., 2013). Telomeres are maintained by the 
enzyme telomerase, which, in adult brain, is still expressed in the hippocampus. In murine 
studies, inhibition of hippocampal telomerase TERT subunit expression induced neuronal 
excitotoxicity, apoptosis, and depressive behavior (Zhou et al., 2011). The SNP rs2736100 
of the human TERT gene has been associated with TL in cohorts of healthy adults (Codd et 
al., 2013). Yabin Wei discussed the results from a recent study showing shorter telomeres, 
decreased TERT expression, and telomerase activity in the hippocampus of the Flinders 
Sensitive Line rats, a genetic rat model of depressive-like behavior (Wei et al., unpublished 
results) compared with the Flinders Resistant Line (Overstreet and Griebel, 2005). A 6-week 
lithium treatment increased TERT and telomerase activity, but not TL. The second part of 
this study was carried out in humans and showed that TL in DNA extracted from saliva is 
shortened in adults with depression without exposure to childhood adversity compared with 
controls. Moreover, rs2736100 was significantly associated with unipolar depression and 
with the number of depressive episodes in BD patients.
Professor Adolfo Sequeira (University of California Irvine) reported results supporting the 
involvement of stress response in psychiatric disorders. In particular, functioning of the HPA 
axis, expression of the enzyme spermidine/spermine N(1)-acetyltransferase 1 (SAT1), the 
rate-limiting enzyme in the catabolism of polyamines (Sequeira et al., 2006), and expression 
of metallothioneins (Sequeira et al., 2012) are all altered in psychiatric disorders. Moreover, 
shorter LTL has been associated with many diseases, suggesting reduced neuroprotection 
against the physiological effects of stress in psychiatric disorders. To elucidate possible 
regional differences in the brain of patients with psychiatric disorders and controls, TL was 
measured in five different brain regions in a sample of 40 individuals (Sequeira et al., 
unpublished results). The study confirmed that TL is not strongly correlated with age in the 
brain, but showed significant differences in TL across brain regions. In particular, MDD 
patients showed a significant decrease in TL, specifically in the hippocampus. Direct RNA 
analysis on the same patients using the NanoString platform suggested a possible role of GR 
and corticotropin-releasing hormone gene expression in stress responses through regulation 
of telomere maintenance gene expression.
Beyond Bonferroni: large-scale inference for complex disorders (reported by Laura 
Huckins)
Peter Visscher (University of Queensland) began the session by suggesting that we are now 
in a time beyond standard GWAS; we have more loci and far better estimates of effect sizes. 
Visscher suggests that it is time to adopt a new null hypothesis: that all variants affect all 
traits. The question then becomes not ‘Is there variance?’, but instead ‘Do we see 
significantly more variance than might be expected by chance?’
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Anders Dale (UCSD) proposes a new model that works with Visscher’s new null hypothesis, 
allowing for small ubiquitous effect sizes, implying that every SNP has at least a low 
association with the trait. This model is a straightforward bivariate and multivariate 
extension of Gaussian mixture modeling. When considering real data, we see that a standard 
model is unable to fit small effect sizes well. Conversely, a polygenic model effectively sets 
large effect sizes to zero. Dale’s proposed model accounts well for both types of effect sizes 
and is thus able to better model the true genetic architecture. Further, the model is able to 
model pleitropy, increase power for discovery, and may help to identify biological 
mechanisms.
Ole Andreassen (University of Oslo) spoke on ‘Leveraging Pleiotropy to Improve Gene 
Discovery and Effect Size Estimation’. Pleiotropy may be leveraged to aid gene discovery, 
boost study power, and increase the replication rate. Andreassen outlines a method using 
conjunctional false discovery rate (FDR), rather than conditional FDR, essentially using 
variants conditioned on one trait to discover variants in a second trait. For example, 
replication rates in SCZ may be increased by conditioning on blood lipids (Andreassen et 
al., 2013), triglycerides (Andreassen et al., 2013), multiple sclerosis (Andreassen et al., 
2015), and college attainment (Lencz et al., 2014). However, this is not a global effect; for 
example, conditioning on ulcerative colitis does not improve SCZ replication rates, implying 
that there must be some biological link between disorders to boost discovery or replication.
Sang Hong Lee (University of Queensland) discussed combined analysis of psychiatric 
disorders using two new programs, STGBLUP and MTGBLUP (single/multitrait genomic 
best linear unbiased prediction), which use genotypes to construct a linear mixed model and 
thus estimate SNP effects. PGC cross-disorder data were used as a discovery set, whereas 
independent SCZ, BD, and MDD samples were used as a validation. After excluding any 
related individuals, this validation set included ~ 60 k individuals. Genetic heterogeneity 
between data sets was tested using a principal components analysis (PCA) and a genetic 
variance analysis.
Prediction accuracy in the validation set was better when using a multitrait approach. Risk 
prediction scores were low (ranging from 0.2 for SCZ to < 0.1 for MDD), although 
stratifying on SNPs involved in central nervous system (CNS) improved SCZ and BD values 
slightly. This filtering approach improves risk prediction accuracy equivalent to adding 5000 
samples to the SCZ and BD studies or 10 000 to the MDD study.
Andrew Schork (UCSD) discussed an attempt to identify functional categories that are more 
likely to contain polygenic effects. All SNPs in the 1000 genomes project were annotated as 
5′UTR, exon, intron, 3′UTR, and intergenic (Schork et al., 2013). As LD-genotyped SNPs 
may act as proxies for potentially causal variants, LD-informed scoring was used to update 
these categories if necessary. This method was tested across 14 GWAS, all of which were 
subjected to stratification because of polygenic effects. The 5′UTR annotation was 
significantly inflated among all of these studies, whereas the intergenic region was always 
underinflated. The functional annotation also affected the likelihood of replication; at a 10−3 
cut-off, only 25% of intergenic variants replicated. However, replication increased to 75% 
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for 5′ UTR SNPs using the same cut-off. This implies that differences in enrichment 
according to functional annotation may be a true finding.
Shared genetics between depression and comorbid physical conditions (reported by 
Lynsey Hall)
Following a strong lead: functional investigation of genome-wide association 
study signals for schizophrenia (reported by Jose Estrada)—As the number of 
candidate genes increases with each published GWAS, researchers are now using a number 
of techniques to assign function to individual candidates.
Dr Nick Bray (Kings College London, UK) presented work that looks at identifying the 
direct effects of risk alleles on gene output utilizing an allele-specific discrimination assay. 
Specifically, deviations from a 1 : 1 expression ratio of the risk versus nonrisk allele in 
heterozygous individuals detect those variants that affect gene output. To control for indirect 
effects, homozygotes for each allele are analyzed and must have a 1 : 1 expression ratio. 
ZNF804A analysis shows deviation from risk versus nonrisk allele expression in second-
trimester fetal brain tissue, but not first-trimester or adult brain. NT5C2 and CACNA1C 
analysis identified gene expression distortions within the PFC and the cerebellum, 
respectively.
Dr Matt Hill’s (Cardiff University, UK) research interest lies in understanding the 
downstream functional consequence of risk variants that affect gene expression. Using two 
neural progenitor cell (NPC) lines in combination with small interfering RNA to knock 
down target gene expression, he can then assay for downstream effects using microarrays 
and GO analysis. Hill’s initial investigations focused on three genes that are downregulated 
in SCZ and regulate gene output: ZNF804A, a member of the zinc finger protein family 
capable of binding RNA and DNA; miR-137, a microRNA that potentially targets and 
represses many genes; and the transcription factor 4 (TCF4). Knockdown of ZNF804A in 
NPCs suggests that it regulates 154 candidate genes. GO analysis shows many of these 
genes to be involved with cell adhesion. miR-137 knockdown analysis shows a smaller 
number of candidates, but focuses predominantly on genes involved in neurodifferentiation. 
TCF4 knockdown analysis indicates a number of candidates involved in cell cycle 
regulation.
Dr Emmanuel Schwarz (Central Institute of Mental Health Mannheim, Germany) is 
investigating neural mechanisms linked to GWAS candidates in SCZ using functional MRI 
and several cognitive endophenotypes associated with SCZ participants and their first-degree 
relatives. Schwarz reports that individuals with the SCZ GWAS-associated risk allele for 
neuregulin1 also show dysfunction in the ventral striatum when completing a reward/
salience task. Individuals with the GWAS-associated risk allele for ZNF804A completing 
the two back working memory task show abnormal dorsal lateral PFC–hippocampal 
connectivity. Individuals with a risk allele for SCGN within the GWAS-associated major 
histocompatibility complex (MHC) locus show defects related to hippocampal volume/
connectivity. Individuals with a risk allele for CACNA1C show defects in hippocampus and 
subgenual anterior cingulate activity when completing a face recognition/episodic memory 
task.
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Dr Andrew McIntosh (University of Edinburgh, UK) is investigating the overlap between 
polygenic psychiatric diseases (SCZ, alcohol abuse, and autism) and cognitive ability – 
which itself is a polygenic phenotype. Negative correlations with the three disorders and the 
IQ score have been observed; this is considered to be a genetic association based on twin 
and bivariate studies. PRSs for SCZ, alcohol abuse, and autism were generated in 
population-based samples with corresponding GWAS and cognitive data. PCA was utilized 
to identify correlations between the various cognitive tests and the polygenic score for each 
disorder. PRSs for SCZ and alcohol abuse correlated negatively with cognitive ability. 
However, in the case of autism, PRSs were associated positively with cognitive ability.
The investigators of this panel are at the forefront of assigning molecular and cellular, 
spatial, temporal, and cognitive function to GWAS-identified candidate genes.
New Findings from the Enhancing NeuroImaging Genetics through Meta-
Analysis (ENIGMA) Consortium (reported by Gabriëlla Blokland)—Dr Derrek 
Hibar (Imaging Genetics Center, University of Southern California, USA) introduced the 
Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium, which 
aims to learn more about psychiatric disorders by studying changes in the brain and linking 
those to genetic variation. ENIGMA is a collaborative network of researchers working 
together on a range of large-scale studies that integrate data from many institutions 
worldwide. The ENIGMA consortium currently encompasses 185 institutions, with over 300 
investigators from 33 countries. ENIGMA is organized into Working Groups that tackle 
questions in neuroscience, genetics, and medicine. Active working groups include those on 
ADHD, autism, addiction, HIV, MDD, obsessive–compulsive disorder, BD, SCZ, and 
diffusion tensor imaging (DTI). Currently, these groups are working on finding the best 
endophenotypes – that is, which brain regions are the best biomarkers for distinguishing 
patients from controls, but ultimately the goal is to run GWAS. Results from the ENIGMA1 
pilot project, a GWAS meta-analysis of hippocampal volume and intracranial volume (ICV) 
in a combined discovery and replication data set of n≈21 000, were published in 2012 (Stein 
et al., 2012). Crucial to the success of this study – and of ENIGMA – is that MRI processing 
and genetic analysis were carried out at each site using a set protocol, after which each site 
submitted genetic association statistics for meta-analysis. Identical data-processing across 
sites and strict QC make it less likely that the lack of effect is because of noise introduced by 
merging heterogeneous data sets. One genetic variant, located between HRK and FBXW8, 
explained a significant proportion of the variance in hippocampal volume; it was associated 
with a 1.2% decrease in the average hippocampus volume per risk allele. In addition, three 
significant loci for ICV were identified. ENIGMA joined forces with the CHARGE 
consortium (Bis et al., 2012) to replicate each other’s hits and found that the top five variants 
from each structure were exactly the same. Interestingly, this study did not confirm many of 
the classical candidate genes for brain structure, such as BDNF and APOE.
Dr Sarah Medland (QIMR Berghofer Medical Research Institute, Australia) discussed 
ENIGMA’s current main project, a GWAS of seven subcortical brain structures 
(ENIGMA2), in a discovery sample of n = 13 688 (30 cohorts) and a replication sample of n 
= 15 748 (18 cohorts). Across phenotypes, five genome-wide significant loci (P < 7.1 × 
10−9) were identified and the replication added another five loci. Significant loci were 
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associated with 0.5–1.5% differences in volume per risk allele, explaining 0.2–0.52% of the 
phenotypic variance. Effect sizes are no greater for imaging endophenotypes than for any 
other complex physical trait. This challenges the original assumption that endophenotype 
effect sizes would be greater than disease phenotype effect sizes because they are closer to 
the biology. According to GCTA, full GWAS results explained 7–15% of the phenotypic 
variance in the subcortical volumes after correction for covariates. Importantly, the 
ENIGMA1 hits for hippocampus and ICV were supported, and the associations did not 
disappear when excluding all patients from the analyses. Most hits were structure specific; 
there was not a lot of genetic overlap because of the orthogonalizing effect of correction for 
ICV. Multivariate cross-phenotype analyses using the TATES method (van der Sluis et al., 
2013) confirmed the univariate results, but no additional loci reached genome-wide 
significance. At a multiple-phenotype-corrected genome-wide significance threshold, no 
significant variants were identified for the thalamus, pallidum, amygdala, caudate nucleus, 
or NAc, although several strong signals for the amygdala and NAc will likely reach 
significance with increased power. However, four genome-wide significant variants were 
identified for the putamen (which were also replicated in the CHARGE consortium data). 
One of the loci identified is 14q22, a region with many epigenetic markers, which houses the 
KTN1 gene. KTN1 codes for kinectin, a protein found in the dendrites (but not axons) of 
neurons. Gene expression differences for KTN1 in frontal and putamen brain tissue confirm 
localization of the GWAS signal in KTN1 and developmental expression data indicate that 
these effects likely begin in the late prenatal stage and continue through adulthood. Finally, 
support for the validity of this finding comes from an animal study, in which increased 
KTN1 expression in the striatum of 31 isogenic BXD strains of mice was associated with 
larger striatal volumes.
Dr Ole Andreassen (University of Oslo, Norway) leads the ENIGMA Bipolar Disorder 
working group. He pointed out that many of the brain effects in psychiatric disorders are 
very subtle; thus, we need large samples to identify them. Although ENIGMA was initially 
formed with the goal of undertaking imaging genetics, it has evolved into a consortium that 
also analyzes patient scans using the same processing pipeline so as to be able to identify the 
best endophenotypes for various neuropsychiatric disorders. In a BD case–control meta-
analysis of the seven subcortical brain volumes, accounting for age, sex, and ICV, the largest 
effects of BD were detected in the hippocampus, thalamus, and amygdala (volume 
reductions), and lateral ventricles (increase). No striking differences were found between BD 
subtypes I and II, although hippocampus and amygdala volumes were significantly different. 
There was a highly significant effect of lithium use on the thalamus and to a lesser extent on 
the hippocampus. This is likely not an effect of treatment responsiveness because most 
patients included in these studies respond quite well to medication. Similar patterns of 
subcortical abnormalities were observed in SCZ (working group led by Jessica Turner) and 
MDD(working group led by Lianne Schmaal). In a meta-analysis of more than 2000 SCZ 
patients and more than 2500 controls, the most striking finding was a reduction in 
hippocampal volume, followed by significant volume decreases in the amygdala, thalamus, 
and NAc. There seems to be an effect of chlorpromazine dose equivalent, age of onset, and 
duration of illness in SCZ (i.e. abnormalities are much less severe in first-episode than in 
chronic patients). Similarly, in the MDD data (n≈9000 cases and n≈7000 controls), effects 
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are partly driven by the reoccurrence rate and age of onset, where higher numbers of major 
depressive episodes and/or earlier onset are associated with smaller subcortical volumes. 
Interestingly, ADHD (n≈1500 cases and n≈1500 controls; working group led by Martine 
Hoogman) is associated with strong reductions in the NAc, amygdala, caudate, and putamen, 
but not the hippocampus, indicating a different neural mechanism in this disorder.
Dr Neda Jahanshad (Imaging Genetics Center, University of Southern California, USA) 
discussed multisite genetic analysis of DTI scans by the ENIGMADTI working group. DTI 
allows us to study the brain’s white matter, the bundles of myelinated axons connecting 
cortical regions. This technique makes use of the fact that the diffusion of water molecules is 
not uniform across the brain because of anatomical constraints and the myelin that surrounds 
the axons. Postmortem research has shown reduced myelin content in the brains of 
psychiatric patients and this is reflected in a DTI-derived measure called fractional 
anisotropy (FA). However, additional technical challenges are associated with combining 
DTI data from different sites, such as a greater number of artifacts, and differing numbers of 
gradient directions, which affect the power to accurately measure diffusion. The ENIGMA-
DTI group attempts to address some of these issues and asks whether it is possible to 
combine DTI data from multiple sites and obtain consistent measures. Using a streamlined 
processing and quality control pipeline, Kochunov and colleagues (Jahanshad et al., 2013; 
Kochunov et al., 2014) processed DTI scans from five family-based cohorts and assessed the 
heritability of tract-based measures of FA. A few tracts were not reliable or not heritable 
because of size or registration problems; thus, these were not taken forward to GWAS. The 
GWAS study focused on the comparison of meta-analysis pooling methods: sample size 
based versus standard error based. Irrespective of the pooling method, the findings were 
highly similar. Furthermore, to investigate whether mega-analysis is more powerful than 
meta-analysis, they compared the two methods for 15 candidate SNPs previously shown to 
have associations with DTI measures, including a BDNF variant, which was significantly 
associated with FA in two of the five cohorts. There were no significant differences in the 
results of the two methods; however, standard errors for each SNP were greater with mega-
analysis than with meta-analysis, indicating that meta-analysis can deal better with some of 
the intersite heterogeneity.
A small window to psychiatric genetics in China (reported by Jie Song)
Dr Chunyu Liu (University of Illinois at Chicago, USA) opened the session by stressing the 
global diversity taskforce in psychiatric genetic studies and the aims to promote psychiatric 
genetic research in developing countries. So far, there are nine psychiatric GWAS in China 
involving dozens of sites. They call for support from international communities and 
collaboration, hopefully to turn a small window to an opening door.
Dr Hong Xue (Hong Kong University of Science and Technology, China) reviewed work on 
the function of GABRB2 in SCZ. Their group first reported the association between SCZ 
and SNPs in GABRB2 (Lo et al., 2004; Petryshen et al., 2005; Lo et al., 2007a). Later, they 
reported the functional impacts of SCZ-associated noncoding SNPs in GABRB2 at both 
mRNA and protein levels (Zhao et al., 2006, 2009). They further showed GABRB2 to be 
under strong positive selection (Lo et al., 2007b), active recombination (Ng et al., 2010), and 
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genomic imprinting (Pun et al., 2011), likely contributed by a human lineage-specific 
insertion of an AluY transposable element. Moreover, epigenetic regulation of GABRB2 
showed its developmental control and disruption in SCZ (Zhao et al., 2012). Most recently, 
they extended GABRB2 association to social cognitions (Tsang et al., 2013). Their work has 
improved the current understanding of SCZ and relevant intermediate phenotypes as related 
to GABRB2.
Dr Yin Yao (National Institutes of Health, USA) presented a study using functional MRI 
data to investigate the compensatory plasticity mechanism in healthy siblings of treatment-
resistant SCZ patients. Compared with SCZ patients, healthy siblings presented connectivity 
variations involving greater than 60% of the whole brain regions, whereas they showed 
modest connectivity alterations in small brain regions in contrast with healthy controls. 
However, SCZ patients have greater than 40% comparable brain regions that showed 
connectivity variations compared with healthy controls and those brain regions partially 
overlapped with that of a sibling/case study. Moreover, the altered connectivity features 
numbers between cases and controls that are smaller than those between cases and siblings. 
Their study indicated that connectivity variations in SCZ patients and their healthy siblings 
are in different scales or even opposite directions, which may be a form of virtuous 
compensatory regulation preventing the healthy siblings from becoming ill.
Dr Chao Chen (Central South University, China) presented studies on the regulatory network 
inferences in psychiatric disorders from different levels. They applied weighted gene 
coexpression network analysis (WGCNA) to gene expression microarray data, and found 
that NOTCH2 in network M1A and MT1X in network M3A were associated with SCZ and 
BD across two brain regions. Moreover, their study on DNA methylation suggested four 
novel candidate genes, PIK3R1, BTN3A3, NHLH1, and SLC16A7, for the investigation of 
neuropsychiatric diseases.
Dr Miaoxin Li (University of Hong Kong, China) introduced gene-based and pathway-based 
methods (http://statgenpro.psychiatry.hku.hk/limx/kgg/) to efficiently reanalyze GWAS data 
of psychiatric diseases. Using the data released by the PGC, their knowledge-based 
secondary analyses in an early meta-analysis of SCZ (Ripke et al., 2013) showed a number 
of additional interesting genes and pathways that were successfully replicated by a larger 
meta-analysis of SCZ (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014). The same genes showed interesting coexpression patterns in brain–tissue 
networks. Still, validation in an independent dataset is necessary. This speaker also 
mentioned that the use of the knowledge-based mining system for GWAS to carry out set-
based association analysis for intergenic regions is under development and that epigenomic 
markers are being used to define functional regions for set-based association analysis. Their 
study supported the polygenic model of major psychiatric disorders, and it showed that 
introducing genomic knowledge into conventional statistical genetic analysis is a powerful 
strategy to characterize risk genes of complex diseases.
Dr Pak Sham (University of Hong Kong, China) closed the session by stating that as a 
country with the largest population, China should contribute more toward psychiatric genetic 
studies. With more than 100 risk genes identified for SCZ, studies on what the risk genes 
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share in common and how they work together may be one of the main directions in the 
following years. From a clinical perspective, studying the different endophenotypes may 
help investigate the complicated etiology of SCZ.
Family genome sequencing in bipolar disorder (reported by Alex Shaw)
Dr Seth Ament (Institute for Systems Biology, USA) discussed sequencing efforts in BD 
using densely affected pedigrees. So far, 215 affected individuals, 152 of their unaffected 
relatives, and more than 1000 population controls have been whole genome sequenced. 
Although initially he had expected to find highly penetrant ‘pseudo-Mendelian’ variants 
within the pedigrees, analyses carried out so far have overwhelmingly pointed to an 
oligogenic or a polygenic structure. Focusing on genes that are recurrently mutated in BD 
pedigrees, but not control pedigrees, a number of pathways were found to be enriched 
including neuronal excitability, GABA receptors, and voltage-gated calcium channels. 
Examining the contribution of rare variants [< 5% minor allele frequency (MAF)] overall 
using elastic net regression, he developed a rare variant burden polygenic score and found 
that rare variants in 140 genes explained several percent of the risk for BD. Another 
recurring theme is that rare risk variants are overwhelmingly found in gene-regulatory 
regions rather than coding regions. Accordingly, he focused on identifying transcriptional 
networks that rare variants are likely to disrupt collectively. By combining gene expression 
data from BrainSpan (http://www.brainspan.org) with DNAse I hypersensitivity footprinting 
data from ENCODE, he constructed a brain transcriptional regulatory network. Using mixed 
models to test for the association between rare variants within predicted transcription factor-
binding sites (~7000/individual), he found that these explained a substantial fraction of the 
heritability of BD.
Dr Maja Bucan (University of Pennsylvania, USA) discussed sequencing of a large Old 
Oder Amish pedigree of 700 individuals. She outlined some of the advantages of studying 
BD within the pedigree, including the uniformity of the environment and extensive medical 
records available. She calculated relatedness using SNP data (from ~ 400 individuals) and 
performed whole-genome sequencing of trios based around distantly related individuals. She 
used a combination of methods, including linkage within nuclear families on the basis of 
microsatellite data, phasing, and imputation, and family-based association testing. Although 
a number of common, potentially damaging SNPs were identified that were absent in the 
general population, no genome-wide significant association was identified. Turning to 
linkage analysis, four peaks were identified with Log of the Odds (LOD) more than 2.8 and 
family-based association testing was performed within these regions. Although many 
variants under the peaks are putatively damaging and are novel or rare, there were no 
genome-wide significant associations at the gene level. These results suggest that linkage 
peaks mark clusters of small-effect to moderate-effect variation, again underscoring the 
polygenicity and heterogeneity of BD heritability, even within a relatively genetically 
homogenous population. The speaker raised the need to enrich phenotypic data by including 
non-psychiatric comorbidities where known.
Dr William Byerley (University of California, San Francisco, USA) examined a genetic 
isolate on the island of Palau, Micronesia, that included 203 psychotic cases, 221 unaffected 
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relatives, and 125 controls who were genotyped by an SNP chip. The psychotic cases had a 
range of diagnoses, including SCZ, probable SCZ, and schizoaffective disorder, depressed or 
bipolar type. On carrying out analyses for regions of homozygosity, there was minimal 
evidence for highly penetrant recessive or common recessive alleles. Whole-genome 
sequencing was performed on 26 individuals. Variants were filtered to determine putatively 
damaging missense variation. After filtering, variants in two genes were identified: PCDH10 
and RAB33B, with variants ~ 6 Mb apart on the same haplotype. Byerley examined the 
presence of variants in these genes in other Palauan families and other datasets – SCZ trios 
and unrelated individuals – and found that they were very rare. It is likely that much larger 
sample sizes will be necessary to detect the effects of such very rare damaging variations at 
the individual gene level (Zuk et al., 2014).
Dr Tadafumi Kato (RIKEN, Japan) presented his work in exome sequencing of BD trios. 
Fifty-nine probands and their parents were sequenced including 28 probands with a first-
degree relative with the disorder and the remainder with an apparently sporadic disorder. 
This design allowed the stratification of discovered variation into transmitted and 
nontransmitted categories, and the examination of whether any genetic liability was specific 
to one of these modes. A GO enrichment analysis was carried out, with ‘calcium ion 
binding’ identified as a top hit, consistent with pathway analysis within GWAS and previous 
mechanistic studies showing elevated levels of calcium in blood cells (Kato et al., 2003). 
The specificity of these categories to BD was confirmed using healthy siblings of patients 
with ASD and by simulation with synonymous mutations, which are not expected to affect 
protein function. On comparing the transmitted versus nontransmitted variants, no 
significant difference was found in the number of damaging or nonsense mutations; 
however, there was no complete overlap between GO terms enriched in transmitted and 
nontransmitted variants.
In discussion, Dr Peter Zandi (Johns Hopkins, USA) raised the question of the value of 
performing family studies, given that ‘pseudo Mendelian’ variants have largely not been 
identified in BD as originally anticipated. The speakers of the session raised the point that 
family studies capture more of a range in phenotypes and comorbidities than case–control 
studies, which, by design, target only individuals with a definite diagnosis and control 
individuals without a history of psychiatric illness. Dr Bucan raised the point that families 
also have a longitudinal value, in that information on individuals has often been collected 
over a number of years and individuals can be followed up. Dr Ament pointed out that 
individuals in multiply affected families often have a very high genetic load, an enrichment 
that is inherently valuable when attempting to identify genetic factors across the spectrum of 
allele frequencies.
The application of isolated populations in the identification of rare risk variants for 
psychiatric disorders (reported by Erik Loken)
Dr Hreinn Stefansson (deCODE genetics) reported findings on CNVs conferring the risk of 
autism or SCZ and their effect on cognition in Icelandic control samples (Stefánsson et al., 
2014). He presented data that fecundity was impaired in carriers of 16p11.2 deletions. Data 
in 41 643 trios also suggested that more high-impact CNVs have a higher proportion of de-
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novo origins, for example over 80% of 16p11.2 deletions were de novo, but less than 20% 
were for 16p13.1 duplications. Carriers of the 15q11.2 deletion were shown to have an 
increase in the volume of the corpus callosum. Dr Stefansson explained that studying these 
neuropsychiatric CNVs in normal control patients might be an entry point into the 
mechanisms of brain function and dysfunction. He drew parallels between relatives of SCZ 
patients also having cognitive deficits that were partly independent of disease status and the 
incomplete penetrance of the CNVs. In the future, he plans to use functional MRI to move 
beyond structure and define the neural systems affected by CNVs.
Dr Aarno Palotie (University of Helsinki) reported on data from studies in the Finnish 
population. The advantages of the Finnish population for genetic studies are that it had a 
small number of founders, very low immigration, linguistic cultural isolation, and a rapid 
population expansion with multiple bottlenecks in the 16th century. Dr Palotie studied SNPs 
in 36 262 Finns and found loss-of-function (Lof) variants in LPA that are more common in 
the Finnish population and exerted a cardioprotective effect (Lim et al., 2014). He extended 
this methodology to neuropsychiatric disease and studied 256 Lof variants in 7728 Finnish 
exomes. His group found that the autism and SCZ risk gene C12orf65 contained Lof 
variants that were heavily enriched in Kuusamo, an isolated and genetically homogenous 
part of Northern Finland. They also observed an increase in missense variants in the SCZ 
risk genes NCAN, KCNB1, and FAM109B.
Dr Todd Lencz (Zucker Hillside Hospital) presented data on a rare variation in an Ashkenazi 
Jewish case–control SCZ cohort. The Ashkenazi Jewish population went through a 
population bottleneck 33 generations ago with an effective founder population of 270. Dr 
Lencz compared long IBD segments in a cohort of 1000 cases versus 1600 controls, used 
previously in a GWAS implicating that NDST3 confers a risk of SCZ (Lencz et al., 2013), 
and found more segments in cases for the MHC locus (10.23 vs. 8.35, P = 0.003). For rare 
variants, the recessive model was the strongest model in this segment with 46/858 
homozygous cases versus 24/1616 homozygous controls.
Dr Francesco Lescai (Aarhus University) presented a study of rare and de-novo variations in 
patients with BD in the Faroe Islands. He studied 28 BD cases and 214 controls with 35 × 
whole-exome and 6 × whole-genome sequencing. In a meta-analysis with another study by 
University College London of 2025 bipolar cases and 1358 controls, variants in FBXO21, 
NOS1, and P2RX7 were significant. The PIK3C2A and BEND4 genes were significant in a 
gene-based analysis, and NCL and MYL12A were implicated in an analysis using Disease 
Association Protein–Protein Link Evaluator (DAPPLE) (Rossin et al., 2011). These genes 
are implicated in neurotransmission and neurodevelopmental hypotheses for BD.
Endophenotypes for gene discovery in major mental disorder (reported by Suhas 
Ganesha)
This session was chaired by Dr Andrew McIntosh (University of Edinburgh) and moderated 
by Laura Almasy (Texas Biomedical Research Institute). Four panelists including the chair 
presented their findings in the area of using endophenotypes for gene discovery in 
depression, SCZ, and BD.
Aas et al. Page 25
Psychiatr Genet. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dr Andrew McIntosh introduced the session with an elaborate description of what 
endophenotypes mean, methods of measurement, polygenic architecture of these traits, and 
their importance in gene discovery using linkage and family-based association studies.
He described the use of quantitative endophenotypes as alternatives to clinical bivariate 
diagnoses in GWAS for MDD. Variables from the General Health Questionnaire (GHQ), 
Eysenck Personality Questionnaire, Cognitive Battery, measures of Schizotypy, and Bipolar 
Spectrum were assessed as endophenotypes. The study used two methods of analysis, first 
involving prioritizing of variables with genetic correlation with MDD and using multivariate 
GWAS with the vector of these traits. Second, the investigators used PCA of the genetic and 
phenotypic correlations. Both methods showed convergent results, with Neuroticism, 
Schizotypal Personality Questionnaire, Mood Disorder Questionnaire, Digit Symbol Coding, 
and GHQ identified as being endophenotypes for MDD and having utility in identifying 
genetic risk loci.
Dr David Glahn (Olin Neuropsychiatry Research Centre in the Institute of Living, Yale) 
discussed endophenotype discovery in SCZ in randomly ascertained pedigrees. Beginning 
with the MDD experience as the context, his use of a novel endophenotype ranking value 
(named after Irving Gottesman) was discussed. Applying this in a population sample with 
six cases of SCZ supplemented with 233 individuals at various levels of genetic risk, he 
described 10 ranked endophenotypes among neurocognitive markers and cortical surface 
areas.
Dr Kristen Nicodemus (University of Edinburgh) in the presentation titled ‘Epistasis 
Increases Variation Explained in Endophenotypes above the Contribution of the Polygenic 
Scores’ proposed the role of epistasis in variation of endophenotypes. In a study that 
examined ZNF804A pathway genes in 424 psychosis patients using a novel statistical model 
that simultaneously modeled both PRSs and epistasis, the latter was found to explain 2–3 
times the variability for memory in psychosis than was explained by PRSs. The use of 
similar methods in cognitive endophenotypes in fragile X syndrome was introduced.
Dr Carrie Bearden (University of California, Los Angeles) discussed the results of a study 
from Latin America in an isolated population with 26 large families heavily loaded with BD. 
Neuroimaging and circadian rhythm phenotypes were characterized on the basis of high 
heritability and association with disease. The developmental expression of these phenotypes 
was studied in adolescent offspring in the families. The results suggested high rates of 
anxiety, inattentiveness, decreased ability to recognize facial emotions, and decreased 
inhibitory control in adolescents at high risk. The speaker also proposed further investigation 
of amygdala volume as a putative endophenotype in adolescents at risk for BD.
Dr David Porteus (University of Edinburgh) reiterated the importance of dimensional 
approaches such as the use of quantitative endophenotypes for examining psychiatric 
disorders as opposed to DSM-like categorical classificatory systems.
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Eating disorders: breakthroughs and new directions in genomics and epigenomics 
(reported by Laura Huckins)
Cindy Bulik (UNC) introduced the session by describing anorexia nervosa (AN), bulimia 
nervosa (BN), and binge-eating disorder (BED). Both AN and BN patients describe a 
reinforcing and anxiolytic effect from restriction and/or purging, whereas satiety is described 
as unpleasant. BED occurs because of a variety of emotional triggers and may be a form of 
impulse-control disorder. There is a large diagnostic crossover between disorders, with 
roughly 50% of AN patients also at some point experiencing BN. There is also considerable 
crossover between BN and BED.
Stephan Ripke (Broad Institute of MIT and Harvard) described the results of a meta-analysis 
of two previously published AN datasets: the 2011 CHOP study (Wang et al., 2011) and the 
2014 Wellcome Trust Case Control Consortium 3 (WTCCC3) study (Boraska et al., 2014). 
No hits were genome-wide significant. However, two regions of interest were identified, 
both on chromosome 12. These regions encompass SNPs that have been associated 
previously with type 1 diabetes, vitiligo, polycystic ovary syndrome, systemic sclerosis, and 
obesity-related traits.
Nadia Micali (UCL Institute of Child Health) described a gene–environment (G × E) 
interaction study of eating-disorder related behaviors such as fat avoidance, fear of weight 
gain, bingeing, and purging. The study focused on environmental factors such as exposure to 
stressful life events (SLEs) and parenting abilities, and a set of previously identified 
candidate variants, including 5-HTTLPR, SLC6A4, rs6311 (HTR2A), rs6265 (BDNF), and 
variants in the MAO-A region. Participants in this study were recruited from the Avon 
Longitudinal Study of Parents and Children cohort (Golding et al., 2001). Roughly 10 000 
mothers and daughters from this study replied to questionnaires, sent when the daughters 
were aged 14 and 16 years. Participants were genotyped on the Illumina HumanHap550.
The experience of SLEs was found to influence bingeing and purging behaviors. Variants in 
MAO-A were found to influence fat avoidance and fear of weight gain. There was also a 
correlation between better parenting and slightly lower odds of developing these behaviors, 
although no correlation was found between the lowest decile of parenting ability and an 
increased risk. No G × E interactions were found.
Gerome Breen (Institute of Psychiatry, King’s College, London) discussed methods to 
elucidate SNP heritability in AN. The heritability of AN has been estimated at 56% (Bulik et 
al., 2006). AN patients often have a number of comorbid disorders, and there is evidence for 
shared polygenic etiology between AN and other psychiatric disorders. Breen described a 
method (Bulik-Sullivan et al., 2015) that examines shared heritability using LD score 
regression. For an SNP j, an LD score is obtained as a sum of all the information available 
for SNP j, and all SNPs in LD with SNP j. A χ2 regression is then performed on that LD 
score. This method indicates a significant genetic correlation between AN and BMI and AN 
and SCZ. Correlation is also noted with other pertinent traits, including HDL, insulin 
resistance, TG, B-cell function, LDL, and rheumatoid arthritis (RA).
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Bulik (UNC) discussed attempts to recruit new study participants using social media. This 
approach allows researchers to expand the reach of their studies, to communicate more 
closely with parents and advocacy communities, and provide results to study participants in 
real time. Communicating with participants and their families enables researchers to 
understand and address potential concerns and questions.
Bulik (UNC) concluded the session by discussing other aspects of AN/ED research, 
including promising optogenetic models of binge eating in mice (Jennings et al., 2013), 
evidence for reduced gut microbiota diversity in AN patients, and a desire to investigate the 
effects of hormones, infection, stressors, and developmental stage on eating disorder 
development.
Report of the International Society of Psychiatric Genetics genetic testing taskforce 
(reported by Kate Wolfe)
Dr Francis McMahon (National Institute of Mental Health, USA) provided an introduction 
to the session, outlining the key measures for diagnostic genetic testing in psychiatry. 
Genetic tests should have analytical validity, in that they should accurately measure what 
they set out to measure, and clinical validity, whereby the association between the genetic 
variant and disease is validated. Large sample sizes and replication studies will be crucial for 
ensuring clinical validity. Clinical utility is another important element for consideration, 
particularly the potential for therapeutic interventions (http://www.cdc.gov/genomics/
gtesting/ACCE/index.htm). In 2008–2009, the ISPG taskforce broadly recommended against 
all genetic testing, with the exception of causal genetic and chromosomal regions 
(phenylketonuria, fragile X, and Huntington’s disease). In 2013–2014, the taskforce 
reconvened to update the statement and a summary of the new recommendations has now 
been published on the ISPG website, with a journal article under review in the American 
Journal of Psychiatry (http://ispg.net/genetic-testing-statement/#ref1). Dr McMahon 
introduced specialist members of the taskforce, who each presented on specific areas of the 
recommendations.
Dr Elliot Gershon (University of Chicago, USA) presented on the role of CNVs in 
psychiatric disorders. The first CNV to be characterized as a psychiatric risk locus was 
found on chromosome 22q11; deletions in this region were shown to increase susceptibility 
for SCZ (Karayiorgou et al., 1995). Gershon discussed the role of CNVs in relation to effect 
size versus frequency of genetic mutations, adapting the previous work of Manolio et al., 
2009. Both rare and de novo CNVs can be shown to have a large effect size for psychiatric 
disorders. Specific risk calculations for both rare and de-novo CNVs were presented from 
the research of Gershon and Alliey-Rodriguez (2013). In particular, it was noted that for the 
rare 22q11.21 deletion, the associated risk of having SCZ, BD, or ASD is 82%. The 
presence of a de-novo CNV anywhere in the genome has an aggregated risk of 14% for the 
development of a neuropsychiatric disorder, which is much higher than the population risk. 
Finally, Dr Gershon discussed the complex ethical implications of population-based genetic 
screening, particularly stigmatization and discrimination, also discussed in Gershon and 
Alliey-Rodriguez (2013). Dr Gershon concluded that rare disease-associated CNVs can 
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increase the risk for several psychiatric disorders; they have high odds ratios and potentially 
have large effects on risk when involving sites contributing toward polygenic susceptibility.
Dr Daniel Mueller (University of Toronto, Canada) spoke about the use of genetic testing to 
guide optimal treatment in psychiatric practice. Historically, a ‘trial and error’ approach has 
guided psychiatric treatment, but the advent of pharmacogenetic markers provides the 
opportunity to improve physician effectiveness, reducing healthcare costs as well as the risk 
of serious side effects. The Mayo Clinic (USA) (under the direction of the late Dr David 
Mrazek) has led the field of clinical pharmocogenomic testing, utilizing a novel algorithm of 
drug responsiveness that is of particular benefit for patients with a poor treatment history. 
The initial focus was on variation in genes encoding cytochrome p450 (CYP450) enzymes 
(e.g. CYP2D6 and CYP2C19), which are involved in the metabolism of many drugs 
including antidepressants and antipsychotics (Hicks et al., 2013). Polymorphisms in the 
serotonin transporter gene and response to antidepressants (Porcelli et al., 2012) and 
polymorphisms in the dopamine D2 receptor and anti-psychotic response (Zhang et al., 
2010) have also been explored, although more research is needed in this area. There have 
also been some promising results for genes involved in side effects and addiction-treatment 
compounds. Future research will be needed to investigate the role of epigenetics as well as 
genotype treatment versus treatment as usual.
Professor Marcella Rietschel (Central Institute for Mental Health, Germany) discussed the 
issues surrounding reporting of incidental or secondary findings, which has become a 
pertinent issue with the advent of exome and whole-genome sequencing. The American 
College of Medical Genetics and Genomics (ACMG) have produced a recommended list of 
genes for which incidental findings should be reported back to patients by clinicians, 
irrespective of the original reason for genetic testing and the age of the patient (Green et al., 
2013). The ISPG taskforce concurs with this statement, but highlights that the seriousness of 
the disease, consequences of nondisclosure, the patient’s wishes, ability to rationalize and 
participate in intervention, and the psychological consequences of disclosure are all 
important factors to consider. Although it is not yet part of clinical practice to perform 
exome and genome sequencing for psychiatric disorders, it is of concern that for many of the 
genes identified by the ACMG recommendations, we lack evidence of the predictive value 
of testing, genotype penetrance, spectrum of phenotypes, and efficacy of interventions in 
unselected populations (Burke et al., 2013). The importance of exome and genome 
sequencing in the research setting makes the issue of incidental and secondary findings more 
pertinent. Professor Rietschel went on to discuss patient opinions on genetic testing. Surveys 
have indicated that 97% of research participants would want to be informed of genome 
sequencing results that could have implications for their health and 83% of respondents 
would want this information irrespective of whether preventive measures or treatment are 
available (Bui et al., 2006). Further research by Professor Rietschel found that one-third of 
research participants want to know their genetic results, even if they are not relevant to the 
original scientific question, and some participants were even prepared to pay for feedback. 
Overwhelmingly, participants felt that their right to determine what they wish to know is the 
most important factor. It remains unclear how the ACMG recommendations should be 
applied in research settings and it poses a challenge in this era of rapid development; 
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however, involving participants in discussions as part of the informed consent process will 
be key to managing these issues.
Dr Jehannine Austin (University of British Columbia, Canada) spoke about the 
psychological, ethical, and clinical implications of genetic testing. Dr Austin’s experience is 
that there is a need to understand why disease has occurred, and this is no less true in the 
context of psychiatric disorders. The ISPG recommends that genetic risks should be 
communicated in a way so as to maximize understanding. Importantly, risk not only 
describes the probability of an event occurring, but is a broader concept integrating 
individual perceptions of the severity of the outcome involved. For example, it is important 
to frame numbers in different ways, such as reporting to parents that there is a 90% chance 
your child will not develop SCZ, as opposed to a 10% chance that they will. Addressing 
psychological issues related to changed perceptions of cause is another important role of 
genetic counseling (GC). Patient outcomes recorded in a psychiatric GC service were 
measured, and empowerment and self-efficacy were both clinically and statistically 
improved following GC (Inglis et al., 2015). The ISPG taskforce believed that genetic 
testing of minors to detect adult-onset conditions for which there are no treatment options 
should be discouraged, although genetic testing in those unable to consent may be 
appropriate under some circumstances (e.g. to identify potential CNVs where there could be 
relevance for associated medical issues). Dr Austin briefly discussed direct to consumer 
testing, provided by companies such as 23andMe, and the vital importance of GC by 
appropriately qualified professionals to prevent patient misinformation about genetic test 
results.
The discussion was led by Professor Philip Mitchell (University of New South Wales, 
Australia). Professor Mitchell highlighted that it is important to consider when genetic tests 
should enter the clinical arena, with reference to the American Journal of Psychiatry 
commentary ‘a bridge too far too soon’ (Braff and Freeman, 2008). The analytical and 
clinical validity of genetic tests is particularly of concern for direct to consumer testing, with 
new companies emerging such as Sundance Diagnostics, who are offering a genetic test for 
suicidal ideation in response to SSRI treatment in depression. Another pertinent issue is 
whether we should now be testing routinely for CNVs in patients with SCZ (Baker et al., 
2014). Professor Mitchell invited Paulina, from the Swedish National Association for Social 
and Mental Health, who herself has BD, to comment on the proceedings. Paulina felt that 
genetic tests are an important way to gain more understanding, which will in turn help to 
break the stigma of psychiatric disorders. It will be of utmost importance to provide support 
to patients with increased genetic risk through GC.
The session was opened up to questions and it was discussed that a broader aspect of clinical 
utility is the patient’s right to know what is causing their illness, striving to place mental 
illness on a par with physical illness. Another concern was that more training should be 
provided for psychiatrists to keep pace with psychiatric genetic knowledge. The ISPG 
taskforce is currently in the process of developing a recommended curriculum to be included 
as an integral component of the psychiatric resident’s curriculum. Finally, the gap between 
the genetically educated versus the lay person in their ability to interpret direct to consumer 
testing was discussed; this gap is a major issue for GC services and healthcare providers.
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Systems biology approaches in psychiatric disorders (reported by Monique van der Voet)
Dr Kasper Lage (Harvard Medical School, Massachusetts General Hospital, Broad Institute) 
opened the session defining systems biology as the holistic quantitative view of an entire 
biological system. Scientists produce data on a massive scale across many genomic 
platforms, which can be overwhelming. This session shows the many approaches to interpret 
the data and understand psychiatric disease.
Dr Lage focused on how statistics and web portals can be used to functionally interpret data 
in psychiatric disorders. He announced a new release of InWeb (version5), which is four 
times larger with 1.2 million protein–protein interactions. The DAPPLE uses random 
permutation to quantify whether loci in a network connect at more than a random 
expectation (Rossin et al., 2011). Lage reminded the audience that a network should not be 
the final result of a paper. It is important to validate a network to replicate a finding with an 
independent method. Arking et al. (2014) and Lundby et al. (2014) provide a general 
framework that could be translated to psychiatric disorders. Dr Shaun Purcell (Icahn School 
of Medicine at Mount Sinai) spoke about using biological networks to prioritize rare and 
common variants in SCZ-associated genes. Gene-set enrichment pathway analysis, followed 
by network connectivity analysis is such an approach. Using DAPPLE, the question was 
answered whether seed genes were more connected to each other than expected by chance 
and which genes are especially connected. SCZ de-novo exome sequencing trio datasets are 
enriched for FMRP targets (Purcell et al., 2014). GWAS regions do not have significant 
direct edges to this network, which is puzzling. This could be because of different kinds of 
genes being hit. It is not clear where this difference arises from, but may be related to de 
novo mutations being more constrained and brain expressed.
Professor Søren Brunak (Technical University of Denmark) spoke about integrating patient 
records and temporal data to understand comorbidities between psychiatric disorders and 
other diseases. For this, he used text mining of data from an electronic health registry 
covering the entire population of Denmark (Jensen et al., 2014). The analysis shows 
trajectories of disease development, disease–disease correlation, and adverse drug reactions. 
Initially, it was surprising to observe an epidemiological relationship between gout and 
cardiovascular disease, but other studies support this association. The population-wide 
disease trajectory approach has the power to uncover new disease–disease correlations, 
which will be a powerful approach to understand comorbidities between psychiatric 
disorders and other diseases.
Dr Iiris Hovatta (University of Helsinki) spoke about animal models to understand the 
genetic basis of anxiety disorders (Sokolowska and Hovatta, 2013). She combines mouse 
and human genetic approaches to identify genes that regulate anxiety. Known brain anxiety 
circuits were analyzed in an innate anxiety mouse model. RNAseq and miRNAseq identified 
gene pathways involved in anxiety-like behavior in the mouse, where NF-κB acts like a hub. 
G × E interaction was analyzed in a social defeat mouse model that causes long-term 
changes of 232 genes in the brain. These new genes are good candidates for genetic studies 
in humans.
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Copy number variations in adults with neurodevelopmental disorders (reported by Samuel 
J.R.A. Chawner)
Professor Griet Van Buggenhout (KU Leuven – University of Leuven, Belgium) reported a 
high prevalence of pathogenic CNVs in adults with a dual diagnosis of intellectual disability 
(ID) and neuropsychiatric disorder. It was highlighted that there is a lack of studies 
examining the neurodevelopmental phenotype of adults with pathogenic CNVs. Results 
were presented from an international collaborative effort between University College 
London, Universitat Autonòma de Barcelona and KU Leuven – University of Leuven. Five 
hundred adults with dual diagnosis were recruited through psychiatric units for ID and also 
genetic clinics within psychiatric hospitals. Microarray analysis was carried out on all 
individuals and it was found that 36.4% of adults with dual diagnosis had a likely pathogenic 
CNV and the most frequent CNVs were at the following loci: 2p16.3, 3q29, 7q11.23, 
15q11.2, 15q13, 16p11.2, 17p11.2, 22q11.21, and 22q11.33.
Dr Ramon Novell (Institut Assistencia Sanitaria, Spain) presented case studies from three 
families with deletion of the 2p16.3 region that includes the NRXN1 gene. The psychiatric 
and cognitive phenotype of probands and family carriers was variable and included SCZ, 
bipolar, autism, ADHD, and generalized anxiety disorder, and there were carriers with no 
diagnosis. All three probands fulfilled the criteria for mild ID and their IQ ranged from 53 to 
65. Intellectual functioning in family carriers ranged from mild ID to being within the 
normal range, with IQ scores ranging from 69 to 91. Both probands and carriers showed 
impairments in executive function. The phenotype of carriers suggests that the 2p16.3 
deletion has variable expressivity instead of incomplete penetrance.
Professor Sébastien Jacquemont (Université de Lausanne, Switzerland; Université de 
Montréal, Canada) spoke about the contrasting phenotype of reciprocal rearrangements at 
the 16p11.2 locus, a region implicated in head size, obesity, and neurodevelopmental 
disorder (Shinawi et al., 2010; Jacquemont et al., 2011). Fourteen individuals with the 
deletion of the 16p11.2 region, 17 with duplication of the region, and 23 intrafamilial 
controls underwent neuroimaging. An effect of genomic copy number was found for whole-
brain volume, both gray and white matter volume, cortical surface area, and for the volume 
of regions involved in the reward pathway (after correction for whole-brain volume). The 
pattern of brain anatomy changes in carriers spatially overlapped with established structural 
abnormalities in autism and SCZ. Using measures of peripheral mRNA levels, analysis 
confirmed the results obtained with genomic copy number. The findings highlight 
endophenotypes that mediate the effect of the 16p11.2 locus on behavior.
Professor Annick Vogels (KU Leuven – University of Leuven, Belgium) reported the 
phenotype of individuals with 22q11.2 deletion syndrome (22q11.2DS) [recognized as a 
genetic model for SCZ (Schneider et al., 2014)] who were diagnosed in adulthood. A 
retrospective study examined clinical records of 65 individuals with 22q11.2DS diagnosed 
as adults. They were recruited through a genetics clinic (referred to the outpatient clinic), a 
residential unit for ID (actively recruited), and a psychiatric unit for adults with ID (actively 
recruited). There were high rates of psychiatric disorder including 45% with SCZ spectrum 
disorder, 45% with personality disorder, and 10% with mood disorder. Physical features 
such as facial or cardiac abnormalities were rare. The results emphasize the need to consider 
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the diagnosis of 22q11.2DS in adults with ID and psychiatric disorder even in the absence of 
obvious physical features.
In the discussion, the role of the psychiatrist in managing patients with pathogenic CNVs 
was considered and there was consensus that intervention during childhood was important, 
given the high rates of psychiatric disorder in adulthood. However, the panel mentioned that 
there is a current lack of guidelines for appropriate intervention strategies in these clinical 
populations. The ethics of prenatal testing of pathogenic CNVs were discussed and the panel 
believed that such testing should be accompanied by specialized GC.
Immunomics: exploring new territory in schizophrenia (reported by Luca Pagliaroli)
Jennie Pougeut (Centre for Addiction and Mental Health) focused on the immune hypothesis 
of SCZ. From the GWAS-SCZ sample with 9394 cases and 12462 controls, 927 ‘immune’ 
genes and 18 165 immune SNPS tagging 814 genes were identified. However, the only 
genome-wide significant signals were detected in PGG1 and PGG2. No improvement in the 
analysis of the data has been found using hypothesis-driven GWAS. This approach 
prioritizes the SNPs in immune–nonimmune genes to calculate the data-driven weighting for 
immune–nonimmune data and q-values for each SNP. Nevertheless, prioritization does not 
improve the discovery of immune loci in SCZ. In conclusion, the immune system does not 
seem to be the major etiological pathway in SCZ and it may be involved downstream rather 
than at the beginning of the disease.
Dr Wray (the University of Queensland) spoke about the epidemiological puzzle of RA and 
SCZ. This puzzle is complicated as smoking is a major risk factor for RA and smoking rates 
are high in those with SCZ. The investigation of the genetic relationship is not possible 
using the traditional epidemiological approaches because of the following reasons: the need 
for very large samples, complications of age of onset and sex, and risk of incurring both 
SCZ and RA by chance 0.01%.
The main messages of this talk were (i) the need to intensively analyze the available data in 
order to generate hypotheses and (ii) the necessity of further analysis for a better 
understanding of this complex puzzle.
Dr McCarroll (Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard) 
illustrated his project aiming to understand those forms of structural polymorphism that are 
not present in HapMap or 1000 genome, not visible to array-based copy number analysis, 
and not tagged by di-allelic SNPs. In particular, attention was focused on HLA-C4, which is 
an interesting candidate in SCZ and exists in long (L) or short (S) form and in an A or a B 
variant. He was able to show that AL-BS segregates into five different haplotypes, AL-BL 
segregates into three different haplotypes, and AL-AL segregates into two different 
haplotypes. He further suggested an association between allelic haplotypes of the C4 
structure and SCZ according to the following pattern: ‘the more the brain C4A expression is 
associated to a structure the more SCZ risk is associated with that structure’.
Dr Yolken (Johns Hopkins) talked about the microbiome. The assumption is that every 
individual has a unique set of microorganisms at mucosal sites that are larger and more 
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complex than the human one and is partially inherited from the mother and partially 
acquired from the environment. A high-throughput sequencing of throat swab samples, n = 
41 with SCZ and n = 32 without psychiatric disorders, showed that the composition of the 
control microbiome is different from that of SCZ patients. Although the two groups do not 
differ in age, sex, race, cigarette smoking, and oral hygiene, they differ in the rate of deficit 
syndrome and evidence of intestinal inflammation. Further screening of 16 patients and 16 
control participants showed differences in viruses between them, which might be suggesting 
that some kinds of viruses may be protective whereas others could be associated with illness.
In conclusion, the study of the microbiome is an extremely important new approach to the 
pathophysiology, and potentially the treatment, of psychiatric disorders.
The effect of psychosis risk genes across the phenotypic spectrum (reported by Maria 
Tropeano)
Dr Thomas Hyde (Lieber Institute for Brain Development, USA) discussed the importance 
of the study of human postmortem brain to analyze the effects of the SCZ-associated genetic 
variants on a molecular level. For a number of genes, studying the expression of the full-
length transcript does not fully explain how the risk allele might alter gene expression, either 
in the fetus or in the adult. Straub et al. (2007) identified a SNP in the promoter region of the 
GAD1 gene, associated with the risk of SCZ and with decreased expression of the GABA 
synthetic enzyme GAD67 in SCZ postmortem brain. Carrying out gene expression analyses 
in postmortem human brain, Dr Hyde has identified a new transcript derived from the GAD1 
gene, named GAD25, which encodes a truncated protein that lacks the GABA synthetic 
domain and is highly expressed in the developing fetal brain. SCZ cases homozygous for the 
GAD1 risk allele have shown an increase in the expression of GAD25 in the hippocampus, 
which lend support to the hypothesis that SCZ could be caused by anomalies in the normal 
trajectory of brain maturation. A key step toward the understanding of the molecular 
mechanisms of genetic risk relies upon defining the family of transcripts derived from each 
risk gene.
Dr Ole Andreassen (University of Oslo, Norway) presented his work investigating the 
functional consequences of the newly identified SCZ risk genes in vivo using brain imaging 
technology and deep phenotyping in SCZ patients. He showed examples of SCZ GWASs 
hits that have been found to be associated with functional brain abnormalities, such as 
common genetic variants in the MHC, a region repeatedly implicated in SCZ, that have been 
associated with larger ventricular volumes in SCZ patients (Agartz et al., 2011). He also 
described a novel Bayesian statistical framework, developed recently by his group with the 
aim of investigating the complex effect of a series of SCZ-associated risk variants (PRS) on 
neuroimaging phenotypes in SCZ patients; his preliminary findings showed a strong effect 
of the SCZ PRS from the PGC on the dorsolateral prefrontal cortex (DLPFC) of SCZ 
patients from a GWAS of 3000 MRI brain scans. He concluded by highlighting the need for 
novel statistical methods and for larger sample sizes to increase the statistical power of 
imaging genomics studies.
Dr Anil Malhotra (Zucker Hillside Hospital, USA) discussed the potential genetic overlap 
between general cognitive ability and SCZ. Generalized deficits in cognitive ability 
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represent a core component of SCZ; however, to date, there is no molecular evidence in 
support of this overlap. He presented data from a large-scale GWAS, meta-analysis of 
general cognitive ability (g) from the Cognitive Genomics consorTium (COGENT), 
including ~ 5000 healthy volunteers from nine sites across seven countries. Polygenic SNP 
scores from the cognitive GWAS meta-analysis were used to test whether alleles associated 
with reduced g also increased the risk for SCZ in four SCZ case–control cohorts. As 
predicted, SCZ cases had significantly lower cognitive polygenic scores compared with the 
controls. In parallel, PRSs for SCZ were associated with lower g in the COGENT samples 
(Lencz et al., 2014). Finally, Dr Malhotra also presented some preliminary findings from the 
COGENT phase 2 study, including data from 24 544 healthy volunteers. In the new sample, 
he identified an SNP on chromosome 6 (rs1906252) significantly associated with ‘g’; he 
noted that two proxies of this SNP have recently been associated with educational attainment 
(EA) (rs9320913, r2 = 0.91; Rietveld et al., 2013) and with increased risk for BD 
(rs12202969, r2 = 1; Mühleisen et al., 2014) in two other independent GWAS.
Dr Aristotle Voineskos (University of Toronto, Canada) spoke on the use of additive risk 
modeling (Hill et al., 2008) to achieve a more comprehensive neurobiological understanding 
of phenotypic variability among individuals with SCZ. He presented data from a sample of 
198 SCZ patients and healthy controls, in which he investigated the association between 
brain structure and cognitive performance and an additive genetic model, including three 
SCZ-associated risk variants from GWASs (MIR137, CACNA1C, ZNF804A) and two risk 
variants from genes with well-established effects on brain structure and function (GAD1, 
BDNF). He found that the additive SCZ risk score significantly predicted white matter 
integrity throughout the brain and was associated with increased cortical thickness and poor 
cognitive performance (particularly in verbal fluency and motor functioning) in patients with 
SCZ. In conclusion, he emphasized the need for longitudinal studies to confirm these 
findings and also highlighted the potential importance of additive genetic risk models in the 
prediction of disease progression in SCZ patients at early stages of the disease, and to 
inform treatment decisions.
Neuropsychiatric genetic research in Latin America (reported by Antonio Pardiñas)
Dr Henriette Raventos (Universidad de Costa Rica) started the session by commenting on 
the advantages of psychiatric and genetic research in her home country. First of all, Costa 
Rica has a wealth of ecclesiastical records on families from the 18th century on and detailed 
genealogical records since 1890. These have been incorporated into a centralized universal 
healthcare system, which allows medical researchers to access this data. Besides this, 
families are supportive of genetic research and many different population groups exist as 
isolates separated by mountains and valleys. All this together has proven powerful to carry 
out linkage studies using population registries, which have shown the molecular basis of 
several forms of inherited deafness and BD (Leon et al., 1992; Mcinnes et al., 2001). In 
recent years, focus has shifted toward admixture studies, which have shown the presence in 
the Costa Rican population of at least four ancestry components (European, African, Asian, 
and Amerindian), information that can be used for association studies and might highlight 
new risk or protective alleles for medical conditions (Segura-Wang et al., 2010; Campos-
Sánchez et al., 2013). These results, along with the latest studies on psychiatric disorders 
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(Gonzalez et al., 2013), have been influential for public policy within the country. Currently, 
the focus is to develop and complete a large database of clinical and genetic information, 
which will store around 10 000 samples. Also, functional studies on transcription factors 
have been published (Marballi et al., 2014), studies on a microRNA role in psychiatric 
disorders are ongoing, and a laboratory for the study of the zebrafish as an animal model is 
starting its course.
Professor Homero Vallada (University of Sao Paulo Medical School) spoke about Brazil, a 
country that houses 50% of the South American population and 80% of its Research & 
Development budget. Brazil is noteworthy for a huge population expansion since the start of 
the 19th century and for having been the destination of 40% of the Trans-Atlantic slave 
trade. This makes it an admixture melting pot, with patterns that reflect the original 
colonization of the territory (Salzano and Sans, 2014; Magalhaes Da Silva et al., 2015). 
Although the first genetic studies in Brazil started in the 1980s, interest in genetics increased 
after the publication of the first ‘Brazilian Genome Project’, the plant pathogen Xyllela 
fastidiosa (Simpson et al., 2000). The fast subsequent development provided the necessary 
infrastructure to carry out the Baependi Heart Study (De Oliveira et al., 2008), and start 
several major projects on addiction (Lobo et al., 2014), cognition (Santos et al., 2014), and 
pharmacogenomics (Suarez-Kurtz et al., 2014).
Dr Humberto Nicolini (National Institute of Genomic Medicine INMUGEN) introduced the 
latest research developments in psychiatric genetics in Mexico. Several of them built on the 
latest knowledge on BD, with the aim of explaining mood changes (Gonzalez et al., 2014). 
The large familiar structure present in the country is extremely useful for research as 
hundreds of extended families with at least two affected sib-pairs have been recruited in the 
past (Glahn et al., 2010), and these recruitments are still in progress. Also, there is the 
possibility of examining the effects that nutrition and quality-of-life changes over the last 
century might have had on the physical and mental well-being of the Mexican population 
using molecular and genetic techniques (Hare et al., 2010; Estrada et al., 2014).
Professor Carlos Lopez-Jaramillo (University of Antioquia) finished the session. He spoke 
in depth on the research on Colombian population isolates, such as the Paisas (Bedoya et al., 
2006). This population was founded in the 17th century by admixture between Spanish men 
and Native American women, and has been studied extensively because of its increased 
prevalence of psychiatric disorders such as ADHD, PD, and BD (Pineda et al., 2011; Velez-
Pardo et al., 2015), as well as suicidality, which is 10 times higher than that in the general 
Colombian population (Alzate and Benitez, 2011). One of the best-developed lines of 
research in Colombia are pedigree studies as many extended families with 40–50 members 
can be recruited, which enables investigators to carry out detailed studies even at the 
phenotype level (Fears et al., 2014). Recent efforts to phenotype these samples with a higher 
resolution include using actigraphy to study circadian rhythm patterns and substance tests to 
measure abuse. Also, a new study is ongoing in the small population of Aranzazu, an 
isolated village of 12 000 inhabitants in which BD type 1 has a total prevalence of 6–8%, 
and is currently the fourth most common cause of hospitalization.
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Genetics and aggression: the Aggressotype project (reported by Luca Pagliaroli)
Dr Franke (Department of Human Genetics and Psychiatry, Donder’s Institute of Brain, 
Cognition and Behaviour, Radboud University Medical Center) presented an overview of the 
Aggressotype project. As part of the EU FP7 program, the international consortium 
Aggressotype was founded in 2013 and focused on aggression and impulsive behavior in 
ADHD and conduct disorders. This project involves preclinical research at different levels: 
from genetics, to cells, to brain function, and eventually to behavior. The following areas are 
under investigation: (i) epigenetics studies of animal models to find biomarkers; (ii) imaging 
studies of animal models; (iii) alternative and classical animal model approaches suitable for 
behavioral studies and high-throughput screening; and(iv) NeuroIMAGE projects to study 
human behavior.
In conclusion, different levels of research are the key to understanding pathologic 
aggression. To achieve this goal, 24 academic partners and 4 industries have joined forces in 
this project.
Dr Norton (University of Leicester) talked about the use of zebrafish as an animal model for 
aggression. This species seems to be an excellent model because of the possibility of having 
stable mutant lines. The grade of aggression is easily measured either through dyadic fights 
between two fish or by looking at the interaction with a mirror. Spiegeldaino (spd) is a 
zebrafish fgfr1a mutant that shows increase in aggression, boldness, and exploration 
compared to the wild type. Global analysis of 40 neurotransmitters signaling in spd showed 
a 15% increase in hnmt expression and a phenotype rescue after treatment with tacrine 
hydrochloride (1 mg/ml). A new screening for novel aggression therapeutics led to the 
identification of five novel compounds that reduce aggression (data on adult fish). The 
aggression level during ontogeny after days 12, 21, and 25 of treatment showed that at 25 
days, the majority of fish have aggressive interactions with the mirror. Different studies 
showed that fluoxetine hydrochloride reduces aggression in adults, whereas WAY100 635 
exerts the opposite effect. The aggression phenotype has also been addressed in juvenile fish 
with similar results; furthermore, the effect of methylphenidate and risperidone has been 
investigated, showing a reduction of juvenile aggression. Screening for novel drugs is 
expected to start in January 2015.
Dr Glennon’s (Rabdoud University Medical Center) speech was focused on the use of an 
animal model of aggression: the BALB/cJ. Its goal is to investigate whether the aggressive 
traits of rodent models are associated with changes in structural and functional brain 
connectivity, neurochemistry, and epigenetics. The BALB/cJ mouse strain has a C1473G 
polymorphism in the tryptophan hydroxylase-2 gene. This mouse is more aggressive and 
shows an anxious phenotype with more evidence for a hypoarousal state after a fight than 
control. FA MRI-DTI studies indicated altered corticostriatal connectivity in the anterior 
cingulate cortex and the dorsal medial striatum. Mice have also been tested using a novel 
virtual reality setup that enables the analyses of behaviors relevant to aggression combined 
with optogenetics and tetrode recording. The paper of Márquez et al. (2013) suggests that 
early life stress is linked to aggression and leads to MRI changes in the right amygdala. 
Further investigations should involve mapping of genetic and epigenetic markers to neuronal 
networks of aggression.
Aas et al. Page 37
Psychiatr Genet. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dr Zayats (Bergen University) talked about her project on ‘epigenetics in mental disorders, 
maternal and parent of origin effects’ and the need for investigation on ADHD to understand 
the origin of aggression. It is important to gain knowledge of genetics as ADHD is the most 
heritable childhood onset neuropsychiatric condition (30–90%). It has been reported that an 
asymmetry in parental transmission to ADHD affected offspring implicated several genes 
(SNAP25, HTRB1, SLC6A4, SLC6A2, TPH2, DRD4, DRD5, DDC, BDNF). Genome-wide 
examination of imprinting in ADHD suggested the implication of FAS and PDLIM1 genes. 
However, no genome-wide significant findings were reported on GWAS results and 
candidate genes studies failed to replicate. The use of a multinomial regression model to 
investigate the parent of origin effect enables the differentiation of imprinting and maternal 
effects. Its application to the GWAS of Neale et al. (2008) identified rs96766447 with a P-
value of 6.72E − 07 (maternal effect P = 0.0046 and transmission asymmetry P = 0.013). 
Furthermore, from a study of Wang et al. (2011), it has been possible to identify rs7790549 
with an overall P-value of 6.70E − 06 (maternal effect P = 9.82E − 06 and transmission 
asymmetry P = 1.39E − 04). Therefore, the application of a multivariate approach is very 
important to detect ADHD candidate genes.
Toward translational psychiatry: from genomic discoveries to prediction of treatment 
response (reported by Erik Loken)
Dr Yu-Lin Chao (Tzu Chi General Hospital, Taiwan) presented his work on inversely 
regulated microRNAs in a mouse model of psychosis treated with electro-convulsive shock 
(ECS). Dr Chao looked at the microRNA of mouse hippocampus after methamphetamine 
and ECS. The hypothesis tested was whether specific microRNAs modulate response to 
ECS. Dr Chao found that prepulse inhibition (PPI) deficits and abnormalities in the novel 
object recognition test induced by chronic methamphetamine administration were improved 
after repeated ECS. Conditioned place preference deficits showed no sustained treatment 
effect with ECS. On analyzing microRNAs, Dr Chao found that more microRNAs were 
significantly downregulated after ECS. A pathway analysis of the six candidate microRNAs, 
652, 328, 138, 339–5p, 126–5p, and 203, found that they were involved in axon guidance. 
MiR-328 was successfully overexpressed; after injection into the hippocampus, the 
overexpressed miR-328 was associated with further impaired PPI on methamphetamine 
administration. Downregulation of miR-328 reduced the PPI deficit. A question was asked 
about whether any gene targets for these microRNAs overlapped with SCZ risk genes, and 
Dr Chao responded that they had found a very large overlap with both SCZ and BD risk 
genes.
Dr Wei J. Chen (College of Public Health, National Taiwan University, Taiwan) reported on 
blood-based microRNA expression aberration in SCZ. Dr Chen studied 48 SCZ and 37 
controls samples and looked at their peripheral blood miR-34a, miR-449a, miR-564, 
miR-432, miR-548d, miR-572, and miR-652 microRNA levels to observe whether they 
changed from acute admission to partial remission in inpatients with SCZ, and also whether 
they were associated with brain structure differences in patients with SCZ. She found a 
persistence of aberrant expression of the seven microRNAs in peripheral blood from 
admission to discharge, indicating that these microRNAs were not useful for treatment 
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outcome. Dr Chen plans to investigate peripheral microRNA expression further as a 
biomarker for SCZ.
Dr Ya-Chin Lee (College of Public Health, National Taiwan University, Taiwan) presented 
work on the identification of novel biomarkers for manic episodes. He used whole-genome 
transcriptome analysis with the specific aim of finding changes to the transcriptome in 
response to mania, which would hopefully be useful as a new set of biomarkers. Dr Lee 
studied six BD patients and using the Affymetrix Human Transcriptome Array 2.0, used 
paired t-tests to compare remission expression versus manic-episode expression. He used a 
threshold P-value of 0.01 and at least a 1.3-fold change to select 74 annotated transcripts 
fulfilling the criteria. Only five of the transcripts were coding genes. There were 32 
lncRNAs, 15 snRNA, snoRNa, and rRNAs, and 22 miscRNAs. Dr Lee cited research that 
implicates a lncRNA, Gomafu, as downregulated in SCZ postmortem superior temporal 
gyrus (Barry et al., 2014). Dr Lee used STRING in a protein–protein interaction analysis of 
transcriptome data that implicated immune-associated pathways.
Dr Po-See Chen (National Cheng Kung University Medical College, Taiwan) presented 
work investigating treatment response to antidepressants in patients with MDD. Only 40–
50% of patients respond to anti-depressants, which can be predicted by demographics, 
illness features, environmental factors, and genetic factors. He used artificial neural 
networks to analyze the effect of the pharmacodynamics genes GNB3 and BDNF and the 
pharmacokinetic genes 2C19*3 and ABCB1 and C2677A on the treatment response to 
fluoxetine in 73 patients and venlafaxine in 76 patients. In addition to these genetic factors, 
he examined the biomarker hs-CRP and social support scales. Using 80% of patients to train 
and 20% to test the artificial neural network, Dr Chen found the artificial neural network to 
be more useful to predict response to antidepressants than linear regression techniques. 
BDNF, CRP, and social support were significant in the analysis.
The interplay between genetics and early trauma in severe mental disorders (reported by 
Monica Aas)
Marco Riva (Department of Pharmacological and Biomolecular Sciences, University of 
Milan, Italy) presented his recent work investigating the role of epigenetics in early stress 
and long-term psychopathology. Riva described the use of a rat prenatal stress (PNS) model 
to investigate molecular and functional changes that could contribute toward the 
development or the maintenance of a phenotype on the basis of early life adversity. This was 
done by examining changes in the expression of neurotrophins and epigenetic regulators as 
well as changes in prefrontal methylation of gene promoters relevant for neuronal function 
using a cross-species approach. At the molecular level, PNS rats showed a region-specific 
and time-specific reduction in the expression of the neurotrophin BDNF, a marker of 
neuronal plasticity that plays an important role in mood and cognitive function. Professor 
Riva also presented data showing that exposure to PNS produces significant changes in the 
expression of several epigenetic regulators, including DNMT1, Gadd45β as well as HDACs.
Annamaria Cattaneo (King’s College of London, Institute of Psychiatry, UK) presented 
recent work investigating blood transcriptomics as a tool to identify the long-lasting effects 
of childhood trauma on psychopathology. Cattaneo reported that alterations in the mRNA 
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levels of genes involved in the stress response are particularly related to changes in the 
mineralcorticoid receptor, the GR, and the serum glucocorticoid kinase (SGK1), which is 
specifically activated by glucocorticoids. An additive effect of depression and trauma on 
modulation of SGK1 mRNA levels was observed. Similarly, Dr Cattaneo showed that SGK1 
mRNA levels were increased in the hippocampus of adult rats exposed to prenatal stress. 
These findings support a long-lasting effect of prenatal stress on SGK1 levels.
Bruno Etain (APHP – Inserm U955 and Fondation FondaMental, Creteil, France) presented 
his recent work on the topic of childhood trauma and BDs – severe clinical expression and 
moderation by genetic factors. The talk discussed how different types of childhood trauma 
influenced clinical expression and severity indicators in 587 patients with BDs, including 
interaction between early trauma and known variants of the serotonin transporter gene. 
Emotional and sexual abuse was associated with a more severe expression of the disorder 
such as an earlier age at onset (AAO), increase in suicide attempts, more rapid cycling, and 
greater proneness to depression. There was an additional effect of the 5-HTTLPR genotype 
and trauma on time to onset of BD. Finally, a history of childhood trauma, particularly 
emotional abuse, was associated with a significantly higher score on the Affective Lability 
Scale in two independent samples of patients with BDs (collected in France and Norway).
Utilizing family-based information in genetic research (reported by Suhas Ganesha)
This session was chaired by Dr Pippa Thompson (Institute of Genetics and Molecular 
Medicine, University of Edinburgh). She introduced the session by citing the importance of 
high-frequency rare variants in the genetic etiology of neuropsychiatric disorders and the 
shortcomings of routine case–control and cross-sectional approaches for identifying them.
Dr Lan Xiong (University of Montreal) presented on the advantages of using family-based 
cohorts to study neuropsychiatric disorders. In whole-exome and genome sequencing in 
Canadian BD family-based studies, an HTR3A missense variant was reported to be highly 
associated with lithium response. In 31 inbred Iranian bipolar pedigrees, 600 shared/novel 
variants were identified. Thirteen genes were found to have more than one novel/rare variant 
in more than one family. Similarly, large consanguineous pedigrees from Pakistan with SCZ 
cases were presented, including exome sequencing data from a family of 13 affected 
individuals. Dr Simone de Jong (King’s College London) presented linkage and sequencing 
data in a large Brazilian bipolar family with 111 affected cases. Of the samples obtained 
from 300 + members in a family, 30% had from a mood disorder. BD showed anticipation 
across the four generations studied. Genome-wide significant linkage, allowing for multiple 
phenotype definitions, was identified for 2p23.1–p22.3 (LOD = 3.83) for all mood disorders, 
3p23–p24.1 (LOD = 4.18) for narrow bipolar 1, and both 11p14 (LOD = 4.49) and 
12q24.22–q24.32 (LOD = 4.74) for depression. Fine mapping of eight linkage peaks by 
exome sequencing and variant filtering identified mutations in ATR5, DNHD1, and DCHS1 
genes for a depression phenotype. Similarly, fine mapping of all affected mood disorder 
cases identified an association with the ITGA1 gene and the FAM98 gene. These genes are 
known to be involved in cell signaling, adhesion, translation, and neurogenesis.
Dr John Blangero (Texas Biomedical Research Institute) discussed the utility of studying 
rare variants using randomly ascertained pedigree studies, and thus to characterize their 
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biological effects. The San Antonio Family Study/Genetics of Brain Structure and Function 
Study was presented. Caudate volume and frontal cortical thickness were presented as 
prototype heritable traits influenced by rare variants including a novel variant on 
chromosome 19 and a variant on DEGS1 involved in the ceramide synthesis pathway. The 
utility of endophenotype ranking values with cortical surface area as an endophenotype was 
discussed. In an interesting attempt at Neanderthal genomic/phenomic reconstruction, 
evidence for reduced connectivity, impaired memory function, and reduced Broca’s speech 
areas was shown.
In the final presentation, Dr Pippa Thomson (Institute of Genetics and Molecular Medicine) 
presented a study to identify rare variants using exome sequencing data from 277 cases from 
44 families and 148 unrelated individuals of familial recurrent MDD drawn from the 
Generation Scotland: Scottish Family Health Study. Linkage analysis identified two peaks: 
one at the tip of chromosome 12 within a microdeletion region for neurodevelopmental 
delay and the other peak was noted to overlap the centromeric region of chromosome 18, 
which was also additionally linked to depression endophenotypes of AAO, memory, and 
cognitive ability. NINJ2 and ROCK1 on chromosome 12 and chromosome 18, respectively, 
showed an increased frequency of rare variants implicated in neurite outgrowth and response 
to nerve injury.
Dr Andrew McIntosh led the discussion and stressed the reemerging importance of family-
based studies in the identification of rare variants in psychiatric disorders.
Exploring the evidence that postpartum depression is a more homogeneous biological 
subtype of major depression (major depressive disorder) (reported by Martin Tesli)
Dr Patrick Sullivan (University of North Carolina, USA) introduced this session by 
comparing the success of the PGC with SCZ with the lack of identification of new risk loci 
for MDD. He discusses potential causes for this lack of findings, including low statistical 
power, hidden G × E interactions, and phenotypic heterogeneity. He also suggested that 
postpartum depression (PPD) may be more homogenous and heritable than the broad 
category of MDD.
Alexander Viktorin (Karolinska Institutet, Stockholm, Sweden) followed up on this 
discussion by arguing that perinatal depression (PND) is probably neither totally overlapping 
nor totally independent from MDD, but somewhere in between. He moved on to presenting 
his own research on the heritability of PND and genetic overlap with nonperinatal major 
depressive disorder (NPMDD), a major depressive episode at any other time of life. For this 
purpose, the authors investigated heritability in 3427 parous twin women with a classical 
twin-model using a lifetime version of the Edinburgh Postnatal Depression Scale and 
estimated narrow sense heritability of PND at 54%. Further, using data from Swedish 
national registers, they divided MDD into PND and NPMDD and investigated heritability in 
over 580 000 parous female siblings. Using the register data, they estimated the heritability 
of PND at 44% and the heritability of NP-MDD at 32%, while also showing that one-third 
of the genetic variation in PND was unique for the disorder and not seen in NP-MDD, 
supporting the hypothesis that depression during the perinatal period is influenced by genes 
to a greater extent than depression at other times of life.
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Dr Naomi Wray (University of Queensland, Brisbane, Australia) pointed out the dilemma in 
MDD between sample size on the one hand and phenotypic homogeneity on the other. To 
test the hypothesis of PPD as a genetically more homogeneous category than MDD, Wray 
and colleagues compared BD PRS between PPD and MDD patients in two independent 
populations: one from Australia (1450 MDD cases including 484 PPD, 1703 controls) and 
the other from the Netherlands (1699 MDD cases including 208 PPD, 1765 controls). 
Interestingly, they found that BD PRS explained more of the phenotypic variance for PPD 
(r2 > 1.1%, P < 0.008) than for MDD (r2 = 0.06%, P = 0.08), suggesting that PPD and BD 
share more genetic risk than MDD and BD (Byrne et al., 2014).
Dr Samantha Meltzer-Brody (University of North Carolina, USA) discussed the possibility 
of identification of more homogeneous subtypes of PPD by latent class analysis. Data were 
described from the international perinatal psychiatry consortium, PACT (Postpartum 
Depression: Action towards Causes and Treatment), comprising 24 institutions in seven 
countries, and 27 776 patient records submitted with phenotypic data. Using the latent class 
analysis approach, the researchers found that a three-class solution yielded the best fit of the 
phenotypic data. Severity, timing of onset, comorbid anxiety, and suicidal ideation were the 
most distinguishing characteristics. Dr Meltzer-Brody concluded that precise phenotyping is 
important for further exploration of underlying biomarkers and etiological factors in PPD.
Dr Divya Mehta (the University of Queensland, Australia) spoke on the possibility of using 
gene expression profiles from women in the third trimester as a biomarker for PPD. In a 
sample of 29 PPD cases and 40 controls, 116 gene transcripts were expressed differentially 
(corrected P < 0.01), distinguishing cases from controls with 88% accuracy. Further, 
functional annotation implied a role of estrogen signaling (Mehta et al., 2014). Dr Mehta 
also highlighted the need for large international collaboration projects to achieve statistical 
power for detecting robust and reproducible biomarkers in PPD.
The following issues were addressed during the panel discussion: (i) the relation between 
PPD, BD, MDD, and postpartum psychosis. (The PACT study will also investigate 
postpartum psychosis.) (ii) The heterogeneity of PPD (e.g. there is evidence for hormonal 
trigger sensitivity in PPD). Environmental risk may also play a role.(iii) How to get the 
‘noise’ out of PPD, while increasing sample size. (iv) The possibility of recruiting PPD 
cases through social media and creating an online community.
Genetics of lithium response in bipolar disorder (reported by Jie Song)
Dr John Kelsoe (University of California, San Diego School of Medicine, USA) introduced 
the session by stressing that response to lithium in BD may distinguish mechanistically 
different forms of illness. The identification of genetic variants associated with good lithium 
response may therefore yield a way to dissect BD into less heterogeneous parts.
Dr Urs Heilbronner (Ludwig–Maximilian University Munich, Germany) presented the latest 
GWAS results of the International Consortium on Lithium Genetics (ConLiGen) in 2587 
patients. Two definitions of lithium response (dichotomous and continuous) were used on 
the basis of the ‘Retrospective Criteria of Long-Term Treatment Response in Research 
Subjects with Bipolar Disorder’ scale (informally referred to as ‘Alda Scale’) (Manchia et 
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al., 2013). The inter-rater agreement and reliability were moderate to substantial. ConLiGen 
carried out two nonoverlapping GWASs on 1186 and 1401 patients, respectively. A meta-
analysis combining them yielded one directly genotyped SNP, rs74795342, along with three 
imputed SNPs showing genome-wide significant associations with lithium response using 
the continuous response definition. These four SNPs in high LD are located in a long 
intergenic noncoding RNA (lincRNA) region on chromosome 21. Recent studies suggest the 
widespread roles of lincRNAs in gene regulation and other cellular processes. Further 
studies might provide insights into the biological mechanism of lithium’s action. He also 
mentioned that the associations showed robust association in a subgroup of the sample 
diagnosed with bipolar I disorder. The dichotomous definition of lithium response did not 
yield a genomewide significant result. Using this phenotype, the result with the lowest P-
value was also located in a lincRNA region on chromosome 14.
Dr Martin Alda (Dalhousie University, Canada) summarized work in the past two decades 
investigating responders to lithium as a distinct subgroup of BD. Applying the five-point 
criteria of diagnostic validity (Robins and Guze, 1970) to BD responsive to long-term 
lithium treatment, they identified that patients responsive to lithium showed specific clinical 
features (Grof et al., 1993; Calabrese et al., 1996; Greil et al., 1997; Baldessarini et al., 
2000; Bowden, 2001; Passmore et al., 2003). In addition, response to lithium is a 
longitudinally stable and familial characteristic (Grof et al., 2002; Berghofer et al., 2008). 
Both clinical observational and neurobiological studies (Passmore et al., 2003; Kruger et al., 
2006) supported the view of lithium responders as a distinct group that differs from 
responders to other mood stabilizers. In the review of genetic findings, their group 
previously showed CREB family of genes (Mamdani et al., 2008; Alda et al., 2013) and 
synapse-related genes (Lopez de Lara et al., 2010; Cruceanu et al., 2012) associated with 
lithium response. Moreover, Alda presented their newest genome sequencing results. Whole-
exome sequencing and whole-genome sequencing were performed combining samples of 
families and unrelated probands characterized for their response to long-term treatment. The 
most interesting findings included rare variants in HTR3A, HTR3B, and HTR3C genes in 
single families and enrichment of G-protein-coupled receptor gene deleterious variants in 
lithium-responsive families. He finally pointed out that specific genetic variants associated 
with lithium response may not be directly useful because of their modest effect or rare 
frequency, but they can provide insight into the mechanisms of the illness and the 
medication.
Dr Sarah E. Bergen (Karolinska Institutet, Sweden) described GWAS results involving both 
self-reported measures (in 2698 bipolar patients) and objective clinical records (in 1211 
bipolar patients) of lithium response in cases and 8899 healthy controls. When comparing 
lithium responders and nonresponders, the genome-wide association meta-analysis 
combining Swedish and UK samples together showed no genome-wide significant 
associations. In addition, they carried out genome-wide association analyses comparing the 
lithium-responsive subgroup of patients with controls without a history of psychiatric 
disorders. The meta-analyses yielded two SNPs, rs146727601 (located in the PTS gene) and 
rs116323614 (located in the SESTD1 gene), with genomewide significant associations for 
the objective response group. Although the confirmation through direct genotyping of these 
imputed markers and replication in larger samples is warranted, their findings again 
Aas et al. Page 43
Psychiatr Genet. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
suggested that lithium-responsive bipolar patients may define a more etiologically 
homogeneous patient population.
Dr John Kelsoe (University of California, San Diego School of Medicine, USA) described 
two cellular phenotypes that distinguish bipolar lithium responders from nonresponders 
using samples in the Pharmacogenomics of Bipolar Disorder Study. As it is cost prohibitive 
to phenotype very large samples for drug response for GWAS, an efficient strategy may be 
to use cellular models to identify a set of candidate genes that are more likely to be involved 
in drug response, and then test those genes for association to response by targeted 
sequencing or genotyping. In their study, iPSCs derived from lithium responders, matched 
nonresponders, and controls were differentiated into PROX1-positive hippocampal dentate 
gyrus/glutamatergic neurons. Patch-clamp studies showed extended trains of action 
potentials in responder lines and similarly in nonresponder lines, but not in control lines. 
They also observed a corresponding alteration in calcium flux. The hyperexcitability by both 
electrophysiology and calcium flux measures was rescued by lithium, but only in 
responders. Lymphoblasts from lithium responders and nonresponders were treated with 
lithium and gene expression was compared within each patient. Results showed that 
nonresponders show a markedly reduced gene expression response to lithium compared with 
responders, which suggested that the clinical response to lithium is because of a much 
greater change in the physiological state in the cells. The most notable differentially 
expressed genes were CRIP2, AHNAK, ANTXR2, and MYADM. These current findings 
supported lithium-responsive BD to be a mechanistically distinct form of illness. A 
WGCNA is in progress.
(Epi)genetics and (epi)genomics of psychological treatment response (reported by Marcos 
L. Santoro)
Jonathan Coleman (King’s College London, UK) began the session by presenting the first 
GWAS to examine the differential response to cognitive behavioral therapy (CBT) in a 
cohort of children with anxiety disorders. The GWAS was completed on 980 children after 
CBT, and although they did not find any SNP that reached GWAS significance, they raised 
some findings above suggestive significance (P < 5 × 10−6) that are near (± 100 kb) 
candidate genes such as VAV3. He discussed that these variants involved in response to CBT 
probably have small effect sizes, and thus this lack of significance is probably because of the 
sample size, which indeed is large for a study of response therapy, but still small for a 
psychiatric GWAS.
Dr Susanna Roberts (King’s College London, UK) presented her work on gene expression in 
response to exposure-based CBT. They have analyzed the genomewide expression using 
Illumina Human HT12 V4 Expression BeadChip in 78 adults at three time points 
(pretreatment and post-treatment, and follow-up). Using Eigengene Networks, they 
generated nine modules in pretreatment expression data and associated them with clinical 
traits (sex, age, remission time point, and changes in severity). After comparing the 
expression characteristics of treatment responders and nonresponders, they found some 
enriched pathways such as neurotrophins and neurotrophic signaling, cytokines, and immune 
system; these pathways have been implicated in anxiety disorders.
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Dr Michael Meaney (McGill University, Canada) substituted for Rachel Yehuda (Mount 
Sinai School of Medicine, USA) and spoke about her recent findings in promoter 
methylation of glucocorticoid-related genes (NR3C1 and FKBP51) in response to post-
traumatic stress disorder (PTSD) treatment. This was a preliminary test with 16 completers 
of prolonged exposure psychotherapy at three time points (pretreatment, post-treatment, and 
follow-up) to support a large trial (Yehuda et al., 2013). They found that methylation in the 
promoter of NR3C1 exon 1f predicted treatment outcome (more methylated in responders’ 
pretreatment compared with nonresponders). For FKBP51, they found a decrease in 
methylation of exon1 promoter associated with recovery.
Dr Elisabeth Binder (Max Planck Institute of Psychiatry, Germany) presented findings in 
blood gene expression to find predictors for major depression involved in the response to 
CBT, antidepressant drugs, or deep brain stimulation. They used the Illumina HT12 V4 array 
to verify the gene expression at different time points and found that from the top 72 
transcripts of each treatment, more than a half of them had a binding site in the myc-
associated zinc finger protein (MAZ) transcription factor. They also found that MAZ itself 
showed increased expression over the time of treatment. Thus, she showed that MAZ could 
be a biomarker of recovery, but not a biomarker for a specific treatment response.
Dr Thalia Eley (King’s College London, UK) ended the session by discussing where we are 
and where we are going in the still growing field of therapy genetics. She highlighted the 
importance of prediction of treatment response and mentioned that G × E should be better 
explored and that we should clarify the exact mechanisms involved in these specific 
alterations.
Oral sessions
The genomics of affective disorders and ADHD (reported by Maximilian Friedrich and Alex 
Shaw)
Joanna Martin (MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff 
University) discussed to which extent common and rare genetic variants contribute toward 
an ADHD phenotype. Given the strong heritability (76%) of the disease, she underlined that 
even though the burden of large and rare CNVs is significantly higher in children with 
ADHD, common genetic variants can be used to distinguish ADHD cases from controls. 
Thus, both types of variants may contribute toward the disorder. She concluded that rare 
CNVs are independently predictive of ADHD case status, which accords to the polygenic 
liability threshold model postulated for ADHD.
Christel M. Middeldorp (VU University Amsterdam, Biological Psychology) carried out a 
bivariate twin analysis to investigate whether ADHD PRSs enable prediction of the most 
common ADHD comorbidities such as aggressive behavior as well as anxiety and 
depression. Middeldorp pointed out that for the aggressive phenotype, a consistent 
prediction by the ADHD PRS could be made between 3 and 18 years of age, but not so for 
the anxious depression phenotype. The high monozygotic scores in the twin correlation 
study suggest that this is an effect of common genetic factors, whereas for anxious 
depression, a common environmental risk seems more likely. She put in perspective that 
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these findings may be because of ‘cross-assortative mating’, a phenomenon explaining that 
patients with high ADHD scores preferentially mate, with more anxious individuals leading 
to an increased comorbidity of those conditions. Following her talk, the question arose as to 
why bivariate analyses were used instead of multivariate analyses. Middeldorp clarified that 
the latter approach can be used to identify associated genes for both phenotypes without 
allowing further differentiation, whereas the bivariate approach enables a more concise 
discrimination of genetic factors contributing toward both comorbidities.
Evie Stergiakouli (MRC Integrative Epidemiology Unit at the University of Bristol) 
investigated whether the same genetic variants contribute toward both behavioral traits in a 
control sample as well as to clinically relevant traits in an ADHD sample. Stergiakouli 
compared PRSs of ADHD symptoms in a general population sample and an ADHD sample 
and elucidated whether they could predict the diagnostic status and severity of the disorder. 
The main findings of this analysis were that PRSs are associated with the total number of 
ADHD symptoms and furthermore can distinguish between clinical samples and the general 
population. She concluded that the same common genetic variants for ADHD traits in the 
general population are implicated in clinical ADHD and that they predict both severity and 
ADHD diagnostic status. She also suggested that additive genetic influences are relevant for 
complex behavioral traits in both general population and clinical ADHD samples.
Dr Najaf Amin (Erasmus MC, the Netherlands) discussed her work aimed at identifying rare 
genetic variants that confer large effects on depression. From a large family of Dutch descent 
spanning 23 generations, 1686 individuals were exome sequenced and 1522 individuals 
were genotyped on an exome variation SNP chip. Several approaches were used to identify 
relevant variation including linkage, haplotype reconstruction, and association analyses, with 
three variants of interest identified. A missense variant was found on chr9p24 (P = 9 × 10−4, 
MAF = 1%, effect = 2.47) linked with a high Hospital Anxiety and Depression Score. The 
authors also found a variant with a significant single-variant genome-wide association with 
Hospital Anxiety and Depression Score on chr11q13 (P = 9.2 × 10−8; MAF = 1.7%, effect = 
3.36). The gene harboring this variant is expressed in specific brain regions, is functionally 
associated with neurotransmitters relevant to depression, and has been implicated in BD. A 
highly conserved missense variant on chromosome 18q21 was significantly associated (P = 
1.3 × 10−9, MAF = 1%, effect = 4.37) with Centers for the Epidemiologic Studies of 
Depression score. The variants in 9p24 and 18q21 failed to replicate in the independent 
replication dataset, whereas the variant in the 11q13 region was not found in any replication 
dataset, which highlights one of the difficulties in validating genetic effects of putatively 
functional rare variation across studies. Future functional work will involve the creation of 
iPSCs and study of their metabolomic profiles.
Professor Dr Sven Cichon (University of Basel) presented results from a pathway-based 
analysis of a large BD GWAS dataset. The motivation for this and similar studies is that 
variants associated with psychiatric disease so far have small effect sizes, which are difficult 
to detect using GWAS with currently available sample sizes and that knowledge of each 
associated gene alone may not individually yield deep insights into disease biology. An 
interval-based enrichment (INRICH) pathway analysis was carried out on genes derived 
from a GWAS of 9747 patients with BD and 14278 controls, which represents the combined 
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GWAS data from PGC1-BD and BD-cohorts from the MooDS consortium, and is the largest 
BD GWAS dataset to date (Mühleisen et al., 2014). Genes were tested for enrichment within 
430 sets on the basis of biological pathways including 3881 genes (Reactome; http://
www.reactome.org). A subset of 10 intervals, corresponding to a single gene each, was 
enriched for the Reactome pathway ‘neural cell adhesion molecule signaling for neurite 
outgrowth’. This subset was the only pathway that survived the full multiple testing 
procedure (P = 0.002). There are multiple lines of support for the involvement of the NCAM 
pathway including the presence of genes with significant association from BD GWAS 
(CACNA1C, NCAN, and CREB1; Mühleisen et al., 2014), candidate gene studies showing 
an association, and postmortem brain gene expression studies. Future work will involve 
evaluating different P-value thresholds for inclusion of GWAS SNPs in the analysis using 
alternative methods for enrichment analysis and using protein–protein interactions to define 
the target gene sets with potential enrichment.
Lower EA has been associated with a higher risk for depression (MDD) in multiple studies; 
however, the effects that contribute toward this association and the direction of effects within 
this association remain unclear. Major hypotheses are that low EA has a causal effect on risk 
for MDD, MDD has a causal effect on EA, or a third factor exerts pleiotropic effects on both 
MDD and EA. Dr Wouter J. Peyrot (VU University Medical Center & GGZ inGeest, the 
Netherlands) discussed his study in which he aimed to evaluate the hypothesis of a 
pleiotropic genetic effect contributing toward the association between low EA and high risk 
of MDD. Using logistic regression, EA was associated with MDD in their dataset as 
expected, with an effect size of 0.85 per SD increase in years of education (95% confidence 
interval 0.82–0.88). This association was also found using only MDD cases with an AAO of 
greater than 30 years. However, no consistent evidence was found for pleiotropic genetic 
effects. PRSs were predictive within either EA or MDD, but not when using one dataset as 
the discovery sample and the other as the target sample. Given the association between late-
onset MDD and EA, the causality of MDD on EA seems unlikely. It is possible that there is 
a relatively low genetic correlation that the study had insufficient power to detect or that EA 
exerts an effect on risk for MDD. Future work in this area could examine environmental 
factors, such as socioeconomic status, that may account for pleiotropic effects.
Epigenetic approaches (reported by Denise Haslinger and Luca Pagliaroli)
Sarah Marzi (King’s College London, UK) presented her findings on allele-specific 
methylation (ASM) in brain and blood samples. Although methylation is symmetric on both 
alleles across most of the human genome, there are several studies reporting that ASM is a 
common phenomenon (Schalkwyk et al., 2010). In their discovery sample, they tested 
postmortem brain and whole-blood samples of three control individuals. By measuring the 
change in the relative allele score, they found a cerebellum-specific ASM in rs959246. 
About 4% of the informative SNPs showed allelic skewing with a change in relative allele 
score more than 0.1. They observed a strong and tissue-specific ASM in blood and 
cerebellum, whereas the cortex showed uniformly low ASM. In the replication sample (n = 
38), they found differentially methylated regions in the vicinity of the top 100 tissue-specific 
ASM sites. In addition, they identified regions of hemimethylated probes near polymorphic 
ASM sites and showed that genotype-driven ASM can be tissue specific.
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Dr Chloe Chung Yi Wong (King’s College London, UK) performed a comprehensive 
epigenome-wide scan for autism susceptibility loci across three brain regions (dorsolateral 
prefrontal cortex, primary auditory cortex, and cerebellum) in 218 postmortem brain 
samples of ASD patients. She observed significant ASD-associated DNA methylation 
differences in both novel genomic regions as well as in vicinity of several known ASD 
genes. Disease-associated epigenetic differences were found likely to be brain region 
specific. By carrying out a WGCNA, Dr Wong identified a number of significant ASD-
associated differentially methylated modules that showed enrichment for 
neurodevelopmental pathways.
A recent study on gene–childhood trauma interactions showed that dexamethasone (Dex) 
treatment of human hippocampal progenitor cells (HPCs) induces GR activation, leading to 
a specific demethylation at intron 7 of FKBP5 (Klengel et al., 2013). Here, Dr Nadine 
Provençal (Max Planck Institute for Psychiatry, Munich, Germany) presented a genome-
wide analysis of the epigenetic effects of GR activation in HPCs after Dex treatment. This 
treatment had a broad impact on DNA methylation and hydroxymethylation and could 
induce specific DNA methylation and gene expression changes, some of which are long 
lasting. A comparison of their findings with an epigenomic analysis of probands with a 
history of child abuse (Dunlop et al., 2012) indicated an overlap of DNA methylation in 
Dex-treated HPCs and proband blood samples.
Dr Mill’s (University of Exeter) research suggested a strong correlation between ANK1 
hypermethylation and AD-associated neuropathology. In a comprehensive study of 120 
individuals from the MRC London Brain Bank for Neurodegenerative Disease (KLC), the 
genomic DNA of four different brain regions has been investigated. In particular, he focused 
on the entorhinal cortex, PFC, superior temporal gyrus, and cerebellum. Three replication 
cohorts have been used from the Mount Sinai Alzheimer Disease and Schizophrenia Brain 
Bank (n = 144), the Optima/Oxford Study (n = 61), and the Harvard/Religious Order Study 
(n = 708). The ANK1 correlation was confirmed from both the second and the third 
replication, which showed an AD-associated hypermethylation across an extended region of 
the brain. Meta-analyses across the three sample cohorts (London, Mount Sinai, Oxford) 
confirmed the neuropathology associated with cortex-specific hypermethylation for ANK1 
CpG sites (cg11823178, cg05066953). The fourth study (Harvard) confirmed the previous 
findings once again. These data provide compelling evidence of an association between 
cortex-specific ANK1 hyper-methylation and AD-related neuropathology.
Dr Spiers (King’s College London) analyzed a cohort of fetal brain tissues to investigate the 
level of DNA methylation during brain development. The analysis of 179 samples from the 
fetal cohort showed that 43.6% of sites showed hypermethylation, whereas 56.4% showed 
hypo-methylation. Another interesting result is that, although the majority of sites were 
located on the X-chromosome, 521 autosomal sites showed sex differences in DNA 
methylation. Weighted gene comethylation network analysis identified 22 modules of 
comethylated loci enriched for functional pathways associated with fetal brain development. 
In conclusion, this study provides increased knowledge of the molecular mechanisms that 
regulate dynamic gene expression across human brain development. Moreover, it identifies 
pathways contributing toward sexual differentiation of the brain.
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Starting from previous studies that showed a hypermethylation of CpG3 and CpG4 at the 
SLC6A4 promoter in both lymphoblastoid cells and brain specimens from patients with BD, 
Dr Ikegame (the University of Tokyo) investigated DNA methylation in blood samples of 
patients with BD. The ratio between 456 controls and 448 cases separated by sex showed a 
hypermethylation at CpG3 in male BD as reported previously by Philibert et al. (2008). The 
comparison of the DNA methylation ratio at CpG3 separately by genotype showed a 
hypermethylation in L variant carriers of male BD. Further analysis on the basis of L variant 
subtypes showed a specific SLC6A4 hypermethylation in male L variant (16–3) carriers with 
BD. Furthermore, a luciferase assay showed enhanced gene expression in the SLC6A4 
promoter region.
Novel ‘Omics’ insights into schizophrenia and bipolar disorder (reported by Siri Ranlund 
and Antonio Pardiñas)
Robert Power (Institute of Psychiatry, King’s College London, UK) reported findings from a 
PRS analysis investigating the link between psychiatric illnesses and creativity. PRS for SCZ 
and BD were calculated from the PGC results (Psychiatric GWAS Consortium Bipolar 
Disorder Working Group, 2011; Schizophrenia Psychiatric Genome-Wide Association Study 
(GWAS) Consortium, 2011). The target sample included 104 220 Icelandic individuals 
(1312 individuals in creative industries; 521 schizophrenic patients, 680 bipolar patients, and 
92 647 population controls). The creative individuals included chess players, painters, 
writers, musicians, and dancers. Results showed that both SCZ and bipolar PRS significantly 
predicted creativity. Thus, individuals with high genetic risk for these disorders were more 
likely to be creative. Bipolar (but not SCZ) PRS also predicted whether an individual goes to 
university as well as higher grades. Hence, bipolar genetic risk seems to be associated with 
increased cognitive ability. Replication of these findings is currently underway. Power 
concluded that common variants for bipolar illness and SCZ may not be entirely deleterious 
and that bipolar PRS appears to be linked to higher cognitive functioning, whereas SCZ PRS 
is not.
Dr Manuel Mattheisen (Centre for Integrated Register-based Research, Aarhus University, 
Denmark), on behalf of Professor Esben Agerbo, reported results from a study investigating 
the link between family history and PRSs in the risk of developing SCZ. PRS for SCZ were 
calculated using results from the PGC mega-analysis (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014). The target data set was a Danish population-based 
sample, including 866 schizophrenic patients and 871 controls. Family history was defined 
as those with a first-degree relative with a psychiatric illness. Results indicated that there is 
an interaction between family history and PRS. A family history of SCZ/psychosis had only 
a limited impact on the risk of developing SCZ among patients with low genetic liability, but 
the impact increased rapidly with increasing liability. Mediation analysis showed that up to 
47.7% of the effect of family history was mediated through PRS. For the remaining52.3%, 
different explanations are possible, including shared environmental risk factors and 
undetected genetic risk variants, and most likely a combination of the two. Mattheisen noted 
the limitations of the study including the small sample size and the fact that the PRS analysis 
does not take into account all genetic risk factors (i.e. rare variants).
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Dr Stephan Ripke (Massachusetts General Hospital, Boston, USA) reported an update of the 
recent SCZ PGC results (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014), finding more than 100 significantly associated loci. Among the 
associated variants are calcium channel genes, which could provide possible novel drug 
targets, as well as glutamate-related genes and dopamine DRD2 receptor genes, both in line 
with hypotheses of SCZ. However, there are also associated regions with yet unknown 
biological functions and there are several methods available to investigate this. Tissues 
showing enrichment include the nervous system and also the immune system, again in line 
with hypotheses of SCZ pathogenesis. Enriched gene-set analysis can identify candidate 
genes for further investigation. Ripke concluded by arguing that the PGC has been 
successful with its core work in identifying new risk variants for SCZ. However, the 
secondary analyses, to investigate the biological mechanisms linked to the identified risk 
loci, require more work. This is currently underway by several collaborators.
As a representative of the Commonmind Consortium (http://www.commonmind.org), 
Professor Pamela Sklar (Icahn School of Medicine at Mount Sinai) summarized their 
preliminary first analysis of 700 postmortem brain samples from SCZ patients and healthy 
controls. These samples were genotyped on an OmniExpressExome platform, which, after 
quality control, delivered a median of 16 423 genes valid for analysis in each sample. These 
data were supplemented by chromatin immunoprecipitation sequencing and RNA 
sequencing procedures, which provided expression data. Differential expression was found 
between cases and controls, with 199 downregulated genes and 267 over-regulated genes in 
cases, including members of the Ephrin and Semaphorin families, and the Slit-Robo 
pathway. A possible duplication of the KCTD13 gene was also found in cases, which has 
been previously linked to changes in cell proliferation and apoptosis (Golzio et al., 2012). 
Genome-wide patterns of expression showed depletion of expression quantitative trait loci 
(eQTLs) in intergenic regions, which might be related to SNP associations found in the most 
recent GWAS of SCZ (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014). Finally, an analysis pipeline using Bayesian Causal Expression 
Networks was shown, which might potentially lead to increased detection of functional 
connections between causal genes. The full details of data generation and analysis of this 
project are available on Synapse (http://www.synapse.org).
Dr Douglas Ruderfer (Mount Sinai School of Medicine) reported the extended analysis of a 
Swedish cohort of 4978 SCZ cases and 6256 healthy controls that had been screened 
previously for psychiatric CNVs (Szatkiewicz et al., 2014). The new methodology included 
exome sequencing and indel calling by a hidden Markov model (Poultney et al., 2013) in an 
attempt to detect a possible burden of rare variation in particular genes. Although no novel 
genetic regions were found with a significant presence of CNVs, an overall burden of these 
was found in cases respective to controls. Also, no CNV enrichment was found on gene-set 
tests, but the analysis of trio families pointed to the presence of deletions in calcium channel 
genes, found in six cases and 0 controls. This dataset is currently being supplemented by the 
addition of roughly 5000 additional individuals.
More details from the same Swedish cohort were provided by Dr Giulio Genovese (Broad 
Institute of MIT and Harvard), who reported on the assessment of somatic mutations. 
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Previous analyses had reported subtle differences in LoF mutations between cases and 
controls, with some of these being within brain expressed genes. As most of the LoFs were 
population singletons, they were considered to be de novos, but they could be as recent as to 
have occurred in embryonic or postembryonic phases. These somatic mutations are not 
heritable but, depending on the tissues in which they manifest, can have an impact on 
clinical phenotypes. By the analysis of allelic fractions (Carter et al., 2012), somatic 
mutations can be detected in sequence data from blood because of their amplification by 
clonal expansion in hematopoietic tissues. In the Swedish cohort dataset, 3111 somatic 
mutations were found, all of them singletons. These mutations constituted LoFs in several 
genes related to tumor suppression in leukemia (DNMT3A, TET2, and ASXL1) and were 
themselves associated with a 13-fold risk of this disease. The raw number of somatic 
mutations was found to be increased in SCZ cases (odds ratio = 2.2), which may be related 
to the increased prevalence of cigarette smoking in patients with SCZ.
Genomic approaches in schizophrenia, substance abuse, and post-traumatic stress 
disorder (reported by Giorgia Quadri and Stefanie Malan-Müller)
Dr Duncan (Broad Institute at MIT and Harvard) presented the first results of a GWAS on 
PTSD carried out by the PGC. PTSD is a common psychiatric disorder. Its phenotype 
depends on experiencing a traumatic event and its symptoms involve the re-experiencing of 
the traumatic event and having increased physiological arousal such as hypervigilance in 
response to the trauma. Although the biology of this condition is considered to be well 
understood, genetic variants contributing toward the heritability of PTSD are still largely 
unknown. To gain more insight into the genetic architecture of this disorder, the PGC formed 
a PTSD group to perform a GWAS. The interesting aspect of the datasets used for this 
GWAS on PTSD is the ancestry. A typical PGC dataset predominantly comprises European 
samples; the PTSD dataset instead included six African American datasets, six European 
American datasets, and one Hispanic origin dataset. The challenge of this was the absence of 
a method to assign ancestry in a way that is replicable and standardized – this is normally 
dealt with by carrying out a PCA with reference populations. Duncan and her group 
developed a methodology relying on SNP weighting to overcome this issue. The first stage 
of this analysis involved a meta-analysis across the African American dataset, one across the 
European American sample, and finally a meta-analysis across the three ancestry groups. In 
the meta-analysis carried out across the three ancestry groups, there were two loci that 
crossed the threshold of genome-wide significance; one of them appears to be a false 
positive, but the other locus did not. This SNP found in the intergenic region of chromosome 
4 has a P-value of 3.76E − 8 and a MAF of 8%.
The other interesting aspect of this study was the sign test between SCZ and these datasets; 
indeed, both in the African American and in the European American datasets, there were 
stretches of genome with a significant P-value. 3 : 4 showed significance for the European 
American; 1 : 4 showed significance in the African Americans, whereas in the Hispanic 
cohort, the sign test was not significant, likely because of the small sample. It is also 
important in terms of equity in science that diverse samples are included in the projects.
Aas et al. Page 51
Psychiatr Genet. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dr Duncan and her team hope to follow the trajectory of other similar studies to gain more 
insight into the genetic architecture of PTSD.
Dr Benros (Mental Health Centre, Copenhagen) carried out a study on the association 
between infections and SCZ and the influence of PRSs. Several studies have suggested an 
important role of infections and immune responses in the etiology of SCZ. However, the 
causal pathway underlying an increased risk of SCZ in individuals with infections is still 
unknown. SCZ presents itself with a series of immune alterations such as increased 
cytokines, increased autoantibodies, dysfunction of the blood–brain barrier, and low-grade 
nerve inflammation.
Benros and his group used the Danish registers (1981–2008), which, together with the 
psychiatric registers, allowed the identification of 39 076 individuals with SCZ. The cases 
utilized for this study included individuals with a diagnosis of SCZ from 1994 to 2008 born 
from 1981; matched controls were identified in the registers. All individuals analyzed were 
adjusted by age, sex, and date of birth. Results showed that individuals with autoimmune 
diseases and three or more hospital contact infections had 3.5 times increased risk of 
developing SCZ. The same pattern was observed when excluding individuals who used 
substances of abuse and those with a psychiatric family history. This association could be 
because of the genetics of the shared risk factors but could also be explained by the 
possibility that individuals affected by SCZ may be more genetically vulnerable to infections 
causing the development of SCZ.
The polygenic scores were based on the PGC discovery data without the Danish population 
and the Danish replication sample and included 1697 schizophrenic patients and 1725 
controls. The Danish replication study showed a significant association between the 
polygenic score and SCZ, and when used as a continuous variable, it increased the risk of 
SCZ by 47%. It was shown that 40% of patients with SCZ had previous hospital contact 
with infections and that hospital contact with infections increased the risk of developing 
SCZ by 55%. When dividing the PRSs into quartiles, it was shown that the upper quartile of 
the polygenic score was associated with SCZ by 2.29 times in individuals with no hospital 
contact with infection and by 3.36 times in individuals with previous hospital contact with 
infections. Instead, when the PRS was used as a continuous variable, it was shown that in 
individuals who had previous hospital infection, the risk for SCZ was increased by 44%, 
whereas in individuals who did not have hospital infections, the risk decreased by 36%. 
There was no interaction between the effects of the infections and the PRS and the risk of 
developing SCZ.
The study itself has several strengths such as having a prospective study design using 
population-based registers, and having data obtained by following a large population 
longitudinally in time with follow-up. The limitations instead include the sample inclusion 
being based on clinical diagnosis rather than criterion-based diagnosis, but previous studies 
have confirmed the validity of the information recorded in the registers. In conclusion, 
infections are associated with an increased risk of developing SCZ also after adjusting for 
the polygenic score, which did not influence the association between infections and SCZ or 
the risk of acquiring infections.
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Dr Paciga’s presentation aimed to summarize some of the work of the Neuroscience Group 
from Pfizer carried out in the last year to identify new targets for SCZ and to explain how 
human genetics is applied to the discovery of new targets for drug development and the 
process established for triaging novel loci mechanisms for SCZ.
Human genetics can be applied to all stages of drug development, with a focus primarily on 
discovery genetics, and to clinical genetics; human genetics is applied to identify and also 
validate new drug targets and to help in the development of new mechanistic therapeutic 
hypotheses. The process developed by the company to go from risk loci to a new medical 
entity involves the definition of a phenotype and or endpoint that is strongly associated with 
a locus/loci. Then, the locus is mapped to a gene and insight has to be gained on how that 
gene can be causal or protective for the disease. The identified genes then have to be 
considered in the biology of the disease with a final need to identify a testable therapeutical 
hypothesis that can be tested.
The PGC has a very productive SCZ working group that has been in place for several years 
now; Dr Paciga and the Neuroscience Group from Pfizer joined this group in 2012 using 
data generated using a SCZ case–control dataset. As a result of the PGC release 2, 125 
genomewide significant loci were identified. However, a list of loci does not equal a drug 
target; thus, a process was needed to obtain associated loci to test in a clinic.
A group that included geneticists, clinicians, and chemists was established to map those loci 
to specific genes. The process involved taking the 125 loci and using an LD gene mapping 
process with the assumption that each independent locus would be associated with one 
causal gene; the list was then narrowed down to 114 genes; and the resulting genes were 
then annotated to other available data including eQTL data for functional variants within 
those genes and previous literature knowledge was used to understand what could be 
associated with those genes. With manual curation, the list went down to 14 lead genes; 
subsequently, through a manual process using other available data and literature in 
consideration of animal models and knockouts, a list of around five priority genes was 
produced for the follow-up. Finally, with target reviews of animal models, the aim is to get 
to 1–2 target genes.
This method was first used for cardiovascular disorders and performed well for SCZ too. 
The loci identified here as enriched were for biological functions related to SCZ; in addition, 
the genes identified were enriched in relevant tissues with a two-fold enrichment of these 
genes for high brain expression.
Dr Younes Moukrab (Eli Lilly, UK) developed a pipeline to aid in the functional annotation 
of significant variants identified during GWASs for further biological analysis. The pipeline 
uses Variant Effect Predictor (http://www.ensembl.org) to annotate variants and their 
associated genes together with publicly available data on various functions and 
characteristics of the gene. The pipeline was applied to summary data of the Schizophrenia 
Working Group of the Psychiatric Genomics Consortium (2014) study that identified 108 
distinct loci associated with SCZ, of which 84 have not been implicated previously in SCZ. 
Variant Effect Predictor analysis identified 268 genes for which variants were located 
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outside gene boundaries; for 36 genes, the variants were located inside a gene and a number 
of genes were affected by missense variants, including SLC39A8, APOPT1, ITIH3, and 
FES. These data can help to build specific hypotheses on changes in gene function and 
subsequent associations with SCZ etiology.
Using one of the items on the Fagerstrom test for nicotine dependence (FTND), the time to 
smoke the first cigarette in the morning (TFC), Dr Xiangning Chen (Virginia 
Commonwealth University, USA) and colleagues at the FTND consortium identified risk 
genes for nicotine dependence. The consortium included 15 independent datasets and over 
19 000 European individuals. Genotype imputation and association analyses were carried 
out at each site independently, and meta-analyses were used to combine data from individual 
datasets. Results indicated that the α5 nicotinic cholinergic receptor (neuronal) (CHRNA5-
A3-B4) gene cluster was associated with FTND scores as well as the TFC phenotype. TFC 
analyses identified three new loci, sorbin and SH3 domain-containing 2 gene (SORBS2), 
and two long noncoding RNAs, BG182718 and AA333164; the latter was replicated in 
independent samples. Some of the other top candidate genes (supported by both FTND and 
TFC analyses) have previously been found to be associated with smoking behaviors 
[cholinergic receptor, nicotinic, β3 (neuronal) (CHRNB3)], cancers [cadherin 12, type 2 (N-
cadherin 2) (CDH12), heparan sulfate (glucosamine) 3-O-sulfotransferase 4 (HS3ST4), and 
major facilitator superfamily domain containing 2A (MFSD2A)], obesity [kinesin family 
member 2B (KIF2B) and CDH12], and psychiatric disorders [CDH12 and zinc finger 
protein 804A (ZNF804A)].
Professor Eske Derks (Academic Medical Center, Amsterdam) and colleagues carried out a 
meta-analysis on one of the largest GWAS on cannabis use/initiation. It included results 
from 11 discovery samples from Europe, the USA, and Australia and two replication 
samples in cohorts from the UK and the Netherlands. Their fixed-effects meta-analysis 
showed no genome-wide significant associations; however, there was enrichment of 
nominally significant findings. The most statistically significant marker was rs2099149, an 
intergenic polymorphism located close to the transmembrane and tetratricopeptide repeat 
containing 1 gene (TMTC1) and the importin 8 (IPO8) gene. These findings were, however, 
not replicated in the replication sample. Gene-based tests identified two significantly 
associated genes in the discovery sample, namely, interleukin 17B (IL17B) and prenyl-
cysteine oxidase 1 like (PCYOX1L). IL17B plays a role in immunity and inflammation; 
again, these results could not be replicated in the replication sample. The initiation of 
cannabis use may be because of various factors, most of which are largely unknown. Future 
studies will focus on alternative phenotypes such as age at initiation, frequency of use, and 
cannabis use disorders.
Novel approaches and tools for bench and bedside (reported by Luca Pagliaroli)
Dr Steven McCarroll (Stanley Center of Psychiatric research, Broad Institute of MIT and 
Harvard) held a conference on DropSeq. Riding the motto ‘less smoothie and more fruit 
salad’, he developed a new approach that uses beads to ‘isolate cells in millions of tiny 
droplets’. He developed a cell ‘barcode’ by a progressive split-pool synthesis on beads that, 
after 12 rounds, allows the generation of 16 million beads with different barcode sequences. 
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In the DropSeq, the cells are lysed in droplets and the mRNAs are hybridized to the beads 
that are subsequently collected and amplified in a single reaction. After 100 experiments, it 
has been possible to distinguish 100 000 transcripts per cells.
So far, it is possible to originate 10 000 single cell libraries per day at 0.06€/cell. The current 
challenge is focused on the understanding of (i) brain tissues and their development, (ii) 
pathological states (e.g. SCZ), and (iii) the relationship between genetic results and specific 
cell populations.
Dr Niels Tommerup (Wilhelm Johannsen Center for Functional Genome Research, 
University of Copenhagen) analyzed data from the Danish prenatal cohort seeking 
unselected carriers of de-novo balanced chromosomal rearrangements. It was possible to 
identify eight carriers among the neurodevelopmental/neuropsychiatric disorders that are the 
main causes of deletions, inversions, or translocations. The first unbiased mutagenesis screen 
(10 000 breakpoint; 150 laboratory; 50 countries) provided evidence that the screening 
becomes more cost-efficient with a database search for known mutations. Indeed, this study 
identified 2700 protein-coding genes; 1500 long noncoding genes; less than 200 regulatory 
domains specifying the body plan; and more than 20% associated with NDD.
Dr Stephan Ripke (Massachusetts General Hospital) presented the PsychChip. The aim of 
this project is the genotyping of 100 000 + psychiatric disease samples. Its goals are to find 
new associated loci, to determine the rate of rare mutations, and estimate the role of CNVs. 
The PsychChip is designed with 50 000 SNPs (PsychSNP), a 256 000 SNP GWAS 
Backbone, and 240 000 rare and low-frequency exome variants (exome chip). Each sample 
costs $83. The custom content accounts for (i) all independent signals with P-value less than 
0.01 in any study (25 702/38 178) and (ii) the fine mapping of loci with P-value less than 1 × 
10−5 (4498/7242). Its efficiency derives from the choice of SNPs that are already known in 
psychiatric diseases with SCZ as the front runner (23%) for GWAS-significant findings.
There are three steps to data generation: (i) genotype calling using Birdseed and GenCall; 
(ii) merging the data, followed by further genotype calling using zCall (rare variant); and 
(iii) final elaboration (QC). This method proved to perform well even at a lower price 
compared with other chips available on the market. So far, 40 268 samples have been 
genotyped and the data are available at http://www.med.unc.edu/pgc/psychip.
Dr Rebecca Knickmeyer (UNC Chapel Hill) focused her attention on GWAS studies. One of 
the goals is to investigate whether common SNPs are associated with global brain volume at 
2 weeks of age. ‘By the time the symptoms arise everything has already happened’, and for 
this reason, it is important to study infants. Indeed, the prenatal period is the ‘main window’ 
of brain development and strong evidence suggests that multiple diseases have their origins 
in early life (in the first year of age, the brain volume has already reached 82% of its final 
dimensions).
In a comprehensive study of tissue volumes of 988 neonates, different loci have been 
identified as able to increase the mental disability rate, including rs8030297 on chr15q13.3, 
RBFOX2 (cerebrospinal fluid), DPYSL3–ZNF385D (cortical white matter), and 13q14.2–
q14.1 (cortical gray matter). Future studies should investigate (i) the surface area and 
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cortical thickness, (ii) functional connectivity, (iii) DTI phenotype, (iv) G × E interactions, 
and (v) exome sequencing in extreme phenotype.
Dr Emma Sprooten (School of Medicine, Yale University) focused her attention on the study 
of valid endophenotype to discover, localize, and validate risk variants. A source-based 
morphometry has been applied to investigate the endophenotype of gray matter in several 
studies. Sprooten showed evidence for linkage of 12q24 to gray matter in the insula and 
mPFC, variation of gray matter in the insula and mPFC between individuals, and suggested 
that reductions of gray matter may be associated with SCZ. Therefore, insula and mPFC 
morphology may be a neuroanatomical correlate to SCZ that is coinherited with SCZ 
susceptibility variants at 12q24.
Dr Bryan Dechairo (AssureRx Health) spoke on the use of combinatorial 
pharmacogenomics to avoid the worsening of patient conditions under medication treatment. 
He presented GeneSight, a genetic test that can analyze genes to help healthcare providers in 
selecting the medications that are more likely to work for patients. He compared this 
approach with three clinical studies: PineRest, Ham Clinic, and LaCrosse. In his opinion, 
medications can be divided into three categories: green (right), red (wrong), and yellow 
(uncertain). In the PineRest RCT study, almost 30% of patients in a typical psychiatric 
practice are taking red category medications. Treatment guided by GeneSight resulted in up 
to a four-fold greater improvement in symptoms. The use of ‘red bin medication’ results in 
an increase of $5188 in healthcare utilization costs annually, whereas medication based on 
GeneSight results in a saving of $1035.60/patient.
Dr Franke (Department of Human Genetics and Psychiatry, Donder’s Institute of Brain, 
Cognition and Behaviour, Radboud University Medical Center) presented an overview of the 
Aggressotype project. As part of the EU FP7 program, the international consortium 
Aggressotype was founded in 2013 and focused on aggression and impulsive behavior in 
ADHD and conduct disorders. This project involves preclinical research at different levels: 
from genetics, to cells, to brain functions, and eventually to behavior. The following areas 
are under investigation: epigenetic studies of animal models to find biomarkers; imaging 
studies of animal models; alternative and classical animal model approaches suitable for 
behavioral studies and high-throughput screening; and NeuroIMAGE projects to study 
human behavior.
Functional genomics and endophenotypes (reported by Jose Estrada and Stefanie Malan-
Müller)
James Crowley (University of North Carolina at Chapel Hill, USA) is studying how the 
antipsychotic drug olanzapine induces changes in the gut microbiome to induce metabolic 
side effects. In this study, a mouse model was utilized in which mice on a high-fat diet were 
administered either oral doses of olanzapine or placebo control. Mice in the olanzapine 
cohort showed a 20% increase in weight gain compared with non-olanzapine mice. The 
weight-gain effect is lost in olanzapine-treated mice that are bacteria free and raised in an 
antiseptic environment. Weight-gain effects in olanzapine-treated aseptic mice are regained 
if the mouse gut is allowed to be recolonized. Fecal pellets from olanzapine-treated and 
placebo control mice were genetically analyzed and decreased growth was identified in three 
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species of gut microbiota: Bacteroidia, Erysipelotrichi, and Gammaproteobacteria. Analysis 
of in-vitro Escherichia coli growth when treated with olanzapine shows that the drug has 
antimicrobial properties.
Xueying Jiang (National Institute of Mental Health, USA) presented work that examines the 
effects of valproic acid (VPA) on Trank1 expression, a gene implicated by GWAS studies in 
bipolar individuals. Jiang analyzed four iPSC and seven NPC lines that were treated with 
placebo or VPA for 72 h. VPA treatment on all cell lines increases Trank1 expression, 
whereas the risk allele rs9834970 of Trank1 is associated with lower expression. Lithium 
treatment did not increase Trank1 expression. The negative correlation between Trank1 and 
HDAC1 provides early evidence that Trank1 expression may be regulated by an epigenetic 
mechanism.
Stefanie Malan-Müller (Stellenbosch University, South Africa) studied the molecular 
mechanisms of D-cycloserine (DCS) in the extinction of fear in rodent models and relief of 
PTSD symptoms in humans. Left dorsal hippocampi tissue was taken from rodents that were 
subjected to a fear assay with and without DCS or no fear exposure with and without DCS, 
and analyzed for RNA and microRNA expression using next-generation sequencing 
technologies. Bioinformatics were utilized to identify microRNA–mRNA interactions 
specific to the fear condition-DCS treated rodent. One hundred and twenty-one genes and 32 
microRNAs were predicted to be biologically significant for PTSD. Follow-up analysis on 
the candidate microRNA rno-mi31a-5p is being completed to identify whether it is capable 
of regulating a subset of the candidate genes.
Annika Forsingdal (Lundbeck A/S and University of Copenhagen, Denmark) investigated 
behavioral and transcriptomic alterations in homozygous 15q13.3 knockout (15q13.3−/−) 
mice. The 15q13.3 hemizygous deletion (15q13.3+/−) has been shown to strongly increase 
the risk of SCZ and other psychiatric diseases (Malhotra and Sebat, 2012) and animal 
models of this hemizygous microdeletion syndrome helped to identify disease-related 
phenotypes; the phenotypes were, however, subtle (Fejgin et al., 2013). The current study 
utilized homozygous 15q13 knockout mice to create stronger phenotypes to aid in the 
mechanistic understanding of the effects of this CNV. The knockout mice were characterized 
using basic physiological, behavioral, and disease-related behavioral tests. They also 
performed RNA sequencing of brain and body samples of knockout and wild-type mice. 
Basic and behavioral characterization showed that the phenotypes of the 15q13.3 knockout 
animals were similar to those observed in human homozygous carriers. The phenotypes of 
15q13.3−/− were more pronounced compared with that of 15q13.3+/−. They also observed 
considerable transcriptional regulation. Suggestions were also made to focus on certain brain 
regions and not the whole brain for RNAseq.
Professor Abraham Palmer (University of Chicago, USA) used GWAS data from 398 
healthy, nondrug abusing volunteers to investigate subjective responses to amphetamine 
(Hart et al., 2012). This response is heritable and may serve as an endophenotype for various 
psychiatric disorders. They used a double-blind, placebo-controlled, within-participant 
design and performed GWAS using genotypes from Affy 6.0 imputed to 1000 Genomes. 
Several putative associations were identified; however, there was no convergence on a SNP 
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or LD block and none of these SNPs were coding variants or known eQTLs. An SNP in an 
intron of cadherin 13 (CDH13), rs3784943, was found to be associated with the positive 
subjective effects of amphetamine; this gene has been associated previously with various 
psychiatric traits, including methamphetamine (Uhl et al., 2008) and cocaine dependence 
(Gelernter et al., 2014). By comparing their data with the PGC1 SCZ dataset, they 
discovered that SNPs associated with the euphoric response to D-amphetamine are enriched 
among SNPs associated with SCZ (enrichment driven by alleles associated with increased 
euphoria and decreased SCZ risk) as well as SNPs associated with ADHD.
Lynsey Hall (University of Edinburgh, UK) investigated whether a quantitative 
endophenotype for MDD could be generated using cognitive, mood, and personality traits 
that are genetically correlated with depression. Data from a large family and population-
based study (21 340 individuals), Generation Scotland (GS:SFHS), were used. Three traits 
with the highest genetic correlation were used to create a composite trait, including the 
GHQ, Mood Disorder Questionnaire, and Eysenck Personality Questionnaire for 
Neuroticism. These were subjected to PCA. No genome-wide significant SNPs were 
identified; the top GWAS hit for the composite trait was in the 3′ intron of sushi domain-
containing protein 4 gene (SUSD4), rs4661250. SUSD4 is highly expressed in the white 
matter of oligodendrocytes and in MDD white matter integrity is reduced, therefore 
suggesting a possible role for SUSD4 in the etiology of depression. They also used summary 
data from the PGC-MDD GWAS and generated PRS profiles for MDD in GS:SFHS. The 
association between these scores and MDD and the newly derived composite trait were 
tested. The polygenic score had a stronger association with and explained more of the 
variance of the composite trait compared with depression or recurrent depression. This 
suggests that the trait captures a greater proportion of the heritable component of depression. 
However, this study cannot detect causal variants for depression as it is still under-powered. 
They hope to have a larger GWAS sample once the rest of the GS:SFHS cohort is included.
Schizophrenia: genomics and more (reported by Giorgia Quadri, Denise Haslinger, Erik 
Loken, and Shing-Wan Choi)
Dr Andrew Pocklington (Cardiff University) tested the impact of CNVs in SCZ. Individuals 
with SCZ have been found to have an increased burden of large and rare CNVs more than 
100 kb, frequency less than 1%, compared with matched controls in several studies. So far, a 
few individual loci were strongly implicated more than 500 kb, odds ratio (OR) 2–60, in 
2.5% of patients and 0.9% in controls; most of these span multiple genes (NRXN1). Results 
from set-based analysis on case–control datasets showed enrichment for synaptic and 
developmental genes for SCZ CNVs. De-novo SCZ CNVs were instead enriched in 
postsynaptic N-methyl-D-aspartate receptor (NMDAR), which is central to the synaptic 
plasticity and ARC (neuronal activity-regulated cytoskeleton associated) protein complexes 
(Kirov et al., 2012); this was replicated in other CNV studies.
Pocklington studied CNVs in SCZ in a wider sample and collected European subsets to 
obtain 11 917 cases and 16 416 controls; the focus was on large (>100 kb) CNVs. The aim 
was then to look at previously implicated genes, most importantly, genes related to brain 
function and CNS functional development; 136 gene sets covering various aspects of 
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behavior, memory, social interaction, brain region sizes, white matter sizes, cell morphology 
neurons, and glia were curated. Most of these were taken from the Mouse Genome 
Informatics phenotype database with a focus on single genes, functional genetic studies in 
mice, and neuronal annotation from proteomics studies. Finally, to test for any additional 
enrichment for these gene sets including large and rare CNVs, a logistic regression model 
with covariates was used to correct for CNV size, number of genes hit, and the inclusion of 
multiple studies and genotyping chips. For the three previously implicated sets, there was 
strong evidence for association with the NMDAR receptor complex. P-values were corrected 
for the three tests for deletions and duplications. The NMDAR signals mostly came from 
duplications (NMDAR duplication P = 7.53 × 10−9); there was also a deletion signal in the 
neuronal activity-regulated cytoskeleton-associated protein complexes (ARC deletion P = 
0.001). Compared with permuted data, there was an excess of associated CNS gene sets that 
was also observed across several significance thresholds. Results included gene sets related 
to learning and memory, synaptic physiology, and postsynaptic protein complexes. 
Interestingly, there was a strong evidence of enrichment in the NMDAR complexes and in 
the PSD-95 (important scaffolding component of postsynaptic scaffolding molecule) 
complexes and GABAA. Duplications and deletions showed the same results of the 
combined analysis.
Dr Brady Maher (Lieber Insititute of Brain Development/Johns Hopkins Medical School) 
aimed to study the function of genes during cortical development.
TCF4 is a basic helix-loop-helix transcription factor, which can regulate transcription. It is 
known to bind to E-boxes to either suppress or activate transcription. The main goal of this 
study was to understand which genes TCF4 regulates. The TCF4 region reached genome-
wide significance in several studies and some SNPs in this region have been associated with 
endophenotypes for SCZ including IQ. The Lieber Institute has been developing a dataset 
for RNA sequencing obtained from the dorsal lateral PFC of postmortem brains of 100 
schizophrenic patients and 100 controls; this was used to understand the molecular 
mechanisms increasing the risk associated with TCF4 variants. The function of TCF4 was 
altered by in-utero electroporation to study its expression in developing neocortex in rats. 
The focus of the presentation was to describe the process of knocking down TCF4 
expression using shRNA constructs. Two shRNA constructs were used: one that targeted the 
5′
UTR and one that targeted an exon; this resulted in a 40% knocked down protein in 
neuroblastoma cells and in the rat neuroprogenitor cells. The basic protocol involved the 
development of DNA plasmids to knock down or overexpress a gene; these constructs were 
introduced through in-utero electroporation. This technique allows injecting DNA into 
ventricles of embryos; the DNA is then electroporated into the progenitor cells, which give 
rise to a pure population to layer two-thirds pyramidal cells. Next, functional analysis was 
carried out in acute brain slices using whole-cell electrophysiology and confocal imaging.
Here, it was shown that embryonic knockdown of TCF4 in two-thirds layer pyramidal cells 
caused a decrease in the intrinsic excitability and the ectopic appearance of spike-frequency 
adaptation. Both these phenotypes were associated with an increased afterhyperpolarization 
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amplitude and were rescued by manipulating intracellular and extracellular levels of 
calcium. To rescue this phenotype, ribosome affinity purification was adapted to in-utero 
electroporation (iTRAP technique); this technique enables the purification of pure two-thirds 
pyramidal cells. Only two genes were found to be significantly upregulated: KCNQ1 
(potassium voltage-gated channel) and SCN10A (sodium voltage-gated channel). In 
conclusion, it was shown that TCF4 regulates the intrinsic excitability of layer two-thirds 
neurons in a cell autonomous manner through regulation of the expression of specific ion 
channels (KCNQ1, SCN10A). Also, iTRAP has been shown to be a novel combination of 
techniques that allows for molecular profiling of the translator in a homogeneous population 
of transfected neurons. It was also shown that TCF4’s regulation of transcription is context 
dependent; it is therefore likely that other neuronal cell types may have very different 
excitability phenotypes or none at all. This will be tested in TCF4 heterozygous mice.
Professor Peter Visscher (the University of Queensland/Queensland Brain Institute) 
investigated the role of paternal age and de-novo mutations in the risk of developing 
psychiatric illnesses. It is well established that advanced paternal age is a risk factor for 
psychiatric illness, with a relative risk of 1.2 for children of fathers 10 years older than the 
average. In addition, the rate of de-novo mutations, which are risk factors for psychiatric 
diseases, is higher in older men with approximately two extra mutations per year of 
advanced paternal age (Kong et al., 2012).
To address the question of whether older fathers have more mutations and thus children at a 
higher risk of developing psychiatric illness, Visscher created population genetic models and 
contrasted the model outcomes with empirical observations present in the literature.
The most applicable model is one where paternal age and genetic liability are correlated and 
there is assortative mating. In this scenario, the risk of psychiatric disease of children of 
older fathers is because of inherited rather than de-novo variants and a polygenic threshold 
model was assumed with a correlation between paternal age and his liability and between 
the liabilities of the spouses. This model very easily recreates the empirical observations 
found in real data. There is indeed a correlation of 5–10% between paternal age at first child 
and disease liability that generates a lambda for offspring of 1.2. Therefore, de-novo 
mutations on their own do not add up in explaining the empirical observations and the risk 
of paternal age is not predominantly from de-novo mutations (with or without selfish 
selection), but the correlation of paternal age and liability of the disease with or without 
assortative mating can explain the risk of children of older fathers of developing a 
psychiatric illness.
Thus, shared genetic factors between children and older fathers are a plausible explanation 
for the association between advanced paternal age and risk of psychiatric illness, but de-
novo mutations and additional nongenetic factors may also contribute. This modeling leads 
to some testable hypotheses such as testing the correlation between paternal age at first child 
and liability for psychiatric illness in the empirical data. Second, there could be a better 
integration of epidemiology and genetics in large samples such as deCODE to partition the 
risk to children because of paternal age, paternal age-related denovo mutations, and 
segregating genetic risk factors in large prospective population studies.
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Dr Joseph McClay (Virginia Commonwealth University, USA) presented his work on the 
SCZ-associated gene TCF4. Using chromatin immunoprecipitation sequencing, he aimed to 
characterize the TCF4 regulatory network in the neuronal cell line SH-SY5Y. Analysis of 
mock immunoprecipitation and input control comparisons implicated genes and pathways 
involved in neuronal functions such as neurite growth. McClay further reported that genes in 
the TCF4 regulatory network are more likely to be differentially expressed in brain tissue 
from SCZ or BD patients than in controls. Permutation testing of TCF4 binding sites within 
108 genome-wide significant loci for SCZ reported in a study of the PGC (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014) showed no significant 
enrichment. However, he could identify an overlap with SCZ-implicated genes that may 
suggest novel directed experiments.
Dr Simone Berkel (Institute of Human Genetics, Heidelberg, Germany) presented her work 
on the post-synaptic scaffolding protein SHANK3, which has been implicated previously in 
SCZ. To further elucidate the role of this gene in SCZ etiology, they sequenced the exons 
and flanking intronic regions of SHANK3 in 500 affected individuals and compared their 
results with ancestrally matched controls. Eight out of 500 SCZ individuals carry rare 
SHANK3 missense variants that were not found in controls. To analyze the burden of rare 
deleterious SHANK3 variants, they combined their findings with previous studies on 
mutations of SHANK genes in ASD (Leblond et al., 2014) and SCZ (Gauthier et al., 2010), 
and reported a higher frequency of rare deleterious SHANK3 variants in ASD than in SCZ. 
Association analysis showed five SHANK3 variants with study-wide significance (P < 1E 
− 3) and one variant with genome-wide significance (P < 5E − 8) for SCZ. Furthermore, 
they identified a G < V (glycine to valine) variant of SHANK3 in SCZ and ASD probands, 
but not in controls.
Dr Jonathan Mill (University of Exeter, London, UK) discussed their systematic study of 
SCZ-associated methylomic variation in the adult brain and its relationship with changes in 
DNA methylation during human fetal brain development (Pidsley et al., 2014). They 
compared methylation of PFC and cerebellum samples in postmortem brains of SCZ 
patients with samples of controls and identified differentially methylated positions. On 
carrying out a WGCNA, they identified modules of comethylated loci associated with SCZ 
that are highly significantly enriched for genes involved in neurodevelopmental processes. 
Furthermore, they could show that SCZ-associated differentially methylated positions are 
significantly enriched for loci at which DNA methylation is dynamically altered during 
human fetal brain development.
Dr Daniel Howrigan (Massachusetts General Hospital) presented work on de-novo variation 
in 1109 Taiwanese trios with sporadic SCZ in the proband. He used exome sequencing and 
combined data with sequences from 2084 SCZ trios and 698 control trios previously 
published in the literature. He found an enrichment of Lof (P = 6 × 10−3) and synonymous 
(P = 4 × 10−6) de-novo variants in cases. No single gene surpasses exome-wide correction. 
In a gene-set analysis of previously implicated gene sets (Fromer et al., 2014), the ARC 
complex genes had an enrichment of Lof mutations in the combined analysis (P = 8 × 10−3). 
Evolutionarily constrained regions (Petrovski et al., 2013) were enriched for Lof and 
Aas et al. Page 61
Psychiatr Genet. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
missense mutations. The FMRP targets gene set was also enriched for Lof and missense 
mutations.
Dr James Walters (Cardiff University) presented research on the genomics of treatment-
resistant SCZ. One-third of SCZ patients are treatment nonresponsive. He wanted to test 
whether these patients had an excess of polygenic burden, had a specific signal, or had 
increased CNV burden. He examined the polygenic burden in 5600 treatment-resistant SCZ 
cases and 6300 controls and no difference was found compared with generic SCZ cases from 
the PGC study. The treatment resistant cases on clozapine did have six new GWAS signals 
not in the original PGC analysis, which may be specific to treatment-resistant SCZ. DRD2 
was more significant with the treatment-resistant cases in the analysis. No differences were 
found in CNV rates between treatmentresistant clozapine cases and generic SCZ cases. In 
summary, Walters found no polygenic signal difference between treatment-resistant SCZ 
cases and generic cases, but there may be specific loci for treatment resistance in SCZ. 
Walters was asked whether the DRD2 resulting from the PGC study (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014) was entirely because of 
treatment-resistant cases within the case pool. Walters considered this a possibility as the 
signal was much weaker on removing samples taking clozapine from the analysis.
Dr Vanessa Gonçalves (Centre for Addiction and Mental Health, University of Toronto) 
presented research on the mitochondrial genome’s association with the risk of SCZ. There 
are over 1000 nuclear-encoded mitochondrial genes and 37 mtDNA-encoded genes. 
Gonçalves examined SNPs in these genes in 9394 SCZ cases and 12 462 controls of 
European ancestry from the PGC (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014; Ripke et al., 2011). Using a stratified false discovery method, 
all original PGC associations were significant; in addition, associations with C6orf136, 
VARS2, and FTSJ2 replicated in an independent sample of 11 244. In addition, an oxidative 
phosphorylation gene-set analysis showed inflation in the P-values, indicating a role for 
variation with small effect sizes in the pathway impacting SCZ.
Dr Semanti Mukherjee (the Feinstein Institute for Medical Research, USA) presented the 
work of the Major Histocompatibility Complex-Psychiatric Genomics Consortium (MHC-
PGC2) working group. The working group attempted to use a subset of 38 cohorts of 
European ancestry (29 148 cases, 35 483 controls) to pinpoint the MHC signal in SCZ. They 
followed the PGC2 framework for the analysis of the genotype data and carried out a 
stepwise conditional analysis, followed by meta-analysis using METAL. Imputation was 
performed using IMPUTE2 and SNP2HLA methods. By conditioning on the most 
significant SNP identified in PGC2 (rs115329265), two additional SNPs rs9461856 (P = 
1.8E − 8) and rs115332348 (P = 4.2E − 8) reached genome-wide significance. rs9461856 
falls within the region of the SYNGAP1 gene, which associates with NMDA receptors at 
synapses, whereas rs115332348 falls within the HLA class II locus.
Jack Euesden (King’s College London, UK) presented his work on the study of the 
relationship between SCZ and RA. The study included 1600 controls from the RADIANT 
study, 2000 RA samples from the WTCCC dataset, and 113 075 controls and 36 989 cases 
from the PGC2 SCZ study. Using PRSice (polygenic risk score software; http://
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www.PRSice.info); it was found that there was no association between the polygenic score 
in SCZ and RA status.
Dr Karolina Aberg (Center for Biomarker research and Personalized Medicine, Virginia 
Commonwealth University, USA) presented her work on the study of an association between 
CpGs affected by common SNPs and SCZ disease status. Blood samples from 697 SCZ 
cases and 711 controls were used as the discovery data set, whereas the replication data set 
included a total of 75 postmortem brain samples (BA10, 26 SCZ cases, 22 bipolar cases, 27 
controls). Using MBD-Seq, a total of seven differently methylated SNP-CpGs reached 
genome-wide significance in blood and one of the sites was also replicated in the brain 
sample. This site corresponded to the IL1RAP gene and the signal could be replicated in an 
independent set of blood samples using targeted pyrosequencing and SNP genotyping. By 
combining the discovery blood samples and brain samples, a total of four differently 
methylated SNP-CpGs were found to reach genome-wide significance; the IL1RAP site was 
among the significant sites. Three significant sites were validated in independent samples, 
whereas the last sites were not replicated because of technical difficulties in designing the 
primer for that particular region.
Affective disorders: genomics and more (reported by Jie Song and Alex Shaw)
Jie Song (Karolinska Institutet, Sweden) reported a family-based study using the Swedish 
population to investigate the familial risks for BD and its relation to other psychiatric 
disorders (Song et al., 2015). By linking several Swedish national registers, a total of about 
50 000 BD patients were identified among eight million off-spring from four million nuclear 
families. Compared with matched-population controls, the familial risks for relatives of BD 
probands were 5.8–7.9 in first-degree relatives and decreased with genetic distance. There 
are also strong co-occurrence risks for other psychiatric disorders in individuals with BD 
and a relatively high risk in full siblings of BD probands. Heritability for BD was estimated 
at 58% using a sibling model. The correlations between BD and other psychiatric disorders 
were considerable (0.37–0.62) and primarily because of genetic effects. The results are 
consistent with recently published molecular genetic studies (Cross-Disorder Group of the 
Psychiatric Genomics Consortium et al., 2013a, 2013b), suggesting the pleiotropic effects of 
genes across different psychiatric disorders.
Dr Eli Stahl (Icahn School of Medicine at Mount Sinai) reported their extended results from 
a meta-analysis of PGC2 BD GWAS including 10 000 new case samples and 17 000 new 
controls. Initial analyses yielded thirteen genome-wide significant loci, of which nine are 
new, for BD. Some of these new bipolar risk loci had evidence of association with other 
psychiatric phenotypes and were located in or near biological candidate genes (e.g. MPP6 in 
PGC2 SCZ, SSBP2 in PGC AN). The pathway analyses of the primary GWAS results again 
supported a strong overlap between BD and SCZ and roles for both calcium and potassium 
ion transport. Dr Stahl mentioned that the bivariate analysis of a subset of the new data 
shows that SNP heritability of BD1 is greater than that of BD2 and greater than BD1–BD2 
coheritability, consistent with an incomplete genetic correlation (~84%) between BD1 and 
BD2 diagnoses. PRSs on the basis of other psychiatric disease GWAS differentiate between 
BD subphenotypes; for example, SCZ polygenic scores are higher in BD1 than BD2.
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Niamh Mullins (King’s College London, UK) presented their investigation for interactions 
between polygenic scores and environmental adversity (i.e. childhood trauma and SLEs) in 
the etiology of MDD. They used the discovery results from a mega-analysis on MDD by the 
PGC to construct MDD polygenic scores for the individuals in the RADIANT UK validation 
dataset. They found that polygenic scores for depression showed significant predictive 
ability for depression in the RADIANT UK sample, whereas polygenic score-by-SLE 
interaction showed no predictive ability for case/control status. However, they found a 
significant interaction between polygenic score and childhood trauma. Interestingly, the 
regression coefficient showed a negative association. One possible explanation is that the 
environmental factor childhood trauma could be more important in the development of 
MDD for those individuals with a low genetic risk compared with those with a high genetic 
risk.
Dr Tim Bigdeli (Virginia Commonwealth University, USA) described his study, which 
examined the extent of the shared genetic basis for depression (MDD) across ancestrally 
divergent populations (European and Han Chinese). SNP summary statistics were extracted 
from GWAS results from two relevant cohorts: CONVERGE (China, Oxford and VCU 
Experimental Research on Genetic Epidemiology) and the Psychiatric Genetics Consortium 
study of Depression (PGC-MDD) representing 11 139 Han Chinese (5647 female cases, 
5492 controls) and 18 663 European (9447 cases, 9215 controls) individuals, respectively. 
There were no genome-wide significant hits within an initial cross-population GWAS meta-
analysis; however, after synchronizing phenotypic definitions between the two cohorts, a 
single, potentially sex-specific GWAS hit emerged on chr7, 24 kb upstream of the SLC29A4 
gene [7p22.1; P = 6.2 × 10−8; females-only recurrent MDD (>2 episodes)]. Cross-population 
polygene score associations were assessed, with both the PGC-trained polygene score being 
significantly associated with the CONVERGE score (P = 1.65 × 10−5; recurrent MDD; P-
value threshold < 0.4; variance explained < 0.3%) and the CONVERGE-trained score being 
significantly associated with the PGC score (P = 8.82 × 10−3; females-only MDD; P-value 
threshold < 0.5; variance explained ~ 0.1%). A binomial sign test showed a more consistent 
direction of effects with the PGC cohort in the CONVERGE cohort than expected by 
chance, with the most significant result at a P-value threshold of 0.05 (P = 2.4 × 10−5). 
Although no single variants remained genome-wide significant after multiple-testing 
correction for the number of GWAS performed, taken together, these results support a shared 
polygenic risk of MDD across populations. Overall, the study results support a complex 
etiology for MDD with potentially differing genetic factors across populations.
Dr Margarita Rivera-Sanchez (King’s College London, UK) presented a study that examined 
a polymorphism in the FTO gene and its effect on BMI and depression (MDD). Both a high 
BMI (obesity) and MDD are major risk factors for chronic disease including type 2 diabetes, 
cardiovascular disease, and others. Following up from a study that showed an association 
between the rs9939609 polymorphism and BMI in MDD cases, but not controls (Rivera et 
al., 2012), the authors carried out a meta-analysis in 13 701 individuals from five 
independent studies that had information on BMI and MDD and found an interaction 
between rs9939609, BMI, and MDD (fixed-effects: β = 0.13, P = 3.087 × 10−7; random-
effects: β = 0.12, P = 0.027). Effectively, patients with MDD showed an additional increase 
of 2.2% in their BMI for each rs9939609 risk allele beyond the effect of the rs9939609 
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genotype or MDD alone. This work has implications for understanding comorbidity factors 
and in turn predicting which MDD patients are at risk of high-BMI disorders.
Dr Panagiotis Ferentinos (University of Athens, Greece) introduced a study that investigated 
the familiality of important subphenotypes in MDD that have potential utility to address 
disease heterogeneity, AAO, and episode frequency (episodicity). The familiality was 
assessed in 1498 full siblings with recurrent (MDD) from the DeNt study. The SNP 
heritability of the same MDD subphenotypes was investigated in 3468 genotyped unrelated 
cases from the RADIANT and GSK-Munich studies using the GREML method. Significant 
familial clustering was found for both AAO and episodicity. The strength of the familial 
effect was measured with family-level intraclass correlation coefficients (ICC = 0.28 for 
AAO, 0.07 for episodicity). The authors calculated from respective ICC estimates a maximal 
additive heritability of 0.56 for AAO and 0.14 for episodicity. The SNP heritability of AAO 
was 0.17 (P = 0.04); however, the analysis was underpowered for calculating the SNP 
heritability of episodicity.
Autism: genomics and more (reported by Maria Tropeano and Joanna Martin)
Dr Marta Biagioli (Massachusetts General Hospital, USA) described the transcriptional 
impact of the chromodomain helicase CHD8 suppression in neural precursor cells. She 
identified 1756 genes differentially expressed after CHD8 knockdown, most of which were 
upregulated. To distinguish between direct and indirect transcriptional effects, she also 
investigated the genome-wide sites of CHD8 binding to chromatin from three different 
antibodies. She found 7324 replicated binding sites from all three antibodies; however, just 
9.2% of the corresponding genes were differentially expressed after CHD8 knockdown, 
which suggests that CHD8 produces a much larger network of expression changes through 
indirect regulatory mechanisms. Genes directly downregulated by CHD8 were enriched for 
genes involved in early fetal development, including chromatin modifiers and transcription 
factors; genes indirectly downregulated by CHD8 were enriched for genes involved in neural 
development and ASD.
Dr Susan Santangelo (Maine Medical Center, USA) reviewed the genetic architecture of 
ASDs. She described autism as a clinically and genetically heterogeneous disorder with a 
significant genetic contribution from both common (SNPs) and rare genetic variants (CNVs, 
SNVs, LoF mutations, etc.). A number of these mutations are not specific for ASD, but they 
cross traditional diagnostic boundaries and are shared by different disorders (pleiotropy); as 
an example, she discussed the three genomewide hits shared by ASD and SCZ (TCF4, 
PCGEM1, MIR137), identified by the PGC cross-disorder analyses (Cross-Disorder Group 
of the Psychiatric Genomics Consortium et al., 2013a, 2013b). She also explained that 
autism is characterized by an extreme polygenicity, with many hundreds of genes involved, 
but little overlap is observed between genes implicated by common and rare variants; these 
hundreds of genes identified so far, however, seem to converge on a few common biological 
pathways involved in brain development, synapse function, and chromatin regulation. She 
concluded by emphasizing that biological factors involved in disease causation should be 
used to inform psychiatric nosological systems.
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Kaitlin Samocha (Massachusetts General Hospital, USA) presented an exome sequencing 
study of 3781 cases with an ASD (including 2297 cases from family trios) and 9937 
controls. In an attempt to increase power for gene discovery, she used a Bayesian gene-based 
likelihood model named TADA (transmission and de-novo association) (He et al., 2013), 
which allows the combination of de-novo mutations with inherited variations and case–
control information. She identified 33 genes with FDR less than 0.1 and 107 genes with 0.1 
≤ FDR < 0.3, with an excess of de-novo Lof mutations compared with inherited variants in 
both gene sets. She then refined TADA results by separating the two gene sets by the sex of 
the carrier (male : female in ASD ~ 4 : 1). Genes with FDR less than0.1 showed significant 
enrichment of de-novo variants in female cases (female : male > 2; implied OR ≥ 20); a 
modest enrichment of de-novo variants in females was also observed for genes with 0.1 ≤ 
FDR < 0.3 (female : male 1.3–1.4; implied OR 3–5). No significant difference between 
sexes was observed for inherited variants in both gene sets. It was noted that genes with 0.1 
≤ FDR < 0.3 of moderate impact might contribute toward discrete subsets of ASD.
Dr Beate St. Pourcain (University of Bristol, UK) presented new data examining possible G 
× E correlations of maternal smoking during the first trimester of pregnancy and risk SNPs 
in relation to autistic traits (i.e. social communication difficulties) in children in the general 
population. Sixty-five independent SNPs that showed variance inequality for social 
communication problems at ages 8 and 11 years in the Avon Longitudinal Study of Parents 
and Children sample (N ≤ 5652) were selected for interaction analyses. St. Pourcain and 
colleagues tested whether each SNP showed an interaction effect with the presence of 
maternal smoking during pregnancy. An SNP within the RBFOX1 gene showed the 
strongest interaction effect for social communication traits at 8 years and maternal smoking 
in pregnancy. However, follow-up using a second sample, the UK Twins Early Development 
Study (n = 1330), which assessed autistic traits at age 8 years, did not replicate this finding, 
although this may be because of phenotype measurement differences. St. Pourcain 
concluded that non-additive effects (e.g. G × E interactions) may contribute toward the 
genetic architecture of autistic traits in the population, although the power to identify 
individual effects may be limited.
Dr Danielle Posthuma (Vrije Universiteit, the Netherlands) presented gene-set analyses 
using Joint Analysis of Genetic Variance software in trios from the Autism Genome Project 
(n = 2398) and the Autism Genetic Resource Exchange (n = 1491). Previous pathway 
analyses (11 publications) have tended to utilize pathways available in public databases. 
Posthuma and colleagues analyzed expert-curated synaptic (17 gene sets) and glia-related 
(oligodendrocyte, astrocyte, microglia; 79 sets of genes) biological processes that were 
supported by empirical evidence (e.g. from animal knockout models). The results showed 
two significantly associated gene sets: microglial genes related to (a) cell proliferation and 
(b) cell locomotion and taxis, after accounting for multiple testing of pathways. Posthuma 
pointed out that microglia are the primary immune cells of the CNS and concluded that 
variation in genes related to certain microglial functions may contribute toward the 
pathophysiology of ASD. Work is ongoing to replicate these findings.
Dr Lauren Weiss (University of California San Francisco, USA) presented new data on 
CNVs in children with ASD, their relatives, as well as in control populations. Previous 
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research suggests that females are protected from developing ASD (Robinson et al., 2013) 
and females who do develop ASD are more likely to have large, rare CNVs compared with 
affected males (Jacquemont et al., 2014). Dr Weiss presented data from three clinical ASD 
samples (Autism Genetic Resource Exchange, Autism Genome Project, Simons Simplex 
Collection) and two large control datasets (HapMap, 1000 Genomes). The results show an 
increased burden of large (>30 kb), rare (< 1% frequency) autosomal CNVs in females with 
ASD compared with affected males, in mothers compared with fathers of affected children, 
and also strikingly, in control females compared with control males in the population 
samples. In ASD children matched for number of CNVs, females had higher scores on the 
Social Responsiveness Scale than males. Furthermore, unaffected female siblings of ASD 
probands showed an enrichment of CNVs compared with male siblings. Dr Weiss suggested 
that the results may reflect an early developmental intolerance for CNVs in males, which 
may be associated with the higher rate of male fetal loss. Dr Weiss concluded by stressing 
the importance of controlling for sex or matching cases and controls for sex in genetic 
studies.
Novel biostatistics and bioinformatics (reported by Gabriëlla Blokland and Lynsey Hall)
Dr Robert Power (Institute of Psychiatry, King’s College London, UK) investigated whether 
the heritability of cannabis use overlaps with the genetic predisposition to SCZ (Power et al., 
2014). To determine how much of the variance in cannabis use (r2) in a general population 
sample can be explained by a SCZ PRS, the PGC-SCZ1 GWAS was used as the discovery 
sample. The PGC1 risk alleles and odds ratios were used to construct PRSs in an Australian 
twin sample consisting of n = 1011 cannabis users and n = 1071 nonusers. Cannabis use-
related variables were ‘use over lifetime: ever versus never’, ‘quantity of use’, and ‘age at 
initiation’. A higher genetic risk burden was associated with a greater likelihood of ever 
having used cannabis, and among those individuals who had used cannabis, it was associated 
with a higher quantity of cannabis use. The variance explained peaked at a risk scoring 
threshold of P = 0.1. The association with SCZ risk was not limited to cannabis only, but 
appeared to extend to addiction in general. They found overlap with addiction for all 
substances (opiates, cocaine, amphetamines, alcoholism), except smoking, suggesting that it 
is a general predisposition. However, the direction of causation remains to be determined. As 
the majority of SCZ patients use cannabis and the SCZ risk scores include cannabis risk 
alleles, it could be that these cannabis risk alleles are actually predicting cannabis use. Using 
a discovery sample of non-cannabis-using schizophrenics might help to elucidate the causal 
mechanisms.
Dr Bjarni Vilhjálmsson (Harvard School of Public Health, USA, and Aarhus University, 
Denmark) explained how modeling LD increases the predictive accuracy of PRSs. LD 
between causal markers biases the effect estimates from GWAS. The standard approach of 
P-value thresholding association statistics, followed by LD pruning does not account for this 
bias, and yields suboptimal polygenic risk predictions. LD pruning lowers the heritability 
explained by the genotyped SNPs because you are throwing away markers that may have an 
effect, and ignores bias in the marginal least square estimate because of LD. This negative 
impact of LD on the prediction accuracy is expected to increase as GWAS sample sizes 
continue to grow. Vilhjálmsson and colleagues developed a Bayesian PRS method, LDpred, 
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that estimates LD from a reference panel and reweights the effect estimates obtained from 
GWAS summary statistics to estimate posterior mean causal effect sizes, producing optimal 
PRS when model assumptions hold. These estimates have a closed-form solution under an 
infinitesimal prior where every marker is causal and effect sizes are drawn from a mean-zero 
normal distribution. Under a non-infinitesimal prior where only a fraction of markers are 
causal, estimates are approximated using a Markov Chain Monte Carlo approach, LDpred. 
When applied to simulated traits using real genotypes, LDpred outperforms existing 
methods (LD pruning + thresholding), particularly at large sample sizes. LDpred was 
applied to seven WTCCC diseases and considerable improvements in r2 prediction accuracy 
were observed compared with standard PRS for all except one disease – for example, for 
type 1 diabetes, it improved from 30.4 to 37.8%. When applied to PGC-SCZ2 GWAS 
summary statistics, using ISC as an independent validation sample, a significant 
improvement in prediction r2 was observed as well: from15.7 to 18.3%. The relative 
improvement in r2 was even larger when predicting in samples of non-European descent: 
from 2.0 to 2.6%. Although an improvement, LDpred is limited by how well the reference 
sample reflects the LD structure in the GWAS sample. If LD information from individual 
cohorts is available, the prediction accuracy of LDpred could improve even further.
Andrew Jaffe (Lieber Institute for Brain Development, USA) spoke about technological 
advances in RNA sequencing resolution and coverage permitting characterization of the 
transcription dynamics (Trapnell et al., 2010). He presented research analyzing the 
transcriptome at base-pair resolution in the DLPFC using DERfinder (differentially 
expressed region finder; Frazee et al., 2014). The study used 72 human samples across six 
important life stages – fetal (second trimester), infant, child, teen, adult, and elderly (n = 6/
group). A total of 50 650 differentially expression regions (DERs) were identified, agnostic 
of annotation, with significant and replicated expression changes across fetal and postnatal 
development. The majority of DERs had the highest expression levels in fetal life (81.7%) 
and similar expression profiles of DERs were found across 16 diverse human brain regions 
and within the developing mouse cortex. He concluded that expression changes across 
development were being driven by a changing neuronal phenotype (Guintivano et al., 2013; 
Jaffe and Irizarry, 2014) related to differentiation and maturation, that the data highlighted 
conserved molecular signatures of transcriptional dynamics across brain development, and 
that annotation of the human brain transcriptome is incomplete.
Dale Nyholt (Department of Genetics and Computational Biology, Queensland Institute of 
Medical Research) presented research on using a novel gene-based approach to assess 
pleiotropy across the five major psychiatric disorders – ADHD, autism, BD, MDD, and SCZ 
– using summary data from the Cross-Disorder Group of the Psychiatric Genomics 
Consortium et al. (2013a, 2013b). He discussed the reasons why focusing on shared genes 
rather than shared SNPs may prove fruitful, namely, that genes are the predominant 
functional unit of the human genome, more closely related to biology, and gene-based tests 
incorporate allelic heterogeneity. The gene-based (GATES) test was implemented in the Fast 
ASsociation Tests (FAST) software (Chanda et al., 2013) and incorporated information on 
the P-value of the top SNP in each gene and the total number of effective, independent 
SNPs. Genetic overlap between disorders was assessed using a binomial test. Novel and 
significant overlaps were observed between ADHD and BD, and ADHD and autism, in 
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addition to significant genetic overlap being observed between disorders that SNP-based 
tests had already indicated such as SCZ and BD, SCZ and major depression, SCZ and 
autism, and major depression and autism. He went on to present the results from subsequent 
pathway analysis for adult-onset disorders and between pairs of disorders. He concluded by 
reiterating the benefits of gene-based tests, stating that by combining gene-based association 
results across overlapping disorders, this method had identified numerous genes surpassing 
genome-wide significance, had extended previous findings from single SNP-based genetic 
overlap analysis (Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 
2013a, 2013b), and had provided insight into likely genes and biological mechanisms 
underlying the observed genetic correlation and comorbidity between these major 
psychiatric disorders.
Antonio Pardiñas (Cardiff University, Cardiff) compared the different available 
methodologies for addressing population structure in GWASs compared with PCA. The 
different methods that he discussed were spatial ancestry analysis (SPA) (Yang et al., 2012), 
which uses allele frequency as a function of geographic location, SNPWEIGHTS (Chen et 
al., 2013), which estimates principal components from large panels of individuals with 
known ancestry, and GAGA (Lao et al., 2014), which is based on analysis of molecular 
variance. The International Schizophrenia Consortium (International Schizophrenia 
Consortium et al., 2009) and CLOZUK (Rees et al., 2014) were used to test the corrective 
capabilities of these methods for samples with extensive and little population stratification, 
respectively. He discussed the results of these methods against other commonly used 
correction procedures, which involved PCA using EIGENSTRAT, Cochran–Mantel–
Haenszel stratified analysis, and two mixed linear models computed with GCTA (Yang et 
al., 2011). The suitability of each method was assessed by observing how accurately the 
sample clustered and by measuring the inflation of the regression statistic using the lambda 
parameter (Devlin and Roeder, 1999). The conclusions that he drew were that PCA was 
generally applicable, SPA was good for extensively, but not less stratified populations, 
SNPWEIGHTS did not properly reflect the structure of samples because of the reference 
panels used, and that GAGA clusters were insufficient for adequate correction. He closed by 
stating that although mixed models could overcome these limitations, the most stringent 
procedures available also seem to suffer from overcorrection and power loss, as is consistent 
with recent discussions on their statistical properties (Yang et al., 2014).
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